<SEC-DOCUMENT>0001615774-18-014328.txt : 20181212
<SEC-HEADER>0001615774-18-014328.hdr.sgml : 20181212
<ACCEPTANCE-DATETIME>20181212163952
ACCESSION NUMBER:		0001615774-18-014328
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20181212
DATE AS OF CHANGE:		20181212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		181231244

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>s114606_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-K&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
&nbsp;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <B><U>September 30, 2018</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from ______________ to________________&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number<B>: <U>001-37606</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ANAVEX
LIFE SCIENCES CORP.</U></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>98-0608404</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51
    W 52<SUP>nd</SUP> Street, 7<SUP>th</SUP> Floor, New York, NY USA</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code <U>1-844-689-3939&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered under Section 12(b) of the Act:&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.001 par value</FONT></TD>
    <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    Stock Market LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Common
Stock, $0.001 par value</U></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of class)&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744; No&#9746; </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744; No &#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities
    Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
    reports), and (2) has been subject to such filing requirements for the past 90 days.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9746; &nbsp;No &#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
    Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during
    the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9746; &nbsp;No &#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by checkmark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect; 229.405 of this chapter) is
    not contained herein, and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information
    statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
    reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
    reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting company &#9746;&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company&nbsp;&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9746;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
    for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
    </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9744;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
    by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    &#9744; No &#9746;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 37%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price
at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day
of the registrant&rsquo;s most recently completed second fiscal quarter: $114,432,887 based on a price of $2.71 per share, being
the closing price of the registrant&rsquo;s common stock on March 31, 2018.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of shares outstanding
of each of the registrant&rsquo;s classes of common stock, as of the latest practicable date 46,586,162 issued and outstanding
as of December 12, 2018.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOCUMENTS
INCORPORATED BY REFERENCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">Portions of the registrant&rsquo;s Proxy Statement
for its 2019 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 95%; text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a001_v1">PART I</A></FONT></TD>
    <TD STYLE="width: 5%; text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a002_v1">ITEM 1. BUSINESS</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a003_v1">ITEM 1A. RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a004_v1">ITEM 1B. UNRESOLVED STAFF COMMENTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a005_v1">ITEM 2. PROPERTIES</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a006_v1">ITEM 3. LEGAL PROCEEDINGS</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a007_v1">ITEM 4. MINE SAFETY DISCLOSURES</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a008_v1">PART II</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a009_v1">ITEM 5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a010_v1">ITEM 6 SELECTED FINANCIAL DATA</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a011_v1">ITEM 7 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a012_v1">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a013_v1">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a014_v1">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a015_v1">ITEM 9A. CONTROLS AND PROCEDURES</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a016_v1">ITEM 9B OTHER INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a017_v1">PART III</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a018_v1">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a019_v1">ITEM 11. EXECUTIVE COMPENSATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a020_v1">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a021_v1">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a022_v1">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a023_v1">PART IV</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a024_v1">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a025_v1">ITEM 16. FORM 10-K SUMMARY</A></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
Looking Statements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K includes forward-looking statements. All statements other than statements of historical facts contained
in this Annual Report on Form 10-K, including statements regarding our anticipated future clinical and regulatory milestone events,
future financial position, business strategy and plans and objectives of management for future operations, are forward-looking
statements. The words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;expect&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;suggest,&rdquo;
&ldquo;plan&rdquo; and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to generate any revenue or to continue as a going concern;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to successfully conduct clinical and preclinical trials for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to raise additional capital on favorable terms;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to execute our development plan on time and on budget;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         products ability to demonstrate efficacy or an acceptable safety profile;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to obtain the support of qualified scientific collaborators;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability, whether alone or with commercial partners, to successfully commercialize any
                                         of our product candidates that may be approved for sale;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to identify and obtain additional product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to obtain and maintain sufficient intellectual property protection for our product
                                         candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to comply with our intellectual property licensing agreements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to defend against claims of intellectual property infringement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         anticipated start dates, durations and completion dates of our ongoing and future clinical
                                         studies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         anticipated designs of our future clinical studies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         anticipated future regulatory submissions and our ability to receive regulatory approvals
                                         to develop and market our product candidates; and </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.65pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         anticipated future cash position. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements largely on our current expectations and projections about future events, including
the responses we expect from the U.S. Food and Drug Administration, (&ldquo;FDA&rdquo;), and other regulatory authorities and
financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical and
clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions
including without limitation the risks described in &ldquo;Risk Factors&rdquo; in Part I, Item 1A of this Annual Report on Form
10-K. These risks are not exhaustive. Other sections of this Annual Report on Form 10-K include additional factors which could
adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment.
New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess
the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results
to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements
as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements
will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except
as required by applicable laws including the securities laws of the United States, we assume no obligation to update or supplement
forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Annual Report on Form 10-K, the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and &ldquo;Anavex&rdquo;
mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a001_v1"></A>PART
I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a002_v1"></A>ITEM
1. BUSINESS</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview
and Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&ldquo;CNS&rdquo;) diseases with high unmet need. Anavex analyzes genomic
data from clinical studies to identify biomarkers, which select patients that will receive the therapeutic benefit for the treatment
of neurodegenerative and neurodevelopmental diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead compound, ANAVEX<SUP>&reg;</SUP>2-73, is being developed to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and
potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&ldquo;MECP2&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
total portfolio currently consists of five programs. To prioritize the allocation of our resources, we designate certain programs
as core programs and others as seed programs, and we currently have two core programs and three seed programs. Our core programs
are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes key information about our programs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><IMG SRC="img001_v1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
has a portfolio of compounds varying in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which
is an intracellular chaperone protein with important roles in cellular communication. S1R is also involved in transcriptional
regulation at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order
to validate the ability of our compounds to activate quantitatively the S1R, we performed in collaboration with Stanford University
a quantitative Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<SUP>&reg;</SUP>2-73
target engagement or receptor occupancy (RO) with S1R in the brain.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="img002_v1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cellular
Homeostasis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases
like Rett syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.
In neurodegenerative diseases, such as Alzheimer&rsquo;s and Parkinson&rsquo;s diseases, chronic cellular stress is possibly caused
by age-correlated buildup of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein
or ribonucleic acid (&ldquo;RNA&rdquo;) lead to the death of neurons and dysfunction of the nervous system. The spreading of protein
aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer&rsquo;s and Parkinson&rsquo;s diseases that results
from disorders of protein synthesis, trafficking, folding, processing or degradation in cells. The clearance of macromolecules
in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in nerve cells. For example,
Alzheimer&rsquo;s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates
of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation of microglia.
With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<SUP>&reg;</SUP>2-73, our approach is to restore cellular balance,
i.e. homeostasis. Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental
and neurodegenerative disease progression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ANAVEX</I></B><SUP>&reg;</SUP><B><I>2-73-specific
Biomarkers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
full genomic analysis of Alzheimer&rsquo;s disease (AD) patients treated with ANAVEX<SUP>&reg;</SUP>2-73 resulted in the identification
of actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<SUP>&reg;</SUP>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<SUP>&reg;</SUP>2-73-specific
biomarker hypothesis. It is expected that <I>excluding</I> patients with these two identified biomarker variants (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically
significant improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<SUP>&reg;</SUP>2-73,
which are considered independent of AD pathology, as well as multiple endpoints and time-points, provides support for precision
medicine clinical development of ANAVEX<SUP>&reg;</SUP>2-73 by using genetic biomarkers identified within the study population
itself to target patients who are most likely to respond to ANAVEX<SUP>&reg;</SUP>2-73 treatment in AD as well as indications
like Parkinson&rsquo;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<SUP>&reg;</SUP>2-73 is currently studied
or planned to be studied.<B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Studies Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for
ANAVEX<SUP>&reg;</SUP>2-73 in mild-to-moderate Alzheimer&rsquo;s patients. This open-label randomized trial met both primary and
secondary endpoints and was designed to assess the safety and exploratory efficacy of ANAVEX<SUP>&reg;</SUP>2-73 in 32 patients.
ANAVEX<SUP>&reg;</SUP>2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress
levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer&rsquo;s
disease. In October 2017, we presented positive pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 2a study, which
established a concentration-effect relationship between ANAVEX<SUP>&reg;</SUP>2-73 and study measurements. These measures obtained
from all patients who participated in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker
signals of brain activity. Additionally, the study appears to show that ANAVEX<SUP>&reg;</SUP>2-73 activity is enhanced by its
active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately twice as long as the
parent molecule.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2016, we received approval from the Ethics Committee in Australia to extend the Phase 2a clinical trial by an additional
108 weeks, which had been requested by patients and their caregivers. Subsequently, in May 2018, we received approval from the
Ethics Committee in Australia to further extend the Phase 2a extension trial for an additional two years. The two consecutive
trial extensions have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX<SUP>&reg;</SUP>2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, we presented new long-term clinical data for ANAVEX<SUP>&reg;</SUP>2-73 in a presentation at the 2018 Clinical Trials
on Alzheimer&rsquo;s Disease (CTAD) Meeting. At 148 weeks into the five-year extended Phase 2a clinical study, data confirmed
a significant association between ANAVEX<SUP>&reg;</SUP>2-73 concentration and both exploratory functional and cognitive endpoints
as measured by the Alzheimer&rsquo;s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) evaluation and the Mini Mental
State Examination (MMSE), respectively. The cohort of patients treated with higher ANAVEX<SUP>&reg;</SUP>2-73 concentration maintained
ADCS-ADL performance compared to the lower concentration cohort (p&lt;0.0001). As well, the patient cohort with the higher ANAVEX<SUP>&reg;</SUP>2-73
concentration performed better at MMSE compared to the lower concentration cohort (p&lt;0.0008). A significant impact on the drug
response levels of both the SIGMAR1 (p&lt;0.0080) and COMT (p&lt;0.0014) genomic biomarkers, identified and specified at week
57, was also confirmed over the 148-week period. Further, ANAVEX<SUP>&reg;</SUP>2-73 demonstrated continued favorable safety and
tolerability through 148 weeks.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
larger Phase 2b/3 double-blind, placebo-controlled study of ANAVEX<SUP>&reg;</SUP>2-73 in Alzheimer&rsquo;s disease commenced
in October 2018, which is independent of the ongoing Phase 2a extension study. The Phase 2b/3 study will enroll approximately
450 patients for 48 weeks, randomized 1:1:1 to two different ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo. The trial is currently
taking place in Australia; however, North American sites may also be added. The ANAVEX<SUP>&reg;</SUP>2-73 Phase 2b/3 study design
incorporates genomic precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a study. Primary and secondary
endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer&rsquo;s Disease Assessment
Scale &ndash; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &ndash; Sum of Boxes for cognition and function (CDR-SB).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, we presented positive preclinical data for ANAVEX<SUP>&reg;</SUP>2-73 in Rett syndrome, a rare neurodevelopmental
disease. The study was funded by the International Rett Syndrome Foundation (&ldquo;Rettsyndrome.org&rdquo;). In January 2017,
we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter
Phase 2 clinical trial of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome. This award is being received in quarterly
instalments which commenced during fiscal 2018. Further, in October 2018, the Company received confirmation from the FDA that
its investigational new drug (IND) application is now open for a Phase 2 clinical trial of ANAVEX<SUP>&reg;</SUP>2-73 for the
treatment of Rett syndrome. The Phase 2 study is a randomized double-blind, placebo-controlled safety, tolerability, pharmacokinetic
and efficacy study of oral liquid ANAVEX<SUP>&reg;</SUP>2-73 formulation to treat Rett syndrome. Pharmacokinetic and dose findings
will be investigated in a total of 15 patients over a 7-week treatment period including ANAVEX<SUP>&reg;</SUP>2-73-specific genomic
precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<SUP>&reg;</SUP>2-73
under a voluntary open label extension protocol. This study will be followed by a planned placebo-controlled safety and efficacy
evaluation of ANAVEX<SUP>&reg;</SUP>2-73 over a 3-month treatment period. Primary and secondary endpoints include safety as well
as Rett syndrome conditions such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity. The ANAVEX<SUP>&reg;</SUP>2-73
Phase 2 Rett syndrome study design incorporates genomic precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73
Phase 2a Alzheimer&rsquo;s disease study.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2016, we presented positive preclinical data for ANAVEX<SUP>&reg;</SUP>2-73 in Parkinson&rsquo;s disease, which demonstrated
significant improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded
by the Michael J. Fox Foundation. Additional data was announced in October 2017 from the model for experimental parkinsonism.
The data presented indicates that ANAVEX<SUP>&reg;</SUP>2-73 induces robust neurorestoration in experimental parkinsonism. The
encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer&rsquo;s
disease trial, support the notion that ANAVEX<SUP>&reg;</SUP>2-73 is a promising clinical candidate drug for Parkinson&rsquo;s
disease.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initiated in October 2018 in Spain, Europe a double-blind, randomized, placebo-controlled Phase 2 trial with ANAVEX<SUP>&reg;</SUP>2-73
in Parkinson&rsquo;s Disease Dementia (PDD), which will study the effect of the compound on both the cognitive and motor impairment
of Parkinson&rsquo;s disease. The Phase 2 study will enroll approximately 120 patients for 14 weeks, randomized 1:1:1 to two different
ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo. The ANAVEX<SUP>&reg;</SUP>2-73 Phase 2 PDD study design incorporates genomic precision
medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a study.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development pipeline includes ANAVEX<SUP>&reg;</SUP>2-73 currently in three different clinical studies, and several
compounds in different stages of pre-clinical study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary SIGMACEPTOR&trade; Discovery Platform produced small molecule drug candidates with unique modes of action, based on
our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative
nature, including Alzheimer&rsquo;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin
or development) of disease.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compounds
that have been subjects of our research include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>2-73
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<SUP>&reg;</SUP>2-73
may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Rett syndrome, administration of ANAVEX<SUP>&reg;</SUP>2-73 resulted in both significant and dose related improvements in an array
of behavioral paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org,
ANAVEX<SUP>&reg;</SUP>2-73 was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which
advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment
with ANAVEX<SUP>&reg;</SUP>2-73 for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome
disease mouse. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<SUP>&reg;</SUP>2-73 starting at ~5.5 weeks of age
was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular coordination, balance,
motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<SUP>&reg;</SUP>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome
disease model.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, the Company received confirmation from the FDA that its IND application is now open for a Phase 2 clinical trial
of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016 and June 2016, the FDA granted Orphan Drug Designation to ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome
and infantile spasms, respectively.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Parkinson&rsquo;s disease, data demonstrates significant improvements and restoration of function in a disease modifying animal
model of Parkinson&rsquo;s disease. Significant improvements were seen on all measures tested: behavioral, histopathological,
and neuroinflammatory endpoints. In July 2018 the Company received approval from the Spanish Agency for Medicinal Products and
Medical Devices (AEMPS), to initiate its Phase 2, double-blind, placebo-controlled 14-week trial of the safety and efficacy of
ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Parkinson&rsquo;s disease dementia. The Phase 2 study commenced in October 2018
and will involve approximately 120 patients, randomized 1:1:1 to two different ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo, in
up to 24 clinical study sites.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Alzheimer&rsquo;s disease (AD) animal models, ANAVEX<SUP>&reg;</SUP>2-73 has shown pharmacological, histological and behavioral
evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent
affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<SUP>&reg;</SUP>2-73
has shown a potential dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576,
ANAVEX<SUP>&reg;</SUP>2-73 induced a statistically significant neuroprotective effect against the development of oxidative stress
in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently
amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals,
regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<SUP>&reg;</SUP>2-73.
In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent
dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram
(ECG) parameters. ANAVEX<SUP>&reg;</SUP>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some
subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were
moderate in severity and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ANAVEX<SUP>&reg;</SUP>2-73 Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers
between the ages of 18 and 55 received single, ascending oral doses over the course of the trial. Study endpoints included safety
and tolerability together with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug,
the rate at which a drug enters the blood and the duration of its effect, as well as chemical changes of the substance in the
body. This study was conducted in Germany in collaboration with ABX-CRO, a clinical research organization that has conducted several
Alzheimer&rsquo;s disease studies, and the Technical University of Dresden.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2014, a Phase 2a clinical trial was initiated for ANAVEX<SUP>&reg;</SUP>2-73, which is being evaluated for the treatment
of Alzheimer&rsquo;s disease. The open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX<SUP>&reg;</SUP>2-73
in 32 patients with mild-to-moderate Alzheimer&rsquo;s disease. ANAVEX<SUP>&reg;</SUP>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and
to reverse the pathological hallmarks observed in Alzheimer&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2a study met both primary and secondary objectives of the study. The 31-week preliminary exploratory safety and efficacy
data from the Phase 2a study of ANAVEX<SUP>&reg;</SUP>2-73 in Alzheimer&rsquo;s patients, with most receiving also donepezil,
the current standard of care, demonstrated favorable safety, maximum tolerated dose, positive dose response, sustained efficacy
response through 31 weeks for both cognitive and functional measures, as well as positive unexpected therapeutic response events.
ANAVEX<SUP>&reg;</SUP>2-73 continued to demonstrate a favorable adverse event (AE) profile through 31 weeks in a patient population
of elderly Alzheimer&rsquo;s patients with varying degrees of physical fragility. The most common side effects across all AE categories
tended to be of mild severity grade 1 and were resolved with dose reductions that were anticipated within the adaptive design
of the study protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
57 weeks, Alzheimer&rsquo;s patients taking a daily oral dose between 10mg and 50mg of ANAVEX<SUP>&reg;</SUP>2-73 was well tolerated.
There were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing
of ANAVEX<SUP>&reg;</SUP>2-73 throughout the 57-week study, continued significant improvements from baseline of cognitive, functional
and behavioral scores in a group of patients were observed, respectively. This data was analyzed using refined mathematical modeling
methods in conjunction with the detailed pharmacokinetic (PK) information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, we presented positive PK and PD data from the Phase 2a study, which established a concentration-effect relationship
between ANAVEX<SUP>&reg;</SUP>2-73 and study measurements. These measures, obtained from all patients who participated in the
entire 57 weeks, include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the study appears to show that ANAVEX<SUP>&reg;</SUP>2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which
also targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-specified
exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization
of both cognitive and functional measures in patients treated with ANAVEX<SUP>&reg;</SUP>2-73 was observed. This correlation was
positive within all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000
genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp;
RNA data in patients exposed to ANAVEX<SUP>&reg;</SUP>2-73. The analysis identified genetic variants that impacted response to
ANAVEX<SUP>&reg;</SUP>2-73, among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<SUP>&reg;</SUP>2-73.
Results showed that study participants without the SIGMAR1 (rs1800866) variants, which is about 80 percent of the population worldwide,
demonstrated improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation may enable a precision
medicine approach, since these signatures can now be applied to neurological indications tested in clinical studies with ANAVEX<SUP>&reg;</SUP>2-73
including Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease dementia and Rett syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<SUP>&reg;</SUP>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018,
the Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of early Alzheimer&rsquo;s disease. This Phase
2b/3 study design incorporates inclusion of genomic precision medicine biomarkers identified in the ANAVEX<SUP>&reg;</SUP>2-73
Phase 2a study. The Phase 2b/3 study, which is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different
ANAVEX<SUP>&reg;</SUP>2-73 doses or placebo, commenced in October 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data also validates ANAVEX<SUP>&reg;</SUP>2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&rsquo;s
disease, Parkinson&rsquo;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman
syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX<SUP>&reg;</SUP>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a study sponsored by the Foundation for Angelman Syndrome, ANAVEX<SUP>&reg;</SUP>2-73 was assessed in a mouse model for the development
of audiogenic seizures. The results indicated that ANAVEX<SUP>&reg;</SUP>2-73 administration significantly reduced audiogenic-induced
seizures. In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<SUP>&reg;</SUP>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX<SUP>&reg;</SUP>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed
in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data presented also indicates that ANAVEX<SUP>&reg;</SUP>2-73 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data on ANAVEX<SUP>&reg;</SUP>2-73 related to multiple sclerosis indicates that ANAVEX<SUP>&reg;</SUP>2-73 may promote remyelination
in multiple sclerosis disease. Further, data also demonstrates that ANAVEX<SUP>&reg;</SUP>2-73 provides protection for oligodendrocytes
(&ldquo;OL&rsquo;s&rdquo;) and oligodendrocyte precursor cells (&ldquo;OPC&rsquo;s&rdquo;), as well as central nervous system
neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we presented preclinical data of ANAVEX<SUP>&reg;</SUP>2-73 in a genetic mouse model of tuberous sclerosis complex
(&ldquo;TSC&rdquo;). TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the
body with a high incidence of seizures. The new preclinical data demonstrates that treatment with ANAVEX<SUP>&reg;</SUP>2-73 significantly
increases survival and reduces seizures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>3-71</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<SUP>&reg;</SUP>3-71
is a preclinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric
modulation, which has been shown to enhance neuroprotection and cognition in Alzheimer&rsquo;s disease models. ANAVEX<SUP>&reg;</SUP>3-71
is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. It is highly
effective in very small doses against the major Alzheimer&rsquo;s hallmarks in transgenic (3xTg-AD) mice, including cognitive
deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX<SUP>&reg;</SUP>3-71
indicates extensive therapeutic advantages in Alzheimer&rsquo;s and other protein-aggregation-related diseases given its ability
to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
preclinical study examined the response of ANAVEX<SUP>&reg;</SUP>3-71 in aged transgenic animal models and showed a significant
reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In
April 2016, the FDA granted Orphan Drug Designation to ANAVEX<SUP>&reg;</SUP>3-71 for the treatment of Frontotemporal dementia
(FTD).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
pathological conditions ANAVEX<SUP>&reg;</SUP>3-71 demonstrated the formation of new synapses between neurons (synaptogenesis)
without causing an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer&rsquo;s and
Parkinson&rsquo;s disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that
in addition to reducing oxidative stress, ANAVEX<SUP>&reg;</SUP>3-71 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>1-41</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<SUP>&reg;</SUP>1-41
is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration
or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell
viability. In addition, in animal models, ANAVEX<SUP>&reg;</SUP>1-41 prevented the expression of caspase-3, an enzyme that plays
a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning,
emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
data presented also indicates that ANAVEX<SUP>&reg;</SUP>1-41 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>1066</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<SUP>&reg;</SUP>1066,
a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<SUP>&reg;</SUP>1066
was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic
constriction injury model of neuropathic pain, a single oral administration of ANAVEX<SUP>&reg;</SUP>1066 dose-dependently restored
the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy
was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by
injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX<SUP>&reg;</SUP>1066 returned
the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any
effects on normal gastrointestinal transit with ANAVEX<SUP>&reg;</SUP>1066 and a favorable safety profile in a battery of behavioral
measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX<SUP>&reg;</SUP>1037
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANAVEX<SUP>&reg;</SUP>1037
is designed for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high
affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar
levels. In advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill
human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient
mice models. Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell
death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate
sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions
with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our
programs and realize maximum shareholder value. Further, we may acquire or develop new intellectual property and assign, license,
or otherwise transfer our intellectual property to further our goals.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Target Indications</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed compounds with potential application to two broad categories and several specific indications. including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Central
Nervous System Diseases</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&rsquo;s
                                         disease &ndash; In 2018, an estimated 5.5 million Americans were suffering from Alzheimer&rsquo;s
                                         disease. The Alzheimer&rsquo;s Association<SUP>&reg;</SUP> reports that by 2025, 7.1
                                         million Americans will be afflicted by the disease, about a 29 percent increase from
                                         currently affected patients. Medications on the market today treat only the symptoms
                                         of Alzheimer&rsquo;s disease and do not have the ability to stop its onset or its progression.
                                         There is an urgent and unmet need for both a disease modifying cure for Alzheimer&rsquo;s
                                         disease as well as for better symptomatic treatments. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parkinson&rsquo;s
                                         disease &ndash; Parkinson&rsquo;s disease is a progressive disease of the nervous system
                                         marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated
                                         with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter
                                         dopamine. Parkinson&rsquo;s disease afflicts more than 10 million people worldwide, typically
                                         middle-aged and elderly people. The Parkinson&rsquo;s disease market is set to expand
                                         from $2.1 billion in 2014 to $3.2 billion by 2021, according to business intelligence
                                         provider GBI Research.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rett
                                         syndrome - Rett syndrome is a rare X-linked genetic neurological and developmental disorder
                                         that affects the way the brain develops, including protein transcription, which is altered
                                         and as a result leads to severe disruptions in neuronal homeostasis. It is considered
                                         a rare, progressive neurodevelopmental disorder and is caused by a single mutation in
                                         the MECP2 gene. Because males have a different chromosome combination from females, boys
                                         who have the genetic MECP2 mutation are affected in devastating ways. Most of them die
                                         before birth or in early infancy. For females who survive infancy, Rett syndrome leads
                                         to severe impairments, affecting nearly every aspect of the child&rsquo;s life; severe
                                         mental retardation, their ability to speak, walk and eat, sleeping problems, seizures
                                         and even the ability to breathe easily. Rett syndrome affects approximately 1 in every
                                         10,000-15,000 females.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depression
                                         - Depression is a major cause of morbidity worldwide according to the World Health Organization.
                                         Pharmaceutical treatment for depression is dominated by blockbuster brands, with the
                                         leading nine brands accounting for approximately 75% of total sales. However, the dominance
                                         of the leading brands is waning, largely due to the effects of patent expiration and
                                         generic competition. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epilepsy
                                         - Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked
                                         seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or
                                         synchronous neuronal activity in the brain. According to the Centers for Disease Control
                                         and Prevention, epilepsy affects 3.4 million Americans. Today, epilepsy is often controlled,
                                         but not cured, with medication that is categorized as older traditional anti-epileptic
                                         drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers
                                         in different ways, there is a need for drugs used in combination with both traditional
                                         anti-epileptic drugs and second generation anti-epileptic drugs. GBI Research estimates
                                         that the epilepsy market will increase to $4.5 billion by 2019.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
                                         Pain &ndash; We define neuralgia, or neuropathic pain, as pain that is not related to
                                         activation of pain receptor cells in any part of the body. Neuralgia is more difficult
                                         to treat than some other types of pain because it does not respond well to normal pain
                                         medications. Special medications have become more specific to neuralgia and typically
                                         fall under the category of membrane stabilizing drugs or antidepressants.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malignant
                                         Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes
                                         found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated
                                         with skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment,
                                         chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide
                                         malignant melanoma market is expected to grow to $4.4 billion by 2022.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
                                         Cancer &ndash; Specific to men, prostate cancer is a form of cancer that develops in
                                         the prostate, a gland in the male reproductive system. The cancer cells may metastasize
                                         from the prostate to other parts of the body, particularly the bones and lymph nodes.
                                         Drug therapeutics for prostate cancer are expected to increase to nearly $13.5 billion
                                         in 2024 according to Datamonitor Healthcare.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
                                         Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States,
                                         approximately 55,000 new cases of pancreatic cancer will be diagnosed this year and approximately
                                         44,000 patients will die as a result of their cancer, according to the American Cancer
                                         Society. Sales predictions by GBI Research forecast that the market for the pharmaceutical
                                         treatment of pancreatic cancer in the United States and five largest European countries
                                         will increase to $2.9 billion by 2021.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is intensely competitive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time, our competitors are other biomedical development companies that are trying to discover and develop compounds to be
used in the treatment of Alzheimer&rsquo;s disease and other CNS diseases, and those companies already doing so. Those companies
include Biogen (NASDAQ:BIIB), Axovant Sciences Ltd. (NYSE: AXON), Perrigo Company Plc (NYSE:PRGO), Pfizer Inc. (NYSE:PFE), Allergan
Plc (NYSE:AGN), Novartis AG (NYSE:NVS), GlaxoSmithKline Plc (NYSE:GSK), Merck &amp; Co. Inc. (NYSE:MRK), Eli Lilly &amp; Co. (NYSE:
LLY), Johnson &amp; Johnson (NYSE:JNJ) and Roche Holding AG (VTX:ROG). For additional discussion of the risks related to competition,
see Item 1A &ldquo;Risk Factors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patents,
Trademarks and Intellectual Property </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
holds ownership or exclusive rights to four U.S. patents, nine U.S. patent applications, and various PCT or ex-U.S. patent applications
relating to our drug candidates, methods associated therewith, and to our research programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own one issued U.S. patent entitled &ldquo;ANAVEX<SUP>&reg;</SUP>2-73 and certain anticholinesterase inhibitors composition and
method for neuroprotection&rdquo; claims a composition of matter of ANAVEX&reg;2-73 directed to a novel and synergistic neuroprotective
compound combined with donepezil and other cholinesterase inhibitors. This patent is expected to expire in June 2034, absent any
patent term extension for regulatory delays. A related continuation application is also pending in the U.S. In addition, we own
one issued U.S. Patent with claims directed to methods of treating melanoma with a compound related to ANAVEX<SUP>&reg;</SUP>2-73.
This patent is expected to expire in February 2030, absent any patent term extension for regulatory delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regard to ANAVEX<SUP>&reg;</SUP>3-71, we own exclusive rights to two issued U.S. patents with claims respectively directed to
the ANAVEX<SUP>&reg;</SUP>3-71 compound and methods of treating various diseases including Alzheimer&rsquo;s with the same. These
patents are expected to expire in April 2030, and January 2030, respectively, absent any patent term extension for regulatory
delays. We also own exclusive rights to related patents or applications that are granted or pending in Australia, Canada, China,
Europe, Japan, Korea, New Zealand, Russia, and South Africa, and are expected to expire in January 2030.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own other patent applications directed to enantiomers, formulations and uses that may provide additional protection for one
or more of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regard patents and other intellectual property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective development, protection, and exploitation of our intellectual
property rights. In addition to filings made with intellectual property authorities, we protect our intellectual property and
confidential information by means of carefully considered processes of communication and the sharing of information, and by the
use of confidentiality and non-disclosure agreements and provisions for the same in contractor&rsquo;s agreements. While no agreement
offers absolute protection, such agreements provide some form of recourse in the event of disclosure, or anticipated disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical
questions for which important legal principles are unresolved. For more information regarding challenges to our existing or future
patents, see Item 1A &ldquo;Risk Factors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Government
Approval</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
by governmental authorities in the United States and foreign countries is a significant factor in the development, manufacture,
and expected marketing of our potential drug compounds and in potential future research and development activities. The nature
and extent to which such regulation will apply to us will vary depending on the nature of any potential drug compounds developed.
We anticipate that all of our potential drug compounds will require regulatory approval by governmental agencies prior to commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining these approvals and the subsequent compliance with the appropriate federal statutes and regulations requires
substantial time and financial resources. For more information regarding the risks related to obtaining government approvals,
see Item 1A &ldquo;Risk Factors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
steps ordinarily required before a new drug may be marketed in the United States, which are similar to steps required in most
other countries, include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-clinical
                                         laboratory tests, non-clinical studies in animals, formulation studies and the submission
                                         to the FDA of an IND;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
                                         and well-controlled clinical trials to establish the safety and efficacy of the drug;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         submission of a new drug application, or NDA, or biologic license application, or BLA,
                                         to the FDA; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                         review and approval of the New Drug Application (NDA) or <FONT STYLE="color: #222222; background-color: white">biologics
                                         license application (</FONT>BLA).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-clinical
tests include laboratory evaluation of potential drug compound chemistry, formulation and toxicity, as well as animal studies.
The results of non-clinical testing are submitted to the FDA as part of an IND. A 30-day waiting period after the filing of each
IND is required prior to commencement of clinical testing in humans. At any time during the 30-day period or at any time thereafter,
the FDA may halt proposed or ongoing clinical trials until the FDA authorizes trials under specified terms. The FDA may require
additional animal testing after an initial IND is approved and prior to Phase III trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials to support NDAs are typically conducted in three sequential phases, although the phases may overlap. During Phase I, clinical
trials are conducted with a small number of subjects to assess metabolism, pharmacokinetics, and pharmacological actions and safety,
including side effects associated with increasing doses. Phase II usually involves studies in a limited patient population to
assess the efficacy of the drug in specific, targeted indications; assess dosage tolerance and optimal dosage; and identify possible
adverse effects and safety risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a compound is found to be potentially effective and to have an acceptable safety profile in Phase I and II evaluations, Phase
III trials are undertaken to further demonstrate clinical efficacy and to further test for safety within an expanded patient population
at geographically dispersed clinical trial sites.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
successful completion of the required clinical trials, a NDA is generally submitted. The FDA may request additional information
before accepting the NDA for filing, in which case the NDA must be resubmitted with the additional information. Once the submission
has been accepted for filing, the FDA reviews the NDA and responds to the applicant. The FDA&rsquo;s requests for additional information
or clarification often significantly extends the review process. The FDA may refer the NDA to an appropriate advisory committee
for review, evaluation, and recommendation as to whether the NDA should be approved, although the FDA is not bound by the recommendation
of an advisory committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the United States Orphan Drug Act, a sponsor may request that the FDA designate a drug intended to treat a &ldquo;rare disease
or condition&rdquo; as an &ldquo;orphan drug.&rdquo; A &ldquo;rare disease or condition&rdquo; is one which affects less than
200,000 people in the United States, or which affects more than 200,000 people, but for which the cost of developing and making
available the product is not expected to be recovered from sales of the product in the United States. Upon the approval of the
first NDA or BLA for a drug designated as an orphan drug for a specified indication, the sponsor of that NDA or BLA is entitled
to seven years of exclusive marketing rights in the United States unless the sponsor cannot assure the availability of sufficient
quantities to meet the needs of persons with the disease. However, orphan drug status is particular to the approved indication
and does not prevent another company from seeking approval of an off-patent drug that has other labeled indications that are not
under orphan or other exclusivities. Orphan drugs may also be eligible for federal income tax credits for costs associated with
the drugs&rsquo; development. In order to increase the development and marketing of drugs for rare disorders, regulatory bodies
outside the United States have enacted regulations similar to the Orphan Drug Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
outside the United States of potential drug compounds we develop will also be subject to foreign regulatory requirements governing
human clinical trials and marketing for drugs. The requirements vary widely from country to country, but typically the registration
and approval process takes several years and requires significant resources. In most cases, if the FDA has not approved a potential
drug compound for sale in the United States, the potential drug compound may be exported for sale outside of the United States,
only if it has been approved in any one of the following: the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland
and South Africa. There are specific FDA regulations that govern this process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
a significant portion of our operating expenses has related to research and development. See our Consolidated Financial Statements
contained elsewhere in this Annual Report for costs and expenses related to research and development, and other financial information
for fiscal years 2018, 2017 and 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Scientific
Advisors </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are advised by scientists and physicians with experience relevant to our Company and our product candidates. Our scientific advisors
include clinicians and scientists who are affiliated with a number of highly regarded medical institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employees</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have thirteen full-time employees, and we retain several independent contractors on an as-needed basis. We believe that
we have good relations with our employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Available
Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internet website address is www.anavex.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available
free of charge through our website. We include our website address in this report only as an inactive textual reference and do
not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a003_v1"></A>ITEM
1A. RISK FACTORS&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to other information in this Annual Report on Form 10-K, the following risk factors should be carefully considered in
evaluating our business because such factors may have a significant impact on our business, operating results, liquidity and financial
condition. As a result of the risk factors set forth below, actual results could differ materially from those projected in any
forward-looking statements. Additional risks and uncertainties not presently known to us, or that we currently consider to be
immaterial, may also impact our business, operating results, liquidity and financial condition. If any such risks occur, our business,
operating results, liquidity and financial condition could be materially affected in an adverse manner. Under such circumstances,
the trading price of our securities could decline, and you may lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have had a history of losses and no revenue, which raise substantial doubt about our ability to continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception on January 23, 2004 through September 30, 2018, we have an accumulated deficit of $108,931,967. We can offer no assurance
that we will ever operate profitably or that we will generate positive cash flow in the future. To date, we have not generated
any revenues from our operations. Our history of losses and no revenues raise substantial doubt about our ability to continue
as a going concern. As a result, our management expects the business to continue to experience negative cash flows for the foreseeable
future and cannot predict when, if ever, our business might become profitable. We will need to raise additional funds, and such
funds may not be available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable terms, we
may not be able to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated
requirements. This may seriously harm our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an early stage pharmaceutical research and development company and may never be able to successfully develop marketable products
or generate any revenue. We have a very limited relevant operating history upon which an evaluation of our performance and prospects
can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues,
we may suspend or cease operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early stage company and have not generated any revenues to date and have no operating history. All of our potential drug
compounds are in the concept stage or early clinical development stage. Moreover, we cannot be certain that our research and development
efforts will be successful or, if successful, that our potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. We have no relevant operating history upon which an evaluation of our performance and
prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited
to, risks of unforeseen capital requirements, failure of potential drug compounds either in non-clinical testing or in clinical
trials, failure to establish business relationships and competitive disadvantages against larger and more established companies.
If we fail to become profitable, we may suspend or cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need additional funding and may be unable to raise additional capital when needed, which would force us to delay, reduce
or eliminate our research and development activities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise additional funding and the current economic conditions may have a negative impact on our ability to raise additional
needed capital on terms that are favorable to our Company or at all. We may not be able to generate significant revenues for several
years, if at all. Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through equity
or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate
funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development
activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to our Business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we are able to develop our potential drug compounds, we may not be able to receive regulatory approval, or if approved, we
may not be able to generate significant revenues or successfully commercialize our products, which will adversely affect our financial
results and financial condition and we will have to delay or terminate some or all of our research and development plans which
may force us to cease operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our potential drug compounds will require extensive additional research and development, including non-clinical testing and
clinical trials, as well as regulatory approvals, before we can market them. In particular, human therapeutic products are subject
to rigorous non-clinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in other
countries. Various federal statutes and regulations also govern or influence testing, manufacturing, safety, labeling, storage,
and record-keeping related to such products and their marketing. We cannot predict if or when any of the potential drug compounds
we intend to develop will be approved for marketing. There are many reasons that we may fail in our efforts to develop our potential
drug compounds. These include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         possibility that non-clinical testing or clinical trials may show that our potential
                                         drug compounds are ineffective and/or cause harmful side effects;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         potential drug compounds may prove to be too expensive to manufacture or administer to
                                         patients;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         potential drug compounds may fail to receive necessary regulatory approvals from the
                                         United States Food and Drug Administration or foreign regulatory authorities in a timely
                                         manner, or at all;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
                                         if our potential drug compounds are approved, we may not be able to produce them in commercial
                                         quantities or at reasonable costs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
                                         if our potential drug compounds are approved, they may not achieve commercial acceptance;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         or governmental authorities may apply restrictions to any of our potential drug compounds,
                                         which could adversely affect their commercial success; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         proprietary rights of other parties may prevent us or our potential collaborative partners
                                         from marketing our potential drug compounds.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to develop our potential drug compounds, our financial results and financial condition will be adversely affected, we
will have to delay or terminate some or all of our research and development plans and may be forced to cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
research and development plans will require substantial additional future funding which could impact our operations and financial
condition. Without the required additional funds, we will likely cease operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
will take several years before we can develop potentially marketable products, if at all. Our research and development plans will
require substantial additional capital, arising from costs to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
                                         research, non-clinical testing and human studies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                         pilot scale and commercial scale manufacturing processes and facilities; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                         and develop quality control, regulatory, marketing, sales, finance and administrative
                                         capabilities to support these programs.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future operating and capital needs will depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         pace of scientific progress in our research and development programs and the magnitude
                                         of these programs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         scope and results of pre-clinical testing and human studies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         time and costs involved in obtaining regulatory approvals;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         time and costs involved in preparing, filing, prosecuting, securing, maintaining and
                                         enforcing patents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
                                         technological and market developments;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         ability to establish additional collaborations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in our existing collaborations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         cost of manufacturing scale-up; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         effectiveness of our commercialization activities.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base our outlook regarding the need for funds on many uncertain variables. Such uncertainties include the success of our research
initiatives, regulatory approvals, the timing of events outside our direct control such as negotiations with potential strategic
partners and other factors. Any of these uncertain events can significantly change our cash requirements as they determine such
one-time events as the receipt or payment of major milestones and other payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funds will be required to support our operations and if we are unable to obtain them on favorable terms, we may be required to
cease or reduce further research and development of our drug product programs, sell some or all our intellectual property, merge
with another entity or cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to demonstrate efficacy in our non-clinical studies and clinical trials our future business prospects, financial condition
and operating results will be materially adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our research and development efforts will be greatly dependent upon our ability to demonstrate potential drug compound
efficacy in non-clinical studies, as well as in clinical trials. Non-clinical studies involve testing potential drug compounds
in appropriate non-human disease models to demonstrate efficacy and safety. Regulatory agencies evaluate these data carefully
before they will approve clinical testing in humans. If certain non-clinical data reveals potential safety issues or the results
are inconsistent with an expectation of the potential drug compound&rsquo;s efficacy in humans, the regulatory agencies may require
additional more rigorous testing before allowing human clinical trials. This additional testing will increase program expenses
and extend timelines. We may decide to suspend further testing on our potential drug compounds if, in the judgment of our management
and advisors, the non-clinical test results do not support further development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
success in non-clinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we
cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and non-clinical
testing. The clinical trial process may fail to demonstrate that our potential drug compounds are safe for humans and effective
for indicated uses. This failure would cause us to abandon a drug candidate and may delay development of other potential drug
compounds. Any delay in, or termination of, our non-clinical testing or clinical trials will delay the filing of an IND and NDA
with the Food and Drug Administration or the equivalent applications with pharmaceutical regulatory authorities outside the United
States and, ultimately, our ability to commercialize our potential drug compounds and generate product revenues. In addition,
we expect that our early clinical trials will involve small patient populations. Because of the small sample size, the results
of these early clinical trials may not be indicative of future results. Also, the IND process may be extremely costly and may
substantially delay the development of our potential drug compounds. Moreover, positive results of non-clinical tests will not
necessarily indicate positive results in subsequent clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
successful non-clinical testing, potential drug compounds will need to be tested in a clinical development program to provide
data on safety and efficacy prior to becoming eligible for product approval and licensure by regulatory agencies. From the first
human trial through to regulatory approval can take many years and 10-12 years is not unusual for certain compounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our future clinical development potential drug compounds become the subject of problems, our ability to sustain our development
programs will become critically compromised. For example, efficacy or safety concerns may arise, whether or not justified, that
could lead to the suspension or termination of our clinical programs. Examples of problems that could arise include, among others:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
                                         or safety concerns with the potential drug compounds, even if not justified;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
                                         difficulties or concerns;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                         proceedings subjecting the potential drug compounds to potential recall;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity
                                         affecting doctor prescription or patient use of the potential drug compounds;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure
                                         from competitive products; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
                                         of more effective treatments.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
clinical phase is designed to test attributes of the drug and problems that might result in the termination of the entire clinical
plan can be revealed at any time throughout the overall clinical program. The failure to demonstrate efficacy in our clinical
trials would have a material adverse effect on our future business prospects, financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not obtain the support of qualified scientific collaborators, our revenue, growth and profitability will likely be limited,
which would have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to establish relationships with leading scientists and research institutions. We believe that such relationships are
pivotal to establishing products using our technologies as a standard of care for various indications. Additionally, although
in discussion, there is no assurance that our current research partners will continue to work with us or that we will be able
to attract additional research partners. If we are not able to establish scientific relationships to assist in our research and
development, we may not be able to successfully develop our potential drug compounds. If this happens, our business will be adversely
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to develop, market or generate sales of our products to the extent anticipated. Our business may fail and investors
could lose all their investment in our Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
that we are successful in developing our potential drug compounds and receiving regulatory clearances to market our products,
our ability to successfully penetrate the market and generate sales of those products may be limited by a number of factors, including
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         our competitors receive regulatory approvals for and begin marketing similar products
                                         in the United States, the European Union, Japan and other territories before we do, greater
                                         awareness of their products as compared to ours will cause our competitive position to
                                         suffer;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
                                         from our competitors or the academic community indicating that current products or new
                                         products are more effective or offer compelling other benefits than our future products
                                         could impede our market penetration or decrease our future market share; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         pricing and reimbursement environment for our future products, as well as pricing and
                                         reimbursement decisions by our competitors and by payers, may have an effect on our revenues.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this happens, our business will be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>None
of our potential drug compounds may reach the commercial market for a number of reasons and our business may fail.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
research and development of pharmaceutical products is high risk. Most products and development candidates fail to reach the market.
Our success depends on the discovery of new drug compounds that we can commercialize. It is possible that our products may never
reach the market for a number of reasons. They may be found ineffective or may cause harmful side-effects during non-clinical
testing or clinical trials or fail to receive necessary regulatory approvals. We may find that certain products cannot be manufactured
at a commercial scale and, therefore, they may not be economical to produce. Our potential products could also fail to achieve
market acceptance or be precluded from commercialization by proprietary rights of third parties. Our patents, patent applications,
trademarks and other intellectual property may be challenged, and this may delay or prohibit us from effectively commercializing
our products. Furthermore, we do not expect our potential drug compounds to be commercially available for a number of years, if
at all. If none of our potential drug compounds reach the commercial market, our business will likely fail and investors will
lose all of their investment in our Company. If this happens, our business will be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our competitors succeed in developing products and technologies faster or that are more effective or with a better profile than
our own, or if scientific developments change our understanding of the potential scope and utility of our potential products,
then our technologies and future products may be rendered undesirable or obsolete.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition from industry participants that are pursuing technologies in similar disease states to those that
we are pursuing and are developing pharmaceutical products that are competitive with our products. Nearly all of our industry
competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history
in drug discovery and development, obtaining regulatory approval and pharmaceutical product manufacturing and marketing than we
do. With these additional resources, our competitors may be able to respond to the rapid and significant technological changes
in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend in large part on our ability
to maintain a competitive position with respect to these technologies. Rapid technological development, as well as new scientific
developments, may result in our products becoming obsolete before we can recover any of the expenses incurred to develop them.
For example, changes in our understanding of the appropriate population of patients who should be treated with a targeted therapy
like we are developing may limit the drug&rsquo;s market potential if it is subsequently demonstrated that only certain subsets
of patients should be treated with the targeted therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
reliance on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research
organizations, may result in delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail
to perform under our agreements with them.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of product development, we may engage university laboratories, other biotechnology companies or contract or clinical
manufacturing organizations to manufacture drug material for us to be used in non-clinical and clinical testing and contract research
organizations to conduct and manage non-clinical and clinical studies. If we engage these organizations to help us with our non-clinical
and clinical programs, many important aspects of this process have been and will be out of our direct control. If any of these
organizations we may engage in the future fail to perform their obligations under our agreements with them or fail to perform
non-clinical testing and/or clinical trials in a satisfactory manner, we may face delays in completing our clinical trials, as
well as commercialization of any of our potential drug compounds. Furthermore, any loss or delay in obtaining contracts with such
entities may also delay the completion of our clinical trials, regulatory filings and the potential market approval of our potential
drug compounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to compete successfully with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration
opportunities, we may be limited in our ability to research and develop our potential drug compounds.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors compete with us to attract established biotechnology and pharmaceutical companies or organizations for partnering,
licensing, mergers, acquisitions, joint ventures or other collaborations. Collaborations include contracting with academic research
institutions for the performance of specific scientific testing. If our competitors successfully enter into partnering arrangements
or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities.
Since each of these opportunities is unique, we may not be able to find a substitute. Other companies have already begun many
drug development programs, which may target diseases that we are also targeting, and have already entered into partnering and
licensing arrangements with academic research institutions, reducing the pool of available opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universities
and public and private research institutions also compete with us. While these organizations primarily have educational or basic
research objectives, they may develop proprietary technology and acquire patent applications and patents that we may need for
the development of our potential drug compounds. In some instances, we will attempt to license this proprietary technology, if
available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully
with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop
new products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
use of any of our products in clinical trials may expose us to liability claims, which may cost us significant amounts of money
to defend against or pay out, causing our business to suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nature of our business exposes us to potential liability risks inherent in the testing, manufacturing and marketing of our products.
We currently have one drug compound in clinical trials, however, when any of our products enter clinical trials or become marketed
products, they could potentially harm people or allegedly harm people possibly subjecting us to costly and damaging product liability
claims. Some of the patients who participate in clinical trials are already ill when they enter a trial or may intentionally or
unintentionally fail to meet the exclusion criteria. The waivers we obtain may not be enforceable and may not protect us from
liability or the costs of product liability litigation. Although we intend to obtain product liability insurance, which we believe
is adequate, we are subject to the risk that our insurance will not be sufficient to cover claims. The insurance costs along with
the defense or payment of liabilities above the amount of coverage could cost us significant amounts of money and management distraction
from other elements of the business, causing our business to suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to safeguard against security breaches with respect to our information systems, our business may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of our business, we gather, transmit and retain confidential information through our information systems. Although
we endeavor to protect confidential information through the implementation of security technologies, processes and procedures,
it is possible that an individual or group could defeat security measures and access sensitive information about our business
and employees. Any misappropriation, loss or other unauthorized disclosure of confidential information gathered, stored or used
by us could have a material impact on the operation of our business, including damaging our reputation with our employees, third
parties and investors. We could also incur significant costs implementing additional security measures and organizational changes,
implementing additional protection technologies, training employees or engaging consultants. In addition, we could incur increased
litigation as a result of any potential cyber-security breach. We are not aware that we have experienced any material misappropriation,
loss or other unauthorized disclosure of confidential or personally identifiable information as a result of a cyber-security breach
or other act, however, a cyber-security breach or other act and/or disruption to our information technology systems could have
a material adverse effect on our business, prospects, financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to our Common Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our operations
and would severely dilute existing or future investors if we were to raise funds at lower prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prolonged decline in the price of our common stock could result in a reduction in our ability to raise capital. Because our operations
have been financed through the sale of equity securities, a decline in the price of our common stock could be especially detrimental
to our continued operations. Any reduction in our ability to raise equity capital in the future would force us to reallocate funds
from other planned uses and would have a significant negative effect on our business plans and operations, including our ability
to develop new products and continue our current operations. If our stock price declines, there can be no assurance that we can
raise additional capital or generate funds from operations sufficient to meet our obligations. We believe the following factors
could cause the market price of our common stock to continue to fluctuate widely and could cause our common stock to trade at
a price below the price at which you purchase your shares of common stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                         or anticipated variations in our quarterly operating results;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                         of new services, products, acquisitions or strategic relationships by us or our competitors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in accounting treatments or principles;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                         in earnings estimates by securities analysts and in analyst recommendations; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                         political, economic, regulatory and market conditions.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price for our common stock may also be affected by our ability to meet or exceed expectations of analysts or investors.
Any failure to meet these expectations, even if minor, could materially adversely affect the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we issue additional shares of common stock in the future, it will result in the dilution of our existing stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
articles of incorporation authorize the issuance of 100,000,000 shares of common stock. Our board of directors has the authority
to issue additional shares of common stock up to the authorized capital stated in the articles of incorporation. Our board of
directors may choose to issue some or all such shares of common stock to acquire one or more businesses or to provide additional
financing in the future. The issuance of any such shares of common stock will result in a reduction of the book value or market
price of the outstanding shares of our common stock. If we do issue any such additional shares of common stock, such issuance
also will cause a reduction in the proportionate ownership and voting power of all other stockholders. Further, any such issuance
may result in a change of control of our corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Trading
of our common stock may be volatile and sporadic, which could depress the market price of our common stock and make it difficult
for our stockholders to resell their shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is currently a limited market for our common stock and the volume of our common stock traded on any day may vary significantly
from one period to another. Trading in our stock is often thin and characterized by wide fluctuations in trading prices, due to
many factors that may have little to do with our operations or business prospects. The availability of buyers and sellers represented
by this volatility could lead to a market price for our common stock that is unrelated to operating performance. There is no assurance
that a sufficient market will develop in the stock, in which case it could be difficult for our stockholders to resell their stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by
Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2015, we entered into a Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;) with Lincoln Park Capital
Fund, LLC (&ldquo;<U>Lincoln Park</U>&rdquo;), pursuant to which Lincoln Park committed to purchase up to $50 million of our common
stock. Concurrently with the execution of the Purchase Agreement, we agreed to issue 179,598 shares of our common stock to Lincoln
Park as a commitment fee and shall issue up to 89,799 shares pro rata, when and if, Lincoln Park purchases at our discretion the
$50 million aggregate commitment. The purchase shares sold pursuant to the Purchase Agreement are sold by us to Lincoln Park at
our discretion from time to time over a 36-month period. The purchase price for shares that we may sell to Lincoln Park under
the Purchase Agreement fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such
shares may cause the trading price of our common stock to fall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally have the right to control the timing and amount of any sales of our shares to Lincoln Park, except that, pursuant to
the terms of our agreements with Lincoln Park, we would be unable to sell shares to Lincoln Park if and when the closing sale
price of our common stock is below $3.00 per share, subject to adjustment as set forth in the Purchase Agreement. Additional sales
of our common stock, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by us. Lincoln
Park may ultimately purchase all the shares of our common stock that may be sold pursuant to the Purchase Agreement and, after
it has acquired shares, Lincoln Park may sell all, some or none of those shares. Therefore, sales to Lincoln Park by us could
result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial
number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to
sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of our common stock may cause our share price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2018, we entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co. to offer shares of
our common stock from time to time through &ldquo;at-the-market&rdquo; offerings, pursuant to which we offer and sell shares of
our common stock for an aggregate offering price of up to $50 million. To date, no offerings have occurred under this agreement.
We are not obligated to make or continue to make any sale of shares of our common stock under the &ldquo;at-the-market&rdquo;
offerings. Although any sale of securities pursuant to the &ldquo;at-the-market&rdquo; offerings will result in an increase in
cash for each share sold, it may result in shareholder dilution and may cause our share price to fall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to our Intellectual Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of
the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize product
candidates similar or identical to ours, and our ability to successfully commercialize our product candidates that we may pursue
may be impaired. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in large part on our ability to obtain and maintain protection of our intellectual property, particularly patents,
in the United States and other countries with respect to our product candidates and technology. We seek to protect our proprietary
position by filing patent applications in the United States and abroad related to our product candidates or by in-licensing intellectual
property. U.S. patents related to ANAVEX<SUP>&reg;</SUP>2-73 are directed to a dosage form comprising certain doses of ANAVEX&reg;2-73
and donepezil, and the coverage is limited to the United States only. We may not be able to obtain patent protection for ANAVEX<SUP>&reg;</SUP>2-73
as a single drug or in other jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the
USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings
challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation
could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing on
third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications
is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize
current or future product candidates.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents
may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity
or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could
limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration
of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
drugs similar or identical to ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">We hold ownership or exclusive rights to four issued
U.S. patent and nine U.S. or PCT patent applications with various international counterpart applications, all of which relate to
drug candidates and methods associated therewith. Neither patents nor patent applications ensure the protection of our intellectual
property for a number of reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 5%; text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Competitors may interfere with our patenting process in a variety of ways. Competitors may claim that Anavex is not entitled to an issued patent for a variety of legal reasons. Competitors may also claim that we are infringing their patents and restrict our freedom to operate. If a court or, in some circumstances, a board of a national patent authority, agrees, we would lose some or all of our patent protection. As a company, we have no meaningful experience with competitors interfering with our patents or patent applications.</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Because of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product programs.</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Issuance of a patent may not provide significant practical protection. If we receive a patent of narrow scope, then it may be possible for competitors to design products that do not infringe our patent(s).</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Anavex is seeking patent protection for a number of indications, combination products and drug regimens. The lack of patent protection in global markets for a specific end product or indication may inhibit our ability to advance our compounds and may make Anavex less attractive to potential partners.</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Defending a patent lawsuit takes significant time and can be very expensive.</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">If a court decides that an Anavex compound, its method of manufacture or use, infringes on the competitor&rsquo;s patent, we may have to pay substantial damages for infringement.</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">A court may prohibit us from making, selling or licensing the potential drug compound unless the patent holder grants a license. A patent holder is not required to grant a license. If a license is available, we may have to pay substantial royalties or grant cross licenses to our patents, and the license terms may be unacceptable.</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Redesigning our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties
or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights
that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to an exclusive license agreement with Life Science Research Israel Ltd., with respect to certain in-licensed intellectual
property related to our ANAVEX&reg;3-71 product candidate, and we may need to obtain additional licenses from others in the future.
Our license agreement with Life Science Research Israel Ltd. imposes, and we expect that future license agreements will impose,
various development, diligence, commercialization, and other obligations on us. In spite of our efforts, our licensors might conclude
that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements,
thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements.
If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other
third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required
to cease our development and commercialization of ANAVEX<SUP>&reg;</SUP>3-71 or other product candidates covered by any such future
licenses. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions,
results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
disputes may arise regarding intellectual property subject to a licensing agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is
    not subject to the licensing agreement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by
    our licensors and us and our partners; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         priority of invention of patented technology.&nbsp;&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the agreements under which we currently license intellectual property or technology from third parties are complex,
and certain provisions in such agreements may be susceptible to multiple interpretations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights
to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under
the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of
operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability
to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize
the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of
operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not obtain required intellectual property licenses or rights, we could encounter delays in our product development efforts
while we attempt to design around other patents or even be prohibited from developing, manufacturing or selling potential drug
compounds requiring these rights or licenses. There is also a risk that legal disputes may arise as to the rights to technology
or potential drug compounds developed in collaboration with other parties, all with attendant risk, distraction, expense, and
lack of predictability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will also depend in part on our ability to commercialize our compounds without infringing the proprietary rights of others.
We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not exist or could
be issued which would have an adverse effect on our ability to market our technology or maintain our competitive position with
respect to our technology. If our compounds or other subject matter are claimed under other United States patents or other international
patents or are otherwise protected by third party proprietary rights, we may be subject to infringement actions. In such event,
we may challenge the validity of such patents or other proprietary rights or we may be required to obtain licenses from such companies
in order to develop, manufacture or market our technology. There can be no assurances that we would be successful in a challenge
or be able to obtain such licenses or that such licenses, if available, could be obtained on commercially reasonable terms. Furthermore,
the failure to succeed in a challenge, develop a commercially viable alternative or obtain needed licenses could be materially
adverse. Adverse consequences include delays in marketing some or all of our potential drug compounds based on our drug technology
or the inability to proceed with the development, manufacture or sale of potential drug compounds requiring such licenses. If
we defend ourselves against charges of patent infringement or to protect our proprietary rights against third parties, substantial
costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of
success. An adverse outcome could subject us to significant liabilities to third parties and force us to curtail or cease the
research and development of our technology.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize ANAVEX&reg;2-73 or our other product candidates. Defense of these claims, regardless of their merit,
would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In
the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and
attorneys&rsquo; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses
from third parties, which may be impossible or require substantial time and monetary expenditure. Additionally, parties making
claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised
by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material
adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of
operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected
and our business would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we use reasonable efforts to protect our trade secrets, our employees or consultants may unintentionally or willfully disclose
our information to competitors. Enforcing a claim that someone illegally obtained and is using our trade secrets, like patent
litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are
sometimes less willing to protect trade secrets. Our competitors may independently develop equivalent knowledge, methods and know-how.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to protect our confidential proprietary information, in part, by confidentiality agreements and invention assignment agreements
with our employees, consultants, scientific advisors, contractors and collaborators. These agreements are designed to protect
our proprietary information. However, we cannot be certain that such agreements have been entered into with all relevant parties,
and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.
For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets,
and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality
of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security
of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential
proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
such competitor from using that technology or information to compete with us, which could harm our competitive position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Although
we are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patents or other
intellectual property, which could be expensive, time consuming and unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or other intellectual property. Although we are not currently involved in any litigation, if we were
to initiate legal proceedings against a third party to enforce a patent covering ANAVEX&reg;2-73 or our other product candidates,
the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation
in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written
description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following
legal assertions of invalidity and unenforceability is unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the
priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using
the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing
party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our
competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and,
even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties
associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical
trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships
that would help us bring ANAVEX&reg;2-73 or our other product candidates to market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our
owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or
our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved
in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship
or our or our licensors&rsquo; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If
we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition,
results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to
be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime
of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and
rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent
agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent
application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent
lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations
in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete
loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this
circumstance would have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the United States can be less extensive than those in the United
States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal
and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions
in all countries outside the United States, or from selling or importing products made using our inventions in and into the United
States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection
to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement
is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a004_v1"></A><FONT STYLE="font-size: 10pt; font-style: normal">ITEM
1B. UNRESOLVED STAFF COMMENTS</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a005_v1"></A><FONT STYLE="font-size: 10pt; font-style: normal">ITEM
2. PROPERTIES</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own any real property. We maintain several offices of which the office at 7th Floor, 51 West 52nd Street, New York, NY,
USA is our main office. Our lease costs are approximately $12,500 per month. We believe our offices are suitable and adequate
to operate our business now as they provide us with sufficient space to conduct our operations. We fully utilize our current premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a006_v1"></A><FONT STYLE="font-size: 10pt; font-style: normal">ITEM
3. LEGAL PROCEEDINGS</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&rsquo;s interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a007_v1"></A><FONT STYLE="font-size: 10pt; font-style: normal">ITEM
4. MINE SAFETY DISCLOSURES</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a008_v1"></A><FONT STYLE="font-size: 10pt">PART
II</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a009_v1"></A><FONT STYLE="font-size: 10pt; font-style: normal">ITEM
5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is quoted on the NASDAQ Stock Market LLC (&ldquo;NASDAQ&rdquo;) under the symbol &ldquo;AVXL.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table contains information about the range of high and low sale prices for our common stock over the fiscal quarters
for the last two fiscal years as quoted on NASDAQ. Investors should not rely on historical prices of our common stock as an indication
of future price performance. On December 12, 2018, the closing price of our common stock as reported by NASDAQ was $2.12 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>Quarter Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">High</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Low</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 59%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2018</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3.96</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2.23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2018</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.85</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2018</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2016</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
Agent</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our common stock are issued in registered form. The Nevada Agency and Trust Company, 50 West Liberty Street, Reno, Nevada (Telephone:
(775) 322-0626; Facsimile: (775) 322-5623) is the registrar and transfer agent for shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of Common Stock </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">December 12, 2018, there were approximately 56
holders of record and 46,586,162 shares of our common stock were issued and outstanding.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our common stock and have no intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our
future dividend policy will be determined from time to time by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Securities
Authorized for Issuance under Equity Compensation Plans or Individual Compensation Arrangements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes certain information regarding our equity compensation plan or individual compensation arrangements
as at September 30, 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    Compensation Plan Information</FONT></TD></TR>
<TR STYLE="text-align: center; background-color: White; vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in; margin-left: 0.5in"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan
                                         Category</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                         of securities to </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
                                         <FONT STYLE="font-size: 10pt"><B>be issued upon exercise </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>of outstanding options,</B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>warrants and rights</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>(a)&nbsp;</B></FONT></FONT></P></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted-average</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
                                         <FONT STYLE="font-size: 10pt"><B>exercise price of </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>outstanding options, </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>warrants and rights</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>(b)&nbsp;</B></FONT></FONT></P></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                         of securities </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
                                         <FONT STYLE="font-size: 10pt"><B>remaining available for </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>future issuances under </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>equity compensation </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>plans (excluding </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>securities reflected in </B></FONT><BR>
                                         <FONT STYLE="font-size: 10pt"><B>column (a))</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>(c)</B></FONT></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    compensation plans approved by security holders</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 19%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,146,500</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 19%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.52</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 19%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">890,720</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity compensation
    plans not approved by security holders</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,146,500</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.52</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">890,720</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Option Plan </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2015, our board of directors approved a 2015 Omnibus Incentive Plan (the &ldquo;2015 Plan&rdquo;), which provides
for the grant of stock options and restricted stock awards to our directors, officers, employees and consultants. The approval
of the 2015 Plan was ratified by our stockholders on May 6, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares subject to adjustment in the event of
a change of our capitalization. As a result of the adoption of the 2015 Plan, no further option awards will be granted under any
previously existing stock option plan. Stock option awards previously granted under previously existing stock option plans remain
outstanding in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the 2015 Plan is to retain the services of valued key employees and consultants of our company and such other persons
as will be select in accordance with the 2015 Plan, and to encourage such persons to acquire a greater proprietary interest in
our company, thereby strengthening their incentive to achieve the objectives of the shareholders of our company, and to serve
as an aid and inducement in the hiring of new employees and to provide an equity incentive to consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2015 Plan is administered by the board of directors, except that it may, in its discretion, delegate such responsibility to a
committee of such board. The exercise price will be determined by the board of directors at the time of grant, and the exercise
price of each option shall be at least the fair market value on the grant date; provided, however, that in the event that a grantee
owns more than 10% of our common stock as of the date of grant, the exercise price of an option granted to such grantee that is
intended to be an incentive stock option shall be not less than 110% of the fair market value on the date of grant. Stock options
may be granted under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Sales of Unregistered Securities </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the beginning of our fiscal year ended September 30, 2018, we have not sold any equity securities that were not registered under
the Securities Act of 1933 that were not previously reported in a quarterly report on Form 10-Q or in a current report on Form
8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Repurchases
of Equity Securities by Our Company and Affiliated Purchasers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a010_v1"></A><FONT STYLE="font-size: 10pt; font-style: normal">ITEM
6 SELECTED FINANCIAL DATA</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="18" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the Years ended September
    30,</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in
    thousands, except per share amounts)</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Results of operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Operating Expenses</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,334</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15,680</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15,589</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,109</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,969</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expenses),
    net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,953</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,280</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">882</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,999</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,399</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss before
    provision for income taxes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(17,381</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13,401</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14,707</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,108</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,368</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income tax benefit
    (expense)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(73</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(30</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,400</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss and comprehensive
    loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(17,454</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13,460</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14,737</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,108</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,968</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss per share, basic</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.39</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss per share, diluted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.39</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average number of shares
    outstanding</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,656</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">40,841</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,153</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,585</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,805</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
    Condition</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,931</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,440</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,187</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,291</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,262</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,376</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,838</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,499</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,470</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,354</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long term debt</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,720</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo; equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,492</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,254</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,308</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,809</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">193</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a011_v1"></A><FONT STYLE="font-size: 10pt; font-style: normal">ITEM
7 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion should be read in conjunction with our audited consolidated financial statements and notes thereto for the
fiscal year ended September 30, 2018, included elsewhere in this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Highlights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2018, we utilized $12.6 million to fund our operations, compared to $9.0 million during fiscal 2017. During fiscal 2018,
we received cash of $8.2 million from the issuance of shares of common stock under the Purchase Agreement by and between the Company
and Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;) dated October 21, 2015 (the &ldquo;Purchase Agreement). As a result,
our net cash position decreased by $4.5 million during fiscal 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses for fiscal 2018 were $19.3 million, compared to $15.7 million in fiscal 2017. Of this total, $5.5 million was attributable
to non-cash stock option compensation charges, as compared to $4.1 million for fiscal 2017. The increase in operating expenses
was also attributable to an increase in research and development expenses of $2.6 million in 2018, from $10.7 million in fiscal
2017 to $13.3 million in fiscal 2018. This increase was due to an increase in expenses incurred in preparation for three clinical
trials, two of which commenced in October 2018, including expanding our scientific team. Our general and administrative expenses
also increased by $1.0 million in fiscal 2018 to $6.0 million, primarily as a result of stock-based compensation charges associated
with an increase in salaries and wages associated with our expanded team.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses will continue to increase as our ANAVEX<SUP>&reg;</SUP>2-73 clinical studies for
the treatment of Rett syndrome, Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease continue to progress. We will continue
to target potential research partners to further advance our pipeline compounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss for fiscal 2018 was $17.5 million, or $0.39 per share, as compared to $13.5 million, or $0.33 per share in fiscal 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of Operations</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">We
are in the development stage and have not earned any revenues since our inception in 2004 and we do not anticipate earning any
revenues until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Year
ended September 30, 2018 compared to year ended September 30, 2017</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
Expenses</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
operating expenses for the year ended September 30, 2018 were $19.3 million, which was an increase of approximately $3.6 million
from fiscal 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses for fiscal 2018 were $13.3 million, as compared to $10.7 million fiscal 2017, an increase
of approximately 25%. The increase was associated with expenditures incurred in preparation of our clinical studies
for ANAVEX<SUP>&reg;</SUP>2-73, two of which commenced in October 2018. Of the $13.3 million spent on research and
development, approximately $5.0 million was spent on manufacturing and preparatory activities for these clinical trials.
Additionally, of the $13.3 million, approximately $2.7 million was spent on preclinical activities for
ANAVEX<SUP>&reg;</SUP>3-71, ANAVEX<SUP>&reg;</SUP>2-73, and other pipeline compounds. The remainder of research and
development activities were associated with ANAVEX<SUP>&reg;</SUP>2-73 Phase 2a extension study, personnel, advisory and
consulting costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was also an increase in general and administrative expenses of approximately $1.0 million, primarily related to stock-based compensation
charges associated with an increase in staffing and personnel as a result of our expanded team and associated long-term incentive
compensation. Other general and administrative increases included an increase in insurance costs as a result of increased plan
premiums.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
income </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net amount of other income for the year ended September 30, 2018 was $2.0 million as compared to $2.3 million for the comparable
period of fiscal 2017. During fiscal 2018, we received $1.6 million in the research and development incentive income from the
Australian tax office, as compared to $2.0 million during fiscal 2017. In addition, we received $0.15 million in connection with
a financial grant of $0.6 million from the Rettsyndrome.org foundation, which was awarded to cover some of the costs of the Phase
2 clinical trial of ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Rett syndrome. In addition, we had interest income of $0.26
million during fiscal 2018, as compared to $0.09 million during fiscal 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2018, we had cash and cash equivalents of approximately $22.9 million, compared to approximately $27.4 million at
September 30, 2017. The decrease in cash is primarily a result of an increase in operating expenditures, attributable to the planning
or commencement of three clinical trials during 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss for fiscal 2018 was $17.5 million, or $0.39 per share, compared to a net loss of approximately $13.5 million, or $0.33 per
share for fiscal 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
ended September 30, 2017 compared to year ended September 30, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Expenses </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses for fiscal 2017 were approximately $15.7 million, which was an increase of $0.1 million as compared to fiscal
2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2017, our general and administrative expenses decreased by $3.3 million, or 39.9% compared to fiscal 2016 This decrease
was mainly attributable to a decrease in one-time compensation related charges, including share-based compensation charges, as
well as a decrease in legal fees. The decrease in legal fees was a result of financing and reporting activities in fiscal 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
decreases in general and administrative expenses were offset by an increase in research and development expenses. Our research
and development expenses for fiscal 2017 were approximately $10.7 million as compared to approximately $7.3 million for fiscal
2016, which represents an increase of 47%. The increase was associated with expenditures incurred in preparation of our planned
clinical studies for ANAVEX&reg;2-73, and an increase in preclinical activities for ANAVEX<SUP>&reg;</SUP>3-71 and ANAVEX<SUP>&reg;</SUP>1066.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
and wages, excluding share-based compensation, decreased by $2.6 million, or 58%, in fiscal 2017 as a result of one-time charges
incurred in fiscal 2016 associated with the vesting of restricted stock awards. We continue to expand our team with the addition
of scientific staff and support staff. We incurred non-cash stock-based compensation charges of $4.1 million, compared to $5.1
million during fiscal 2016, associated with the vesting of stock options to management, employees and consultants, as part of
long-term compensation packages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2017, our legal fees decreased to $0.6 million, from $1.3 million during fiscal 2016. This decrease was as a result of
financing and SEC related activities during fiscal 2016 that did not recur in fiscal 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
income (expenses)</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate amount in the other income for the year ended September 30, 2017, amounted to $2.3 million as compared to $0.9 million
for the year ended September 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">The
largest reason for the increase in other income was the receipt during fiscal 2017 of $2.0 million in connection with a research
and development incentive program offered by the Australian Tax Office, or the ATO, as compared to $0.6 million during fiscal
2016. This amount is granted by the ATO in relation to eligible expenditures incurred in Australia in respect of our clinical
trials, and other auxiliary research, and is generally a function of expenditures incurred in Australia. In addition, we received
a research grant from the Michael J. Fox Foundation, or the MJFF, to develop ANAVEX<SUP>&reg;</SUP>2-73 for the treatment of Parkinson&rsquo;s
disease. The MJFF research grant of $0.29 million was received over a period of two years to July 2017 and was recognized as income
as the related expenditures were incurred. During each of the years ended September 30, 2017 and 2016, we recognized $0.14 million
of this grant on our statement of operations. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidity
and Capital Resources </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Working
Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Assets</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,323,740</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,785,933</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Liabilities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,884,626</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,584,334</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Working Capital</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,439,114</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,201,599</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2018, we had $22.9 million in cash and cash equivalents, a decrease of $4.5 million, from $27.4 million at September
30, 2017. The principal reason for this decrease is an increase in operating expenditures incurred in preparation of our planned
clinical studies for ANAVEX<SUP>&reg;</SUP>2-73.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the majority of our capital resources to complete the recently commenced clinical trials for ANAVEX<SUP>&reg;</SUP>2-73,
and to perform work necessary to prepare for further clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
Flows</FONT></P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>2018</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>2017</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>2016</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows used in operating activities</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,582,406</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,017,231</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,236,823</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows provided by financing activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,072,787</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,270,674</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,132,661</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    (decrease) in cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,509,619</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,253,443</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,104,162</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flow used in operating activities</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was an increase in cash used in operating activities of $3.6 million during fiscal 2018 as a result of an increase in operating
expenditures, which is more fully described above, combined with an increase in prepaid research and development expenditures
in association with the commencement of our clinical trials subsequent to the end of our fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was a small decrease in cash used in operating activities of $0.2 million during fiscal 2017 as compared to fiscal 2016. This
decrease is primarily due to the increase in other income received during fiscal 2017, as described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flow provided by financing activities</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for fiscal 2018 and 2017 were related to cash received from the issuance of common shares under
the Purchase Agreement with Lincoln Park. During fiscal 2018, we issued 2.4 million shares for gross proceeds of $8.2 million.
During fiscal 2017, we issued 7.1 million shares for gross proceeds of $27.3 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2016, cash flows from financing activities also related to the exercise of outstanding share purchase warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Financings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Controlled
Equity Offering Sales Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2018, the Company entered into a Controlled Equity Offering Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor
Fitzgerald &amp; Co., as agent (&ldquo;Cantor Fitzgerald&rdquo;), pursuant to which the Company may offer and sell shares of common
stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the &ldquo;At-the-Market
Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
delivery of a placement notice based on the Company&rsquo;s instructions and subject to the terms and conditions of the Sales
Agreement, Cantor Fitzgerald may sell shares of common stock by methods deemed to be an &ldquo;at the market offering&rdquo; offering,
in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.
The Company is not obligated to make any sales of shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend
or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions. Cantor Fitzgerald will
act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable
state and federal law, rules and regulations and the rules of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds
from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. To date, no shares of common stock have been sold pursuant to the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchase
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2015, we entered into a Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Lincoln Park, pursuant to which
Lincoln Park committed to purchase up to $50,000,000 of our common stock. Concurrently with the execution of the Purchase Agreement,
we issued 179,598 shares of our common stock to Lincoln Park as a fee for its commitment to purchase shares of our common stock
under the Purchase Agreement and shall issue up to 89,799 shares pro rata, when and if Lincoln Park purchases, at our discretion,
the $50,000,000 aggregate commitment. The purchase shares that may be sold pursuant to the Purchase Agreement may be sold by us
to Lincoln Park at our discretion from time to time over a 36-month period commencing after the SEC declared effective the related
registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common
stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a
purchase may be increased under certain circumstances provided, however that Lincoln Park&rsquo;s committed obligation under any
single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be
based on the then prevailing market prices of such shares at the time of sales as described in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our rights related to the At-the-Market Offering and the Lincoln Park financing, there can be no assurance that additional
financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we
are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale
down some or all of our research and development activities or perhaps even cease the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we will be able to continue to fund our operations through existing cash on hand and through equity and debt financing
in the future. If we raise additional financing by issuing equity securities, our existing stockholders&rsquo; ownership will
be diluted. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash
commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Contractual
Obligations and Off-Balance Sheet Arrangements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual obligations as of September 30, 2018, excluding amounts related to uncertain tax positions,
funding commitments, contingent development, regulatory and commercial milestone payments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="19" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
    Due by Period</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="19" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual
    Obligations</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1 year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-3
    years</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    - 5 years</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    5 years</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-Term
    Debt</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    Lease Obligations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 35%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
    Leases<SUP>(1)</SUP></B></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,022</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,022</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unconditional
    Purchase Obligations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Long-Term Obligations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Contractual Cash Obligations</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>(1)
R</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">elates to our office lease which expires
on March 31, 2019.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Application
of Critical Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United
States. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management&rsquo;s application of
accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following
aspects of our financial statements is critical to an understanding of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual
results may vary from our estimates due to changes in circumstances, politics, global economics, general business conditions and
other factors. Our significant estimates are related to the valuation of warrants and options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are accounting policies that we believe are significant to the presentation of our financial statements. The most significant
of these accounting policies relates to the accounting for our research and development expenses and stock-based compensation
expense and derivative liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development Expenses</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and developments costs are expensed as incurred. These expenses are comprised of the costs of our proprietary research and development
efforts, including salaries, facilities costs, overhead costs and other related expenses as well as costs incurred in connection
with third-party collaboration efforts. Milestone payments made by us to third parties are expensed when the specific milestone
has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (&ldquo;ASC&rdquo;)
730 Research and Development, as these materials have no alternative future use outside of their intended use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we incur expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability
of success and length of time to developing commercial applications of the drugs subject to the acquired patents and trademarks
is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development
projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due to these risks
and uncertainties, we expense the acquisition of patents and trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
Compensation</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for all stock-based payments and awards under the fair value-based method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees
is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting
period of the award and in the same manner as if we had paid cash instead of paying with or using equity-based instruments. Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based payments
to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date, unless there
is a contractual term for services in which case such compensation would be amortized over the contractual term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for the granting of share purchase options to employees using the fair value method whereby all awards to employees will
be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting
period with a corresponding increase to additional capital surplus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option
pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions
can materially affect the fair value estimate and therefore the Black-Scholes model does not necessarily provide a reliable single
measure of the fair value of our share purchase options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of recent accounting pronouncements and their possible effect on our results, see Note 2(n) to our Consolidated Financial
Statements found elsewhere in this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a012_v1"></A>ITEM
7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to a variety of market risks, including interest rate risk and foreign currency exchange risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
Rate Risk</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
invest a major portion of our cash surplus in bank deposits in the United States and, to a lesser extent, Australia. Since the
bank deposits typically carry fixed interest rates, financial income over the holding period is not sensitive to changes in interest
rates, but only the fair value of these instruments. However, our interest gains from future deposits could decline in the future
as a result of changes in the financial markets. In any event, given the historic low levels of the interest rate, we estimate
that a decline in the interest rate we are currently receiving will not result in a material adverse effect to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Currency Exchange Risk</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant portion of our expenditures, including clinical research expenses relate to our operations in Australia and Europe.
The cost of those expenses, as expressed in US dollars, is influenced by the exchange rate of the Australian Dollar and Euro against
the US Dollar. If the US dollar declines in value in relation to these currencies, it will become more expensive for us to fund
our operations. To limit this risk, the Company holds minimal cash reserves in Australian Dollars and Euros.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a013_v1"></A>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>ANAVEX
LIFE SCIENCES CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">CONSOLIDATED
FINANCIAL STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">September
30, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 6pt 0 0; text-align: justify; "></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 0; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Report
of Independent Registered Public Accounting Firm </B></FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
and Board of Directors</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited Anavex life Sciences Corp.&rsquo;s (the &ldquo;Company&rdquo;) internal control over financial reporting as of September
30, 2018, based on criteria established in <I>Internal Control &ndash; Integrated Framework (2013)</I> issued by the Committee
of Sponsoring Organizations of the Treadway Commission (the COSO criteria). In our opinion, the Company maintained, in all material
respects, effective internal control over financial reporting as of September 30, 2018, based on the COSO criteria<I>. </I></FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;),
the consolidated balance sheets of the Company and subsidiaries as of September 30, 2018 and 2017, the related consolidated statements
of operations, stockholders&rsquo; equity, and cash flows for each of the three years in the period ended September 30, 2018,
and the related notes and our report dated December 12, 2018 expressed an unqualified opinion thereon.</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s management is responsible for maintaining effective internal control over financial reporting and for its assessment
of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management&rsquo;s Report
on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&rsquo;s internal control
over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial
reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness
of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary
in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</FONT></P>



<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definition
and Limitations of Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
company&rsquo;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company&rsquo;s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&rsquo;s
assets that could have a material effect on the financial statements.</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
BDO USA, LLP</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 0 0 4.7pt 63pt; text-align: justify; text-indent: -63pt; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10.5pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
12, 2018</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 0pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
and Board of Directors</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; text-indent: 0pt; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; text-indent: 0pt; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Consolidated Financial Statements </B></FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; text-indent: 0pt; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) as of September
30, 2018 and 2017 and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for each of
the three years in the period ended September 30, 2018. These financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on these financial statements based on our audits.</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;),
the Company&rsquo;s internal control over financial reporting as of September 30, 2018, based on criteria established in I<I>nternal
Control &ndash; Integrated Framework (2013)</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO) and our report dated December 12, 2018 expressed an unqualified opinion thereon.</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; text-indent: 0pt; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an
opinion on the Company&rsquo;s consolidated financial statements based on our audits. We are a public accounting firm registered
with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws
and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the
overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
BDO USA, LLP</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 12pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2013.</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Trebuchet MS,sans-serif; margin: 0; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
12, 2018</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>ANAVEX
LIFE SCIENCES CORP.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">CONSOLIDATED
BALANCE SHEETS&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">September
30, 2018 and 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2018</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2017</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Current</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 74%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">22,930,638</FONT></TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,440,257</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Sales
    tax recoverable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">40,171</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9,748</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Prepaid
    expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,251,798</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">335,928</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred
    costs</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">101,133</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">24,323,740</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,785,933</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deposits</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">52,396</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">52,396</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total
    Assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">24,376,136</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,838,329</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Liabilities
    and Stockholders&rsquo; Equity Current</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,884,626</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,584,334</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total
    Liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,884,626</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,584,334</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Commitments
    - Note 5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Capital
    stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Authorized:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">100,000,000 common shares, par
    value $0.001 per share</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Issued and outstanding:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">45,933,472 common shares (2017
    - 43,330,817)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">45,935</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">43,332</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Additional
    paid-in capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">129,377,542</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">115,689,221</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accumulated
    deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(108,931,967</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(91,478,558</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total
    Stockholders&rsquo; Equity</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">20,491,510</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">24,253,995</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total
    Liabilities and Stockholders&rsquo; Equity</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">24,376,136</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,838,329</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
Accompanying Notes to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>ANAVEX
LIFE SCIENCES CORP.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">CONSOLIDATED
STATEMENTS OF OPERATIONS&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
the years ended September 30, 2018, 2017 and 2016&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2018</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2017</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2016</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Operating
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 61%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">General
    and administrative</FONT></TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5,989,170</FONT></TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5,008,275</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8,334,740</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
    and development</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">13,344,421</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10,672,086</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7,254,303</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total
    operating expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(19,333,591</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(15,680,361</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(15,589,043</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Other
    income (expenses)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Grant
    income</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">149,055</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">140,942</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">141,195</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
    and development incentive income</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,629,513</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2,022,902</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">571,093</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Interest
    income</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">255,092</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">88,098</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11,322</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Gain
    on settlement of accounts payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">75,204</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">151,402</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Gain
    on settlement of debt</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">61,205</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Financing
    related charges</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(30,943</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(5,812</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Foreign
    exchange loss, net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(49,789</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(47,583</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(48,445</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total
    other income (expense), net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,952,928</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2,279,563</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">881,960</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Net
    loss before provision for income taxes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(17,380,663</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(13,400,798</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(14,707,083</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Income
    tax expense</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">72,746</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">59,607</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">29,615</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Net
    loss and comprehensive loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(17,453,409</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(13,460,405</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(14,736,698</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Loss
    per share Basic and diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(0.39</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(0.33</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(0.42</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Weighted
    average number of shares outstanding Basic and diluted</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">44,655,725</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">40,841,033</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">35,153,426</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
Accompanying Notes to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>ANAVEX
LIFE SCIENCES CORP.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
the years ended September 30, 2018, 2017 and 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2018</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2017</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2016</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Cash
    Flows used in Operating Activities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 61%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">Net
loss</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(17,453,409</FONT></TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(13,460,405</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(14,736,698</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Adjustments
    to reconcile net loss to net cash used in operations:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization
    and depreciation</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,252</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accretion
    of debt discount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5,830</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
    compensation</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5,517,004</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4,135,570</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5,062,267</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Gain
    on extinguishment of debt</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(61,205</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Gain
    on settlement of accounts payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(75,204</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(151,402</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unrealized
    foreign exchange</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,065</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Changes
    in non-cash working capital balances related to operations:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Sales
    tax recoverable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(30,423</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">54,435</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(2,507</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Prepaid
    expenses and deposits</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(915,870</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(155,804</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(79,279</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deposits</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(52,396</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accounts
    payable and accrued liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">300,292</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">554,709</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">775,332</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred
    grant income</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(70,532</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1,082</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Net cash
    used in operating activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(12,582,406</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(9,017,231</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(9,236,823</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">Cash
    Flows provided by Financing Activities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Issuance
of common shares, net of share issue costs</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8,173,920</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,270,674</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,167,420</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred
    financing charges</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(101,133</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Repayment
    of promissory notes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(34,759</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Net cash
    provided by financing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8,072,787</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,270,674</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,132,661</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Increase
    (decrease) in cash and cash equivalents during the year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(4,509,619</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">18,253,443</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(6,104,162</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash
    and cash equivalents, beginning of year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,440,257</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9,186,814</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">15,290,976</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash
    and cash equivalents, end of year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">22,930,638</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,440,257</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9,186,814</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
Accompanying Notes to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>ANAVEX
LIFE SCIENCES CORP.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
the years ended September 30, 2018, 2017 and 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Common
    Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Par
    Value</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Additional
    Paid-in Capital</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Common
    Shares to be Issued</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accumulated
    Deficit</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 22%; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance, October
    1, 2015</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">32,044,213</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">32,044</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">74,060,999</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,997,415</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(63,281,455</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12,809,003</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued under purchase agreements</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Purchase shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">740,523</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">741</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,041,619</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3,042,360</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Commitment shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">187,616</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">188</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(188</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Capital
    stock issued pursuant to debt conversions - at $1.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">173,577</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">173</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">173,404</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(167,415</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6,162</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued pursuant to the exercise of warrants</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">41,687</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">42</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">125,020</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">125,062</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued pursuant to cashless exercise of warrants</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,979,246</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,979</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1,979</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued pursuant to employment agreement</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,000,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2,439,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1,830,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">610,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued for rounding in connection with 4:1 reverse split</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1,437</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(2</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
    option compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4,452,267</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4,452,267</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Net
    loss</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(14,736,698</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(14,736,698</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance, September 30, 2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">36,168,299</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">36,169</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">84,290,140</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(78,018,153</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6,308,156</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued under purchase agreement</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Purchase shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7,060,976</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7,061</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,263,613</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27,270,674</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Commitment shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">48,980</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">49</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(49</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued pursuant to cashless exercise of warrants</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">52,562</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">53</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(53</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Share based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4,135,570</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4,135,570</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Net
    loss</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(13,460,405</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(13,460,405</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance, September 30, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">43,330,817</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">43,332</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">115,689,221</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(91,478,558</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">24,253,995</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
Accompanying Notes to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>ANAVEX
LIFE SCIENCES CORP.</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
the years ended September 30, 2018, 2017 and 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Common
    Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Par
    Value</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Additional
    &nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR><FONT STYLE="color: Black">Paid-in
    </FONT><BR><FONT STYLE="color: Black">Capital</FONT></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Common
    &nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR><FONT STYLE="color: Black">Shares
    to be </FONT><BR><FONT STYLE="color: Black">Issued</FONT></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accumulated
    Deficit</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Total</FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 22%; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance, September
    30, 2017</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">43,330,817</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">43,332</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">115,689,221</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(91,478,558</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">24,253,995</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued under purchase agreement</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Purchase shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2,383,580</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2,384</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8,171,536</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8,173,920</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Commitment shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">14,681</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">15</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(15</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued pursuant to cashless exercise of options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">78,646</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">78</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(78</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
    issued pursuant to cashless exercise of warrants</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">125,748</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">126</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(126</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Share based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5,517,004</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5,517,004</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Net
    loss</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(17,453,409</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(17,453,409</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance,
    September 30, 2018</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">45,933,472</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">45,935</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">129,377,542</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&mdash;</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(108,931,967</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">20,491,510</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
Accompanying Notes to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">September
30, 2018 &ndash; Page 1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Business
                                         Description and Basis of Presentation</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Anavex
Life Sciences Corp. (the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&ldquo;CNS&rdquo;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which select patients that will receive the therapeutic benefit
for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&rsquo;s lead compound ANAVEX 2-73 is being
developed to treat Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (&ldquo;MECP2&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basis
of Presentation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&ldquo;SEC&rdquo;) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted
in the United States of America (&ldquo;GAAP&rdquo;).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Liquidity</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">All
of the Company&rsquo;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these consolidated financial statements
are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain. The assumptions
upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the
Company&rsquo;s expenditures will vary depending upon a number of factors including but not limited to the design, timing and
duration of future clinical trials, the progress of the Company&rsquo;s research and development programs and the level of financial
resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical
trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development
programs. Such capital may not be available on commercially acceptable terms, if at all. The Company believes that it will be
able to obtain additional working capital to fund future operations through current financing commitments from third parties,
or through other arrangements; however, there can be no assurance that such additional financing, if available, can be obtained
on terms acceptable to the Company. If the Company is unable to obtain such additional financing, future operations would need
to be scaled back.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">September
30, 2018 &ndash; Page 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note&nbsp;2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Summary
                                         of Significant Accounting Policies</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Use
                                         of Estimates</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
preparation of financial statements in accordance with United States GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of
revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income
tax asset valuations, asset impairment, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions
on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&rsquo;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">b)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Principles
                                         of Consolidation</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">c)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash
                                         and equivalents</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">d)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
                                         and Development Expenses</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&rsquo;s proprietary research
and development efforts, including salaries, facilities costs, overhead costs and other related expenses, as well as costs incurred
in connection with third-party collaboration efforts. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard
Codification (&ldquo;ASC&rdquo;) 730, Research and Development, as these materials have no alternative future use outside of their
intended use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks.
The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents
and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the
development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due
to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus
are expensed as incurred within general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Summary
                                         of Significant Accounting Policies</U> &ndash; (continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">e)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
                                         and Development Incentive Income</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company is eligible to obtain a research and development tax credit from the Australian Tax Authority (the &ldquo;ATO&rdquo;)
for certain research and development activities undertaken in Australia. The tax incentive is available on the basis of specific
criteria with which the Company must comply. Although the tax incentive is administered through the ATO, the Company has accounted
for the tax incentive outside of the scope of ASC Topic 740, Income Taxes, since the incentive is not linked to the Company&rsquo;s
income tax liability and can be realized regardless of whether the Company has generated taxable income in Australia. The Company
recognizes as other income the amount received for qualified expenses in the period they are received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">f)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basic
                                         and Diluted Loss per Share</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of September 30, 2018, loss per share excludes 7,185,296 (2017 &ndash; 6,711,339) potentially dilutive common shares related to
outstanding options and warrants, as their effect was anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">g)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Financial
                                         Instruments</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
carrying value of the Company&rsquo;s financial instruments, consisting of cash and equivalents and accounts payable and accrued
liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management&rsquo;s
opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">h)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Foreign
                                         Currency Translation</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing at the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined
that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian
dollar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Summary
                                         of Significant Accounting Policies</U> &ndash; (continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">i)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Grant
                                         Income</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
and development incentive income is recognized when the research and development activities have been undertaken and the Company
has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income
at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government
and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized
in the consolidated statement of operations in the period they are earned and when the related research and development costs
are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">j)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Income
                                         Taxes</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (&ldquo;ASC 740&rdquo;)
which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax
assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Summary
                                         of Significant Accounting Policies</U> &ndash; (continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">k)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
                                         Compensation</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for all stock-based payments and awards under the fair value method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees
is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting
period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments.
Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based
payments to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date,
unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees
will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their
vesting period with a corresponding increase to additional paid-in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the
grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes
in these assumptions can materially affect the fair value estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">l)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Fair
                                         Value Measurements</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Level
1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Level
3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
September 30, 2018 and 2017, the Company did not have any Level 3 assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Summary
                                         of Significant Accounting Policies</U> &ndash; (continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">m)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Recent
                                         Accounting Pronouncements</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Recently
Adopted Accounting Pronouncements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
November 2015, the FASB issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2015-17 &ldquo;<I>Income Taxes: Balance Sheet
Classification of Deferred Taxes</I>&rdquo; (&ldquo;ASU 2015-17&rdquo;). ASU 2015-17 eliminates the requirement to bifurcate deferred
taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified
as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15,
2016, and for interim periods within those fiscal years. The Company adopted this standard on October 1, 2017. The adoption of
this standard did not have any impact on the Company&rsquo;s financial position, results of operations or cash flows for any period
presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
March 2016, the FASB issued ASC 2016-09, &ldquo;<I>Compensation &ndash; Stock Compensation (Topic 718) &ndash; Improvements to
Employee Share-Based Payment Accounting</I>&rdquo;. These amendments are intended to simplify several aspects of the accounting
for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities,
and classification on the statement of cash flows. The Company adopted this standard on October 1, 2017. The adoption of this
standard did not have a material impact on the Company&rsquo;s financial position, results of operations or cash flows for any
period presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
November 2016, the FASB issued ASU 2016-18, &ldquo;Statement of Cash Flows (Topic 230): Restricted Cash&rdquo; (&ldquo;ASU 2016-18&rdquo;).
ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents,
and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted
cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period
and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after
December 15, 2017. Early adoption is permitted. The Company early adopted this standard on October 1, 2017. The adoption of this
standard did not have any material affect on the Company&rsquo;s consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
SEC staff issued Staff Accounting Bulletin (&ldquo;SAB&rdquo;) 118, which provides guidance on accounting for the tax effects
of the U.S. tax reform announced on December 22, 2017 by the U.S. Government commonly referred to as the Tax Cuts and Jobs Act.
SAB 118 provides a measurement period that should not extend beyond one year from the U.S. tax reform enactment date for companies
to complete the accounting under Accounting Standards Codification (&ldquo;ASC&rdquo;) 740. In accordance with SAB 118, a company
must reflect the income tax effects of those aspects of the U.S. tax reform for which the accounting under ASC 740 is complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Specifically,
the Company was required to revalue its U.S. deferred tax assets and liabilities due to the federal income tax rate reduction
from 35 percent to 21 percent. Since the Company has provided a full valuation allowance against its deferred tax assets, the
revaluation of the deferred tax assets did not have a material impact on any period presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Summary
                                         of Significant Accounting Policies</U> &ndash; (Continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">m)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Recent
                                         Accounting Pronouncements &ndash; (Continued)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Recent
Accounting Pronouncements Not Yet Adopted</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition
from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition
guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017.
The new guidance is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard
is not expected to have a material impact for any period presented and the Company will apply this standard to all future revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
February 2016, the FASB issued Accounting Standards Update No. 2016-02, <I>Leases</I>. The guidance would require lessees to recognize
most leases on their balance sheets as lease liabilities with corresponding right &ndash;of use assets. The guidance is effective
for annual and interim reporting periods beginning on or after December 15, 2018. The new guidance is effective for the Company
on a prospective basis beginning on October 1, 2019. The Company is currently evaluating the impact this guidance will have on
its financial condition, results of operations and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
May 2017, the FASB issued ASU No. 2017-09, &ldquo;Compensation&ndash;Stock Compensation (Topic 718): Scope of Modification Accounting,&rdquo;
clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The
new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the
same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for the Company
on a prospective basis beginning on October 1, 2018, with early adoption permitted. The Company is currently evaluating the impact
this guidance will have on its financial condition, results of operations and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-based Payments
(&ldquo;ASU 2018-07&rdquo;). This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring
goods and services from nonemployees. The effective date for the standard is for interim periods in fiscal years beginning after
December 15, 2018, with early adoption permitted, but no earlier than the Company&rsquo;s adoption date of Topic 606. The new
guidance is effective for the Company beginning on October 1, 2019. The new guidance is required to be applied retrospectively
with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the effect ASU 2018-07
will have on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Other
than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant
impact on its results of operations, financial position or cash flow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Other
                                         Income</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Grant
Income</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Clinical
Study Grant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received
in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for
a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
grant income is deferred when received and amortized to other income as the related research and development expenditures are
incurred. During the year ended September 30, 2018, the Company recognized $149,055 (2017: $Nil; 2016$Nil) of this grant on its
statement of operations within grant income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Preclinical
Study Grant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2015, the Company was awarded grant funding in the amount of $286,455. The grant was received in
exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential
treatment for Parkinson&rsquo;s disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
grant income was deferred and amortized to other income over the related commitment period as the related research and development
expenditures were incurred. During the year ended September 30, 2018, the Company recognized $Nil (2017: $140,942; 2016: $141,195)
of this grant on its statement of operations within grant income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
and development tax incentive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2018, the Company received other income of $1,629,513 (2017: $2,022,902; 2016: $571,093) in respect
of a research and development incentive program offered by the Australian government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 9</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Equity
                                         Offering Agreements</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Controlled
Equity Offering Sales Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
July 6, 2018, the Company entered into a Controlled Equity Offering Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor
Fitzgerald &amp; Co., as agent (&ldquo;Cantor Fitzgerald&rdquo;), pursuant to which the Company may offer and sell shares of common
stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the &ldquo;Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Upon
delivery of a placement notice based on the Company&rsquo;s instructions and subject to the terms and conditions of the Sales
Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an &ldquo;at the market offering&rdquo; offering, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.
The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend
or terminate the offering of Shares upon notice to the other party, subject to certain conditions. Cantor Fitzgerald will act
as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable
state and federal law, rules and regulations and the rules of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds
from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. During the year ended September 30, 2018, the Company incurred $101,133 in legal and
accounting fees associated with the Sales Agreement. This amount is included in deferred costs at September 30, 2018
and is expected to be reclassified to share capital upon issuance of shares under the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Purchase
Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &ldquo;2015 Purchase Agreement&rdquo;) with Lincoln
Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln
Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period
starting from the effective date of the respective registration statement, to September 6, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of
common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount
of a purchase may be increased under certain circumstances provided, however that Lincoln Park&rsquo;s committed obligation under
any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will
be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
consideration for entering into the 2015 Purchase Agreement, the Company issued to Lincoln Park 179,598 shares of common stock
as a commitment fee and agreed to issue up to 89,799 shares pro rata, when and if, Lincoln Park purchases at the Company&rsquo;s
discretion the $50,000,000 aggregate commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2018, the Company issued to Lincoln Park an aggregate of 2,398,261 (2017: 7,109,956; 2016: 452,437)
shares of common stock under the Purchase Agreement, including 2,383,580 (2017: 7,060,976; 2016: 450,000) shares of common stock
for an aggregate purchase price of $8,173,920 (2017 $27,270,674; 2016: $1,357,800) and 14,681 (2017: 48,980; 2016: 2,437) commitment
shares. At September 30, 2018, an amount of $13,197,607 remained available under the 2015 Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 10<FONT STYLE="color: Black">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Commitments</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">Lease
                                         Commitment</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">The
Company has entered into an office lease agreement expiring March 31, 2019. The Company is committed to lease commitments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 46%; text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal
    year ending September 30, 2019</FONT></TD><TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,022</FONT></TD><TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,022</FONT></TD><TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2018 the Company recorded rent expense of $151,405 (2017: $127,993, 2016: $125,317) which is included
in general and administrative expenses on the consolidated statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">Litigation</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company&rsquo;s consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">Share
                                         Purchase Warrants</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of the status of the Company&rsquo;s outstanding share purchase warrants is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 69%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    October 1, 2015</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,272,890</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,463,581</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.67</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,809,309</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(200,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,September
    30, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,609,309</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.66</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(756,143</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(524,787</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">678,379</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.87</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 11<FONT STYLE="color: Black">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Commitments
                                         </U>&ndash; (Continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Share
                                         Purchase Warrants &ndash; (Continued)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
September 30, 2018, the Company had 678,379 share purchase warrants outstanding, with a weighted average exercise price of $2.87
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.8pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry
    Date</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.00</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 51%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    24, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">277,127</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,252</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.68</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    31, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.04</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    31, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">678,379</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2018, 350,000 options granted to a consultant to the Company were converted to 350,000 warrants with
the same exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2018, an aggregate of 737,393 share purchase warrants at $3.00 per share and 18,750 share purchase
warrants at $1.24 per share were exercised on a cashless basis, pursuant to which the Company issued 125,748 shares of common
stock and an additional 80,981 shares of common stock were to be issued. The remaining 524,787 share purchase warrants exercisable
at $3.00 per share until July 5, 2018 expired unexercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2017, 200,000 share purchase warrants were cashless exercised, resulting in the issuance of 52,562
shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2016, the Company issued 1,979,246 shares of common stock pursuant to the exercise of 2,421,894 share
purchase warrants on a cashless basis, and 41,687 shares of common stock pursuant to the exercise of warrants for cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">d)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock&ndash;based
                                         Compensation Plan</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2015
Stock Option Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
September 18, 2015, the Company&rsquo;s board of directors approved a 2015 Omnibus Incentive Plan (the &ldquo;2015 Plan&rdquo;),
which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event
of a change of the Company&rsquo;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will
be granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
2015 Plan provides that it may be administered by the board of directors, or the board of directors may delegate such responsibility
to a committee. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to
the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be
less than 110% of fair market value of the Company&rsquo;s shares of common stock on the grant date. Stock options may be granted
under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may
be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 12</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Commitments
                                         </U>&ndash; (Continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">d)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
                                         Compensation Plan &ndash; (Continued)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of the status of Company&rsquo;s outstanding stock purchase options is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Grant Date Fair Value</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 54%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at October 1, 2015</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,822,500</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,401,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.68</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at September 30, 2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,199,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.76</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,107,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.51</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.44</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(214,470</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.09</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at September 30, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,092,030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,730,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.71</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.09</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164,280</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(150,833</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at September 30, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,506,917</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.83</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    at September 30, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,108,028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.75</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    at September 30, 2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,326,223</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 13</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Commitments
                                         </U>&ndash; (Continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">d)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
                                         Compensation Plan &ndash; (Continued)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
September 30, 2018, the following stock options were outstanding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry
    Date</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life
    (yrs)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.60</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 5,
    2023</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">565,000</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.76</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 7, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,375</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">176,250</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">618,750</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">618,750</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,119,938</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.51</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,167</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,167</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 8, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,625</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.69</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.76</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 15, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.71</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,750</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,750</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.04</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.97</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.64</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,250</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,250</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.68</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.98</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 16, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.04</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.57</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.90</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.66</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 27, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.57</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.75</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">379,625</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,083</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.26</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 5, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.76</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">861,429</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">574,286</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.06</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 18, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.80</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">906,696</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">906,696</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.28</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 22, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.98</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,999</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.63</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 3, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,750</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,750</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.35</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 9, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,667</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 7, 2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.36</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,333</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.26</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 17, 2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.38</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">774,166</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">389,170</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.92</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.61</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,209</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.42</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 9, 2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.86</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,250</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 19, 2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.97</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">540,834</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,834</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 13, 2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.42</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,334</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.72</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 19, 2028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.47</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">780,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">335,400</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.62</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    6, 2028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.85</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,506,917</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,108,028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,353,088</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&rsquo;s stock for the options that were in-the-money at September 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 14</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
         5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commitments </U>&ndash;
                      (Continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: gray"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>d)</I></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>Stock&ndash;based
                                         Compensation Plan &ndash; (Continued)</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company recognized stock-based compensation expense of $5,517,004 during the year ended September 30, 2018 (2017: $4,135,570;
2016: $4,452,267) in connection with the issuance and vesting of stock options and warrants in exchange for services, and $Nil
(2017: $Nil 2016: $610,000), in connection with the vesting of restricted stock in exchange for services. These amounts have been
included in general and administrative expenses and research and development expenses on the Company&rsquo;s statement of operations
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,699,557</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,017,199</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,208,220</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,817,447</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,118,371</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,854,047</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    share based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,517,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,135,570</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,062,267</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">An
amount of approximately $6,827,054 in stock-based compensation is expected to be recorded over the remaining term of such options
through June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.73</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life of options (years)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.86</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.88</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annualized
    volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106.45</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111.58</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114.75</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of restricted stock compensation charges recognized during the years ended September 30, 2018, 2017 and 2016 was determined
with reference to the quoted market price of the Company&rsquo;s shares on the commitment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 15</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Income
                                         Taxes</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">US
Tax Reform</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (&ldquo;Tax Reform Act&rdquo;).
The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a
territorial tax system and imposing a transition tax on deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act
permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued
its ending net deferred tax assets at September 30, 2018. The Company did not need to recognize any provisional tax expense for
the year ended September 30, 2018 as it has recorded a full valuation allowance against its deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Tax Reform Act also provided for a one-time deemed mandatory repatriation of post &ndash; 1986 undistributed foreign subsidiary
earnings and profits (&ldquo;E&amp;P&rdquo;) as well as Global Intangible Low-Taxed Income (&ldquo;GILTI&rdquo;) and Base-Erosion
Anti-Abuse provisions. The Company had no adjustments related to these latter noted provisions at September 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
tax effects of the temporary differences that give rise to the Company&rsquo;s estimated deferred tax assets and liabilities are
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed
    Tax rate</FONT></TD><TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD><TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD><TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD><TD STYLE="width: 1%; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforwards</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,123,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,240,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,223,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development tax credits</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,605,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,344,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,036,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange and other</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unpaid
    charges</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
    asset costs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,152,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,394,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,004,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance for deferred tax assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,993,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,032,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,447,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Income
                                         Taxes</U> &ndash; (Continued)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
provision for income taxes differ from the amount established using the statutory income tax rate as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    benefit at statutory rate</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,215,000</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,577,000</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,010,000</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    income taxed at other rates</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(173,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent
    differences</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible
    finance and accretion expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible
    compensation costs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">738,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    permanent differences</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development tax credit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(77,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">628,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiry
    of foreign net operating loss carryforwards</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment
    and true up to prior years&rsquo; tax provision</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">336,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(55,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">176,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of changes in tax rates</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,166,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">Change
    in valuation allowance related to current <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">year
    provision</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,038,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,585,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,009,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    Tax Recovery</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of September 30, 2018, the Company had net operating loss carry-forwards of approximately $50,557,000 (2017: $41,000,000; 2016:
$33,000,000) in the United States, approximately $986,000 (Approximately AUD$1,365,000) (2017: $850,000; 2016: $250,000) in Australia
and approximately $638,000 (Approximately &euro;549,000) (2017: $13,000; 2016: $Nil) in Germany, available to offset future taxable
income in those jurisdictions. The carry-forwards will begin to expire in 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company evaluates its valuation allowance requirements based on projected future operations. When circumstances change, and this
causes a change in management&rsquo;s judgment about the recoverability of deferred tax assets, the impact of the change on the
valuation allowance is reflected in current income. Because management of the Company does not currently believe that it is more
likely than not that the Company will receive the benefit of these assets, a valuation allowance equal to the deferred tax asset
has been established at September 30, 2018, 2017 and 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Uncertain
Tax Positions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company&rsquo;s
tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities
until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation
years commencing on or after 2009.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Certain
of the Company&rsquo;s net operating loss carryforwards <FONT STYLE="background-color: white">in the United States may be subject
to limitations by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces
the Company&rsquo;s ability to utilize net operating loss carry-forwards, under certain circumstances. The Company completed a
Section 382 analysis through the fiscal year ended September 30, 2018 and currently does not believe Section 382 will apply to
limit the utilization of these tax losses. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2018 &ndash; Page 17</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Note
                            7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Supplemental
                                         Cash Flow Information</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Investing
and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended September 30, 2016;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">i)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
                                         Company issued 6,162 shares of common stock upon conversion of $6,162 in principal amount
                                         of convertible debentures at a conversion price of $1.00 per share and 167,415 shares
                                         of common stock pursuant to the application of an incorrect conversion price for conversion
                                         notices received during the year ended September 30, 2015.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 62; Options: NewSection; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a014_v1"></A>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a015_v1"></A>ITEM
9A. CONTROLS AND PROCEDURES</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disclosure
Controls and Procedures</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC&rsquo;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions
regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management,
including our principal executive and principal financial officer, of the effectiveness of the design and operation of our disclosure
controls and procedures, as defined in Rule 13(a)-15(e) under the Exchange Act. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective, as of September
30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Management&rsquo;s
Annual Report on Internal Control over Financial Reporting </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including
our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our internal
control over financial reporting based on criteria established in the framework in Internal Control &mdash; Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&ldquo;COSO&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on this evaluation, our management concluded that our internal controls over financial reporting were effective as of September
30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BDO
USA, LLP, an independent registered public accounting firm, has provided an attestation report on the Company&rsquo;s internal
control over financial reporting as of September 30, 2018, which is included herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in Internal Control over Financial Reporting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting identified in management&rsquo;s evaluation pursuant to Rules
13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended September 30, 2018 that materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a016_v1"></A>ITEM
9B OTHER INFORMATION</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 63; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a017_v1"></A>PART
III</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a018_v1"></A>ITEM
10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item is incorporated by reference to our definitive Proxy Statement for the 2019 Annual Meeting of
Stockholders to be filed with the SEC within 120 days after the end of our year ended September 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a019_v1"></A>ITEM
11. EXECUTIVE COMPENSATION</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item is incorporated by reference to our definitive Proxy Statement for the 2019 Annual Meeting of
Stockholders to be filed with the SEC within 120 days after the end of our year ended September 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a020_v1"></A>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND <FONT STYLE="text-transform: uppercase">RELATED STOCKHOLDER
MATTERS.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item is incorporated by reference to our definitive Proxy Statement for the 2019 Annual Meeting of
Stockholders to be filed with the SEC within 120 days after the end of our year ended September 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a021_v1"></A>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item is incorporated by reference to our definitive Proxy Statement for the 2019 Annual Meeting of
Stockholders to be filed with the SEC within 120 days after the end of our year ended September 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a022_v1"></A>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this item is incorporated by reference to our definitive Proxy Statement for the 2019 Annual Meeting of
Stockholders to be filed with the SEC within 120 days after the end of our year ended September 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a023_v1"></A>PART
IV</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a024_v1"></A>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 10%; border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    </B><BR>
    <B>Number </B></FONT></TD>
    <TD STYLE="width: 90%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(3)
    </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Articles
    of Incorporation and Bylaws </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000113707005000007/ex31.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000113707005000007/ex31.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation (incorporated by reference to our Registration Statement on Form SB-2 filed on January 13, 2005)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm">Articles of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated by reference to our Current Report on Form 8-K filed on January 25, 2007)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299315005296/exhibit3-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299315005296/exhibit3-1.htm">Certificate of Change filed with the Secretary of State of Nevada on October 6, 2015 (incorporated by reference to our Current Report on Form 8-K filed on October 6, 2015)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(4)
    </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Instruments
    defining rights of security holders, including indentures </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314001492/exhibit10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314001492/exhibit10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Senior Convertible Debenture (incorporated by reference to our Current Report on Form 8-K filed on March 19, 2014)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314001492/exhibit10-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314001492/exhibit10-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A/B Warrant (incorporated by reference to our Current Report on Form 8-K filed on March 19, 2014)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314006111/exhibit10-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314006111/exhibit10-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Common Stock Purchase Warrant (incorporated by reference to our Current Report on Form 8-K filed on October 23, 2014)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314006111/exhibit10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314006111/exhibit10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series B Common Stock Purchase Warrant (incorporated by reference to our Current Report on Form 8-K filed on October 23, 2014)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(10)
    </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
    Contracts</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314001492/exhibit10-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000106299314001492/exhibit10-2.htm">Form of Registration Rights Agreement, dated March 13, 2014, by and among the Company and the parties identified therein (incorporated by reference to our Current Report on Form 8-K filed on March 19, 2014)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015 Omnibus Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on December 29, 2015)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003021/s102057_exhibit10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003021/s102057_exhibit10-1.htm">Purchase Agreement, dated as of October 21, 2015, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on October 26, 2015)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003021/s102057_exhibit10-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003021/s102057_exhibit10-2.htm">Registration Rights Agreement, dated as of October 21, 2015, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on October 26, 2015)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5 </FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 7, 2016)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Employment Agreement by and between the Company and with Sandra Boenisch (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/s111267_ex1-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/s111267_ex1-1.htm">Controlled Equity Offering<SUP>SM</SUP> Sales Agreement, dated July 6, 2018, by and between Anavex Life Sciences Corp. and Cantor Fitzgerald &amp; Co. (incorporated by reference to our Current Report on Form 8-K filed on July 6, 2018)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 10%; border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    </B><BR>
    <B>Number </B></FONT></TD>
    <TD STYLE="width: 90%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
    of Ethics</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577416008914/s104917_ex14-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577416008914/s104917_ex14-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
    of Ethics Adopted on September 13, 2016 (incorporated by reference to our Annual Report on Form 10-K filed on December 14,
    2016)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(21)</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex21-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex21-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
    of the Registrant</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(23)</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s114606_ex23-1.htm">23.1*</A></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s114606_ex23-1.htm">Consent of Independent Registered Public Accounting Firm</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(31)
    </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    302 Certifications</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex31-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex31-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Christopher Missling, PhD.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex31-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex31-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Sandra Boenisch</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(32)
    </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
    906 Certifications</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex32-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="s114606_ex32-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 906 Certification of Christopher Missling, PhD and Sandra Boenisch</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(99)</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
    Exhibits</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy Adopted August 9, 2017 (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577417002182/s106085_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></A></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1314052/000161577417002182/s106085_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Investment Policy Adopted May 4, 2017 (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 10, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(101)</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XBRL</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    INSTANCE DOCUMENT</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION SCHEMA</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><A NAME="a025_v1"></A>ITEM
16. FORM 10-K SUMMARY</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:
    December 12, 2018</B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANAVEX
    LIFE SCIENCES CORP.</B></FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Christopher Missling, PhD&nbsp;</I></FONT></P></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Missling, PhD</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer (Principal Executive Officer)</FONT></P>
                                                                                 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signatures</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title(s)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Christopher Missling, PhD</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    12, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Missling, PhD</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 30%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Sandra Boenisch</I></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 18%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    12, 2018</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
    Boenisch, CPA, CGA</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer and Treasurer (Principal Accounting Officer)</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Athanasios Skarpelos&nbsp;</I></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    12, 2018</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios
    Skarpelos</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Claus van der Velden, PhD</I></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    12, 2018</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus
    van der Velden, PhD</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Elliot Favus, MD</I></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    12, 2018</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot
    Favus, MD</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Steffen Thomas, PhD</I></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    12, 2018</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen
    Thomas, PhD</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Peter Donhauser, D.O.</I></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    12, 2018</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Donhauser, D.O.</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 67; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>s114606_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 9pt 0 24pt; text-align: center"><B>SUBSIDIARIES OF THE REGISTRANT</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 57%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.75pt"><B>Name of Subsidiary</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.75pt"><B>Jurisdiction of Incorporation or Organization</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Anavex Australia Pty Limited</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Australia</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Anavex Germany GmbH</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Germany</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Anavex Canada Ltd.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Ontario, Canada</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>s114606_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Consent
of Independent Registered Public Accounting Firm</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-218292 and 333-207600) and
the Registration Statement on Form S-8 (No. 333-219934) of our reports dated December&nbsp;12,&nbsp;2018, relating to the consolidated
financial statements, and the effectiveness of Anavex Life Sciences Corp.&rsquo;s internal control over financial reporting, which
appear in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
BDO USA, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
12, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>s114606_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 31.1</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Christopher Missling, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I
    have reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    December 12, 2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;/s/ Christopher Missling&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling, PhD </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President, Secretary<BR> (Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 1pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 1pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 26%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 1pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 1pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>s114606_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Sandra Boenisch, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I
    have reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    December 12, 2018</FONT></TD>
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;/s/ Sandra Boenisch</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch, CPA, CGA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer, Treasurer<BR> (Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>s114606_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Annual Report of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ending
September 30, 2018 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), we, Christopher Missling,
Chief Executive Officer (Principal Executive Officer) and Sandra Boenisch, Principal Financial Officer (Principal Financial and
Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section
1350 of the United States Code, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="width: 97%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934,
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company at the dates and for the periods indicated.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
December 12, 2018</FONT></P></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;/s/ Christopher Missling</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling, PhD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
Executive Officer, President, Secretary</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;/s/
    Sandra Boenisch</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch, CPA, CGA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
    Financial Officer, Treasurer<BR>
    (Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>avxl-20180930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Created by S2 Filings, LLC- http://www.s2filings.com -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:avxl="http://anavex.com/20180930">
    <link:schemaRef xlink:href="avxl-20180930.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_ClinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_ClinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_ClinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2015-09-30_custom_PreclinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:PreclinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PreclinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:PreclinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_PreclinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:PreclinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_PreclinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:PreclinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_ResearchAndDevelopmentIncentiveProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_ResearchAndDevelopmentIncentiveProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_ResearchAndDevelopmentIncentiveProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-19</xbrli:startDate>
        <xbrli:endDate>2015-10-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-05to2018-07-06_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-05</xbrli:startDate>
        <xbrli:endDate>2018-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseWarrants3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseWarrants4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseWarrants5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_PurchaseWarrants6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrants3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrants4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrants5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrants6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption16Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption16Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption17Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption17Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption18Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption18Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption18Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption18Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption19Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption19Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption19Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption19Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption21Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption21Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption21Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption21Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption22Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption22Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption22Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption22Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption23Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption23Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption23Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption23Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption24Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption24Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption24Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption24Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption25Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption25Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption25Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption25Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption26Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption26Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption26Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption26Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption27Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption27Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption27Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption27Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption28Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption28Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption28Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption28Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_EmployeeStockOption29Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption29Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_ForeignCountry1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:ForeignCountry1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_ForeignCountry1Member_currency_EUR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:ForeignCountry1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_ForeignCountry1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:ForeignCountry1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_ForeignCountry1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:ForeignCountry1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2016-09-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2018-09-30_custom_EmployeeStockOption29Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:EmployeeStockOption29Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>avxl:Number</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="AUD">
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <us-gaap:Cash contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">27440257</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">22930638</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">9186814</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">15290976</us-gaap:Cash>
    <avxl:GeneralSalesTaxRecoverable contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">9748</avxl:GeneralSalesTaxRecoverable>
    <avxl:GeneralSalesTaxRecoverable contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">40171</avxl:GeneralSalesTaxRecoverable>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">335928</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">1251798</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DeferredFinanceCostsNet contextRef="AsOf2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFinanceCostsNet contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">101133</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">27785933</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">24323740</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">52396</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">52396</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">27838329</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">24376136</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">3584334</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">3884626</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">3584334</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">3884626</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">43332</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">45935</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">115689221</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">129377542</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">-91478558</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">-108931967</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">24253995</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">20491510</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">6308156</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30" unitRef="USD" decimals="0">12809003</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">32044</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">36169</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">74060999</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">84290140</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" decimals="0">1997415</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2015-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-63281455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-78018153</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">43332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">115689221</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-91478558</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45935</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">129377542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-108931967</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">27838329</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">24376136</us-gaap:LiabilitiesAndStockholdersEquity>
    <dei:EntityRegistrantName contextRef="From2017-10-01to2018-09-30">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2017-10-01to2018-09-30">0001314052</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2017-10-01to2018-09-30">10-K</dei:DocumentType>
    <dei:TradingSymbol contextRef="From2017-10-01to2018-09-30">AVXL</dei:TradingSymbol>
    <dei:DocumentPeriodEndDate contextRef="From2017-10-01to2018-09-30">2018-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2017-10-01to2018-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2017-10-01to2018-09-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2017-10-01to2018-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2017-10-01to2018-09-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2017-10-01to2018-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2017-10-01to2018-09-30">2018</dei:DocumentFiscalYearFocus>
    <dei:EntityPublicFloat contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">114432887</dei:EntityPublicFloat>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-09-30" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-09-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">43330817</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-09-30" unitRef="Shares" decimals="INF">45933472</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">43330817</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-09-30" unitRef="Shares" decimals="INF">45933472</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">32044213</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">36168299</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">43330817</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">45933472</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingExpenses contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">19333591</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">15680361</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">15589043</us-gaap:OperatingExpenses>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">13344421</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">10672086</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">7254303</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">5989170</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">5008275</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">8334740</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-10-01to2018-09-30" unitRef="Shares" decimals="INF">44655725</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">40841033</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">35153426</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-10-01to2018-09-30" unitRef="USDPShares" decimals="INF">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-10-01to2017-09-30" unitRef="USDPShares" decimals="INF">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-10-01to2016-09-30" unitRef="USDPShares" decimals="INF">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-17453409</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-13460405</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-14736698</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-14736698</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-13460405</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-17453409</us-gaap:NetIncomeLoss>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">72746</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">59607</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">29615</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-17380663</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-13400798</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-14707083</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">1952928</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">2279563</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">881960</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-49789</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-47583</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-48445</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">30943</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">5812</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <avxl:GainOnSettlementOfDebt contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:GainOnSettlementOfDebt contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:GainOnSettlementOfDebt contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">61205</avxl:GainOnSettlementOfDebt>
    <avxl:GainOnSettlementOfAccountPayable contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:GainOnSettlementOfAccountPayable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">75204</avxl:GainOnSettlementOfAccountPayable>
    <avxl:GainOnSettlementOfAccountPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">151402</avxl:GainOnSettlementOfAccountPayable>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">255092</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">88098</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">11322</us-gaap:InterestIncomeExpenseNet>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">1629513</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">2022902</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">571093</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">149055</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">140942</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">141195</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2016-10-01to2017-09-30_custom_ClinicalStudyGrantMember" unitRef="USD" decimals="0">597886</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2014-10-01to2015-09-30_custom_PreclinicalStudyGrantMember" unitRef="USD" decimals="0">286455</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2017-10-01to2018-09-30_custom_ResearchAndDevelopmentIncentiveProgramMember" unitRef="USD" decimals="0">1629513</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2016-10-01to2017-09-30_custom_ResearchAndDevelopmentIncentiveProgramMember" unitRef="USD" decimals="0">2022902</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant contextRef="From2015-10-01to2016-09-30_custom_ResearchAndDevelopmentIncentiveProgramMember" unitRef="USD" decimals="0">571093</avxl:NonOperatingIncomeFromGrant>
    <avxl:GainOnSettlementOfAccountsPayable contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:GainOnSettlementOfAccountsPayable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">75204</avxl:GainOnSettlementOfAccountsPayable>
    <avxl:GainOnSettlementOfAccountsPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">151402</avxl:GainOnSettlementOfAccountsPayable>
    <us-gaap:ShareBasedCompensation contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">5517004</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">4135570</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">5062267</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">1252</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">61205</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-3065</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:AccretionExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccretionExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccretionExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">5830</us-gaap:AccretionExpense>
    <avxl:IncreaseDecreaseInGrantsPayables contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:IncreaseDecreaseInGrantsPayables contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-70532</avxl:IncreaseDecreaseInGrantsPayables>
    <avxl:IncreaseDecreaseInGrantsPayables contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-1082</avxl:IncreaseDecreaseInGrantsPayables>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">300292</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">554709</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">775332</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">52396</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">915870</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">155804</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">79279</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">30423</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-54435</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">2507</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-12582406</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-9017231</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-9236823</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">27440257</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">22930638</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">9186814</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-4509619</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">18253443</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-6104162</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">8072787</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">27270674</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">3132661</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">34759</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">101133</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2015-10-01to2016-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">8173920</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">27270674</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">3167420</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-07-05to2018-07-06_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="USD" decimals="0">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">8173920</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">27270674</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">3042360</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">741</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3041619</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7061</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">27263613</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2384</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8171536</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">740523</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7060976</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2383580</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2015-10-01to2016-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">188</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-188</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">49</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-49</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">15</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-15</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">187616</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">48980</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14681</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">6162</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">173</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">173404</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" decimals="0">-167415</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">173577</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2017-10-01to2018-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Shares" decimals="INF">350000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">125062</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">42</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">125020</avxl:SharesIssuedPursuantToExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrantsInShares contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">41687</avxl:SharesIssuedPursuantToExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPursuantToExerciseOfWarrantsInShares contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToExerciseOfWarrantsInShares contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2015-10-01to2016-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1979</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1979</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">53</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-53</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">126</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-126</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1979246</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">52562</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">125748</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">610000</avxl:SharesIssuedPursuantToEmploymentAgreement>
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1000</avxl:SharesIssuedPursuantToEmploymentAgreement>
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2439000</avxl:SharesIssuedPursuantToEmploymentAgreement>
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" decimals="0">-1830000</avxl:SharesIssuedPursuantToEmploymentAgreement>
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreement contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2015-10-01to2016-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2</avxl:SharesIssuedForRoundingInConnectionWithReverseSplit>
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2</avxl:SharesIssuedForRoundingInConnectionWithReverseSplit>
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplit contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplitInShares contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1437</avxl:SharesIssuedForRoundingInConnectionWithReverseSplitInShares>
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplitInShares contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <avxl:SharesIssuedForRoundingInConnectionWithReverseSplitInShares contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">5517004</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">4135570</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4135570</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5517004</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2016-10-01to2017-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2016-10-01to2017-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2016-10-01to2017-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">78</avxl:SharesIssuedUponExerciseOfWarrantsCashless>
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2017-10-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-78</avxl:SharesIssuedUponExerciseOfWarrantsCashless>
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2017-10-01to2018-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashless contextRef="From2017-10-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashlessInShares contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <avxl:SharesIssuedUponExerciseOfWarrantsCashlessInShares contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">78646</avxl:SharesIssuedUponExerciseOfWarrantsCashlessInShares>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Business Description and Basis of Presentation&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Business&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Anavex&#13;Life Sciences Corp. (the &amp;#8220;Company&amp;#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated&#13;therapeutics by applying precision medicine to central nervous system (&amp;#8220;CNS&amp;#8221;) diseases with high unmet need. Anavex&#13;analyzes genomic data from clinical studies to identify biomarkers, which select patients that will receive the therapeutic benefit&#13;for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&amp;#8217;s lead compound ANAVEX 2-73 is being&#13;developed to treat Alzheimer&amp;#8217;s disease, Parkinson&amp;#8217;s disease and potentially other central nervous system diseases,&#13;including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked&#13;gene, methyl-CpG-binding protein 2 (&amp;#8220;MECP2&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basis&#13;of Presentation&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission&#13;(&amp;#8220;SEC&amp;#8221;) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted&#13;in the United States of America (&amp;#8220;GAAP&amp;#8221;).&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Liquidity&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;All&#13;of the Company&amp;#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its&#13;research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved&#13;for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.&#13;The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,&#13;if ever, our business might become profitable.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will&#13;be sufficient to meet its cash commitments for at least the next two years after the date that these consolidated financial statements&#13;are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain. The assumptions&#13;upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the&#13;Company&amp;#8217;s expenditures will vary depending upon a number of factors including but not limited to the design, timing and&#13;duration of future clinical trials, the progress of the Company&amp;#8217;s research and development programs and the level of financial&#13;resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical&#13;trials.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development&#13;programs. Such capital may not be available on commercially acceptable terms, if at all. The Company believes that it will be&#13;able to obtain additional working capital to fund future operations through current financing commitments from third parties,&#13;or through other arrangements; however, there can be no assurance that such additional financing, if available, can be obtained&#13;on terms acceptable to the Company. If the Company is unable to obtain such additional financing, future operations would need&#13;to be scaled back.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&amp;#160;2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Summary of Significant Accounting Policies&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Use&#13;    of Estimates&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of financial statements in accordance with United States GAAP requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of&#13;revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income&#13;tax asset valuations, asset impairment, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions&#13;on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the&#13;results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs&#13;and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially&#13;and adversely from the Company&amp;#8217;s estimates. To the extent there are material differences between the estimates and the actual&#13;results, future results of operations will be affected.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Principles&#13;    of Consolidation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex&#13;Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the&#13;laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company&#13;transactions and balances have been eliminated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;c)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Cash&#13;    and equivalents&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;The&#13;Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months&#13;from the date of purchase to be cash equivalents&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;d)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Research&#13;    and Development Expenses&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&amp;#8217;s proprietary research&#13;and development efforts, including salaries, facilities costs, overhead costs and other related expenses, as well as costs incurred&#13;in connection with third-party collaboration efforts. Milestone payments made by the Company to third parties are expensed when&#13;the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard&#13;Codification (&amp;#8220;ASC&amp;#8221;) 730, Research and Development, as these materials have no alternative future use outside of their&#13;intended use.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks.&#13;The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents&#13;and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the&#13;development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due&#13;to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus&#13;are expensed as incurred within general and administrative expenses.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;e)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Research&#13;    and Development Incentive Income&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company is eligible to obtain a research and development tax credit from the Australian Tax Authority (the &amp;#8220;ATO&amp;#8221;)&#13;for certain research and development activities undertaken in Australia. The tax incentive is available on the basis of specific&#13;criteria with which the Company must comply. Although the tax incentive is administered through the ATO, the Company has accounted&#13;for the tax incentive outside of the scope of ASC Topic 740, Income Taxes, since the incentive is not linked to the Company&amp;#8217;s&#13;income tax liability and can be realized regardless of whether the Company has generated taxable income in Australia. The Company&#13;recognizes as other income the amount received for qualified expenses in the period they are received.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;f)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Basic&#13;    and Diluted Loss per Share&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic&#13;loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common&#13;shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except&#13;that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into&#13;shares of common stock that were outstanding during the period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of September 30, 2018, loss per share excludes 7,185,296 (2017 &amp;#8211; 6,711,339) potentially dilutive common shares related to&#13;outstanding options and warrants, as their effect was anti-dilutive.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;g)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Financial&#13;    Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;carrying value of the Company&amp;#8217;s financial instruments, consisting of cash and equivalents and accounts payable and accrued&#13;liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management&amp;#8217;s&#13;opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;h)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Foreign&#13;    Currency Translation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars&#13;at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when&#13;the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates&#13;prevailing at the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income&#13;in the period in which they occur.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined&#13;that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian&#13;dollar.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Grant&#13;    Income&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development incentive income is recognized when the research and development activities have been undertaken and the Company&#13;has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income&#13;at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government&#13;and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized&#13;in the consolidated statement of operations in the period they are earned and when the related research and development costs&#13;are incurred.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;j)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Income&#13;    Taxes&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (&amp;#8220;ASC 740&amp;#8221;)&#13;which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax&#13;assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial&#13;statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities&#13;are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are&#13;expected to be recovered or settled.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes&#13;tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the&#13;tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater&#13;than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and&#13;all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors&#13;when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately&#13;anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax&#13;positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;k)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Stock-based&#13;    Compensation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for all stock-based payments and awards under the fair value method.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based&#13;payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments&#13;issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees&#13;is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting&#13;period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments.&#13;Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based&#13;payments to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date,&#13;unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees&#13;will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their&#13;vesting period with a corresponding increase to additional paid-in capital.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the&#13;grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes&#13;in these assumptions can materially affect the fair value estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;l)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Fair&#13;    Value Measurements&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last&#13;unobservable, that may be used to measure fair value which are the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for&#13;identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable&#13;or whose significant value drivers are observable; and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant&#13;to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the&#13;short-term maturity of those instruments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2018 and 2017, the Company did not have any Level 3 assets or liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;m)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Recent&#13;    Accounting Pronouncements&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recently&#13;Adopted Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;November 2015, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2015-17 &amp;#8220;&lt;i&gt;Income Taxes: Balance Sheet&#13;Classification of Deferred Taxes&lt;/i&gt;&amp;#8221; (&amp;#8220;ASU 2015-17&amp;#8221;). ASU 2015-17 eliminates the requirement to bifurcate deferred&#13;taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified&#13;as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15,&#13;2016, and for interim periods within those fiscal years. The Company adopted this standard on October 1, 2017. The adoption of&#13;this standard did not have any impact on the Company&amp;#8217;s financial position, results of operations or cash flows for any period&#13;presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2016, the FASB issued ASC 2016-09, &amp;#8220;&lt;i&gt;Compensation &amp;#8211; Stock Compensation (Topic 718) &amp;#8211; Improvements to&#13;Employee Share-Based Payment Accounting&lt;/i&gt;&amp;#8221;. These amendments are intended to simplify several aspects of the accounting&#13;for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities,&#13;and classification on the statement of cash flows. The Company adopted this standard on October 1, 2017. The adoption of this&#13;standard did not have a material impact on the Company&amp;#8217;s financial position, results of operations or cash flows for any&#13;period presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;November 2016, the FASB issued ASU 2016-18, &amp;#8220;Statement of Cash Flows (Topic 230): Restricted Cash&amp;#8221; (&amp;#8220;ASU 2016-18&amp;#8221;).&#13;ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents,&#13;and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted&#13;cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period&#13;and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after&#13;December 15, 2017. Early adoption is permitted. The Company early adopted this standard on October 1, 2017. The adoption of this&#13;standard did not have any material affect on the Company&amp;#8217;s consolidated financial statements.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;SEC staff issued Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) 118, which provides guidance on accounting for the tax effects&#13;of the U.S. tax reform announced on December 22, 2017 by the U.S. Government commonly referred to as the Tax Cuts and Jobs Act.&#13;SAB 118 provides a measurement period that should not extend beyond one year from the U.S. tax reform enactment date for companies&#13;to complete the accounting under Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 740. In accordance with SAB 118, a company&#13;must reflect the income tax effects of those aspects of the U.S. tax reform for which the accounting under ASC 740 is complete.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Specifically,&#13;the Company was required to revalue its U.S. deferred tax assets and liabilities due to the federal income tax rate reduction&#13;from 35 percent to 21 percent. Since the Company has provided a full valuation allowance against its deferred tax assets, the&#13;revaluation of the deferred tax assets did not have a material impact on any period presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition&#13;from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition&#13;guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017.&#13;The new guidance is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard&#13;is not expected to have a material impact for any period presented and the Company will apply this standard to all future revenues.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued Accounting Standards Update No. 2016-02, &lt;i&gt;Leases&lt;/i&gt;. The guidance would require lessees to recognize&#13;most leases on their balance sheets as lease liabilities with corresponding right &amp;#8211;of use assets. The guidance is effective&#13;for annual and interim reporting periods beginning on or after December 15, 2018. The new guidance is effective for the Company&#13;on a prospective basis beginning on October 1, 2019. The Company is currently evaluating the impact this guidance will have on&#13;its financial condition, results of operations and cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2017, the FASB issued ASU No. 2017-09, &amp;#8220;Compensation&amp;#8211;Stock Compensation (Topic 718): Scope of Modification Accounting,&amp;#8221;&#13;clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The&#13;new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the&#13;same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for the Company&#13;on a prospective basis beginning on October 1, 2018, with early adoption permitted. The Company is currently evaluating the impact&#13;this guidance will have on its financial condition, results of operations and cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-based Payments&#13;(&amp;#8220;ASU 2018-07&amp;#8221;). This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring&#13;goods and services from nonemployees. The effective date for the standard is for interim periods in fiscal years beginning after&#13;December 15, 2018, with early adoption permitted, but no earlier than the Company&amp;#8217;s adoption date of Topic 606. The new&#13;guidance is effective for the Company beginning on October 1, 2019. The new guidance is required to be applied retrospectively&#13;with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the effect ASU 2018-07&#13;will have on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant&#13;impact on its results of operations, financial position or cash flow.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Other Income&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Grant&#13;Income&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Clinical&#13;Study Grant&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received&#13;in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for&#13;a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;grant income is deferred when received and amortized to other income as the related research and development expenditures are&#13;incurred. During the year ended September 30, 2018, the Company recognized $149,055 (2017: $Nil; 2016$Nil) of this grant on its&#13;statement of operations within grant income.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Preclinical&#13;Study Grant&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2015, the Company was awarded grant funding in the amount of $286,455. The grant was received in&#13;exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential&#13;treatment for Parkinson&amp;#8217;s disease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;grant income was deferred and amortized to other income over the related commitment period as the related research and development&#13;expenditures were incurred. During the year ended September 30, 2018, the Company recognized $Nil (2017: $140,942; 2016: $141,195)&#13;of this grant on its statement of operations within grant income.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development tax incentive&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2018, the Company received other income of $1,629,513 (2017: $2,022,902; 2016: $571,093) in respect&#13;of a research and development incentive program offered by the Australian government.&lt;/font&gt;&lt;/p&gt;</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Equity Offering Agreements&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Controlled&#13;Equity Offering Sales Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;July 6, 2018, the Company entered into a Controlled Equity Offering Sales Agreement (the &amp;#8220;Sales Agreement&amp;#8221;) with Cantor&#13;Fitzgerald &amp;#38; Co., as agent (&amp;#8220;Cantor Fitzgerald&amp;#8221;), pursuant to which the Company may offer and sell shares of common&#13;stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the &amp;#8220;Offering&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon&#13;delivery of a placement notice based on the Company&amp;#8217;s instructions and subject to the terms and conditions of the Sales&#13;Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an &amp;#8220;at the market offering&amp;#8221; offering, in&#13;negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,&#13;or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.&#13;The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend&#13;or terminate the offering of Shares upon notice to the other party, subject to certain conditions. Cantor Fitzgerald will act&#13;as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable&#13;state and federal law, rules and regulations and the rules of Nasdaq.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds&#13;from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Cantor Fitzgerald with customary&#13;indemnification and contribution rights. During the year ended September 30, 2018, the Company incurred $101,133 in legal and&#13;accounting fees associated with the Sales Agreement. This amount is included in deferred costs at September 30, 2018&#13;and is expected to be reclassified to share capital upon issuance of shares under the Sales Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Purchase&#13;Agreement&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &amp;#8220;2015 Purchase Agreement&amp;#8221;) with Lincoln&#13;Park Capital Fund, LLC (&amp;#8220;Lincoln Park&amp;#8221;), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln&#13;Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period&#13;starting from the effective date of the respective registration statement, to September 6, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of&#13;common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount&#13;of a purchase may be increased under certain circumstances provided, however that Lincoln Park&amp;#8217;s committed obligation under&#13;any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will&#13;be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;consideration for entering into the 2015 Purchase Agreement, the Company issued to Lincoln Park 179,598 shares of common stock&#13;as a commitment fee and agreed to issue up to 89,799 shares pro rata, when and if, Lincoln Park purchases at the Company&amp;#8217;s&#13;discretion the $50,000,000 aggregate commitment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2018, the Company issued to Lincoln Park an aggregate of 2,398,261 (2017: 7,109,956; 2016: 452,437)&#13;shares of common stock under the Purchase Agreement, including 2,383,580 (2017: 7,060,976; 2016: 450,000) shares of common stock&#13;for an aggregate purchase price of $8,173,920 (2017 $27,270,674; 2016: $1,357,800) and 14,681 (2017: 48,980; 2016: 2,437) commitment&#13;shares. At September 30, 2018, an amount of $13,197,607 remained available under the 2015 Purchase Agreement.&lt;/font&gt;&lt;/p&gt;</avxl:EquityOfferingAgreementsTextBlock>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Commitments&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000"&gt;a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000"&gt;Lease&#13;    Commitment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has entered into an office lease agreement expiring March 31, 2019. The Company is committed to lease commitments as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 80%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fiscal&#13;    year ending September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2018 the Company recorded rent expense of $151,405 (2017: $127,993, 2016: $125,317) which is included&#13;in general and administrative expenses on the consolidated statement of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000"&gt;b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000"&gt;Litigation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;The&#13;Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently&#13;uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that&#13;the resolution of any such matter will not have a material adverse effect upon the Company&amp;#8217;s consolidated financial statements.&#13;The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its&#13;consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000"&gt;c)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000"&gt;Share&#13;    Purchase Warrants&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of the Company&amp;#8217;s outstanding share purchase warrants is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 71%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,&#13;    October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,272,890&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,463,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,809,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,September 30,&#13;    2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,609,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(756,143&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(524,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,&#13;    September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2018, the Company had 678,379 share purchase warrants outstanding, with a weighted average exercise price of $2.87&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 41.75pt"&gt;&lt;/td&gt;&lt;td style="width: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 67%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February&#13;    24, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;277,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 13, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 13, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 41.75pt"&gt;&lt;/td&gt;&lt;td style="width: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2018, 350,000 options granted to a consultant to the Company were converted to 350,000 warrants with&#13;the same exercise price.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2018, an aggregate of 737,393 share purchase warrants at $3.00 per share and 18,750 share purchase&#13;warrants at $1.24 per share were exercised on a cashless basis, pursuant to which the Company issued 125,748 shares of common&#13;stock and an additional 80,981 shares of common stock were to be issued. The remaining 524,787 share purchase warrants exercisable&#13;at $3.00 per share until July 5, 2018 expired unexercised.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2017, 200,000 share purchase warrants were cashless exercised, resulting in the issuance of 52,562&#13;shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2016, the Company issued 1,979,246 shares of common stock pursuant to the exercise of 2,421,894 share&#13;purchase warrants on a cashless basis, and 41,687 shares of common stock pursuant to the exercise of warrants for cash.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;d)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Stock&amp;#8211;based&#13;    Compensation Plan&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&#13;Stock Option Plan&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;September 18, 2015, the Company&amp;#8217;s board of directors approved a 2015 Omnibus Incentive Plan (the &amp;#8220;2015 Plan&amp;#8221;),&#13;which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of&#13;the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event&#13;of a change of the Company&amp;#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will&#13;be granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing&#13;stock option plans remain outstanding in accordance with their terms.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;2015 Plan provides that it may be administered by the board of directors, or the board of directors may delegate such responsibility&#13;to a committee. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to&#13;the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be&#13;less than 110% of fair market value of the Company&amp;#8217;s shares of common stock on the grant date. Stock options may be granted&#13;under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may&#13;be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of Company&amp;#8217;s outstanding stock purchase options is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 54%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,822,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,401,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,199,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,107,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(214,470&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.09&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,092,030&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,730,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.09&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(164,280&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(150,833&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    at September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,108,028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,326,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2018, the following stock options were outstanding:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intrinsic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Life&#13;    (yrs)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 5,&#13;    2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;565,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 7, 2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;125,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;125,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 8, 2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;176,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;618,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;618,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,119,938&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 8, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 15, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 18, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 2, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 16, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.90&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 31, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 27, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;379,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,083&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 5, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;861,429&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;574,286&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 18, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;906,696&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;906,696&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 22, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,999&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 3, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 9, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 7, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 17, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;774,166&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;389,170&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 12, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,209&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;August 9, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 19, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;540,834&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;135,834&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 13, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,334&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 19, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;780,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 15, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;335,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;August&#13;    6, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,108,028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,353,088&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market&#13;price of the Company&amp;#8217;s stock for the options that were in-the-money at September 30, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company recognized stock-based compensation expense of $5,517,004 during the year ended September 30, 2018 (2017: $4,135,570;&#13;2016: $4,452,267) in connection with the issuance and vesting of stock options and warrants in exchange for services, and $Nil&#13;(2017: $Nil 2016: $610,000), in connection with the vesting of restricted stock in exchange for services. These amounts have been&#13;included in general and administrative expenses and research and development expenses on the Company&amp;#8217;s statement of operations&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General&#13;    and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,699,557&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,017,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,208,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;    and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,817,447&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,118,371&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,854,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    share based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,517,004&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,135,570&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,062,267&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;An&#13;amount of approximately $6,827,054 in stock-based compensation is expected to be recorded over the remaining term of such options&#13;through June 30, 2021.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following&#13;weighted average assumptions:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.73&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options&#13;    (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;106.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;111.58&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;114.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of restricted stock compensation charges recognized during the years ended September 30, 2018, 2017 and 2016 was determined&#13;with reference to the quoted market price of the Company&amp;#8217;s shares on the commitment date.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;US&#13;Tax Reform&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (&amp;#8220;Tax Reform Act&amp;#8221;).&#13;The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a&#13;territorial tax system and imposing a transition tax on deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act&#13;permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities&#13;are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of&#13;existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted&#13;tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued&#13;its ending net deferred tax assets at September 30, 2018. The Company did not need to recognize any provisional tax expense for&#13;the year ended September 30, 2018 as it has recorded a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Tax Reform Act also provided for a one-time deemed mandatory repatriation of post &amp;#8211; 1986 undistributed foreign subsidiary&#13;earnings and profits (&amp;#8220;E&amp;#38;P&amp;#8221;) as well as Global Intangible Low-Taxed Income (&amp;#8220;GILTI&amp;#8221;) and Base-Erosion&#13;Anti-Abuse provisions. The Company had no adjustments related to these latter noted provisions at September 30, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;tax effects of the temporary differences that give rise to the Company&amp;#8217;s estimated deferred tax assets and liabilities are&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Assumed&#13;    Tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net operating loss&#13;    carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,123,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,240,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,223,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&#13;    tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,605,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,344,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,036,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign exchange and&#13;    other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unpaid charges&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;72,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;28,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;152,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible asset costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;28,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;51,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,152,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,394,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation&#13;    allowance for deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(15,993,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(19,032,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,447,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;provision for income taxes differ from the amount established using the statutory income tax rate as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income&#13;    benefit at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,215,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,577,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,010,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign income taxed&#13;    at other rates&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(173,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;132,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-deductible&#13;    finance and accretion expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-deductible&#13;    compensation costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;738,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&#13;    tax credit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(77,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(23,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;628,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry of foreign net&#13;    operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;333,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Adjustment and true&#13;    up to prior years&amp;#8217; tax provision&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;336,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(55,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;176,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effect of changes in&#13;    tax rates&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,166,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(11,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change&#13;    in valuation allowance related to current year provision&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,038,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,585,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,009,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income&#13;    Tax Recovery&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of September 30, 2018, the Company had net operating loss carry-forwards of approximately $50,557,000 (2017: $41,000,000; 2016:&#13;$33,000,000) in the United States, approximately $986,000 (Approximately AUD$1,365,000) (2017: $850,000; 2016: $250,000) in Australia&#13;and approximately $638,000 (Approximately &amp;#8364;549,000) (2017: $13,000; 2016: $Nil) in Germany, available to offset future taxable&#13;income in those jurisdictions. The carry-forwards will begin to expire in 2027.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company evaluates its valuation allowance requirements based on projected future operations. When circumstances change, and this&#13;causes a change in management&amp;#8217;s judgment about the recoverability of deferred tax assets, the impact of the change on the&#13;valuation allowance is reflected in current income. Because management of the Company does not currently believe that it is more&#13;likely than not that the Company will receive the benefit of these assets, a valuation allowance equal to the deferred tax asset&#13;has been established at September 30, 2018, 2017 and 2016.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Uncertain&#13;Tax Positions&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company&amp;#8217;s&#13;tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities&#13;until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation&#13;years commencing on or after 2009.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Certain&#13;of the Company&amp;#8217;s net operating loss carryforwards &lt;font style="background-color: white"&gt;in the United States may be subject&#13;to limitations by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces&#13;the Company&amp;#8217;s ability to utilize net operating loss carry-forwards, under certain circumstances. The Company completed a&#13;Section 382 analysis through the fiscal year ended September 30, 2018 and currently does not believe Section 382 will apply to&#13;limit the utilization of these tax losses.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Note&#13;    7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Supplemental Cash Flow Information&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Investing&#13;and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;the year ended September 30, 2016;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;the Company issued&#13;    6,162 shares of common stock upon conversion of $6,162 in principal amount of convertible debentures at a conversion price&#13;    of $1.00 per share and 167,415 shares of common stock pursuant to the application of an incorrect conversion price for conversion&#13;    notices received during the year ended September 30, 2015.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Use&#13;    of Estimates&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;preparation of financial statements in accordance with United States GAAP requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of&#13;revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income&#13;tax asset valuations, asset impairment, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions&#13;on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the&#13;results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs&#13;and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially&#13;and adversely from the Company&amp;#8217;s estimates. To the extent there are material differences between the estimates and the actual&#13;results, future results of operations will be affected.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Principles&#13;    of Consolidation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex&#13;Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the&#13;laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company&#13;transactions and balances have been eliminated.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;c)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Cash&#13;    and equivalents&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;The&#13;Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months&#13;from the date of purchase to be cash equivalents&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;d)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Research&#13;    and Development Expenses&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&amp;#8217;s proprietary research&#13;and development efforts, including salaries, facilities costs, overhead costs and other related expenses, as well as costs incurred&#13;in connection with third-party collaboration efforts. Milestone payments made by the Company to third parties are expensed when&#13;the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard&#13;Codification (&amp;#8220;ASC&amp;#8221;) 730, Research and Development, as these materials have no alternative future use outside of their&#13;intended use.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks.&#13;The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents&#13;and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the&#13;development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due&#13;to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus&#13;are expensed as incurred within general and administrative expenses.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionIncentives contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;e)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Research&#13;    and Development Incentive Income&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company is eligible to obtain a research and development tax credit from the Australian Tax Authority (the &amp;#8220;ATO&amp;#8221;)&#13;for certain research and development activities undertaken in Australia. The tax incentive is available on the basis of specific&#13;criteria with which the Company must comply. Although the tax incentive is administered through the ATO, the Company has accounted&#13;for the tax incentive outside of the scope of ASC Topic 740, Income Taxes, since the incentive is not linked to the Company&amp;#8217;s&#13;income tax liability and can be realized regardless of whether the Company has generated taxable income in Australia. The Company&#13;recognizes as other income the amount received for qualified expenses in the period they are received.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionIncentives>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;f)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Basic&#13;    and Diluted Loss per Share&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic&#13;loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common&#13;shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except&#13;that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into&#13;shares of common stock that were outstanding during the period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As&#13;of September 30, 2018, loss per share excludes 7,185,296 (2017 &amp;#8211; 6,711,339) potentially dilutive common shares related to&#13;outstanding options and warrants, as their effect was anti-dilutive.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;g)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Financial&#13;    Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;carrying value of the Company&amp;#8217;s financial instruments, consisting of cash and equivalents and accounts payable and accrued&#13;liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management&amp;#8217;s&#13;opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;h)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Foreign&#13;    Currency Translation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars&#13;at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when&#13;the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates&#13;prevailing at the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income&#13;in the period in which they occur.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined&#13;that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian&#13;dollar.&lt;/font&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <avxl:GrantIncomePolicy contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Grant&#13;    Income&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;and development incentive income is recognized when the research and development activities have been undertaken and the Company&#13;has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income&#13;at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government&#13;and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized&#13;in the consolidated statement of operations in the period they are earned and when the related research and development costs&#13;are incurred.&lt;/font&gt;&lt;/p&gt;</avxl:GrantIncomePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;j)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Income&#13;    Taxes&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (&amp;#8220;ASC 740&amp;#8221;)&#13;which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax&#13;assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial&#13;statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities&#13;are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are&#13;expected to be recovered or settled.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes&#13;tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the&#13;tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater&#13;than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and&#13;all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors&#13;when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately&#13;anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax&#13;positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;k)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Stock-based&#13;    Compensation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for all stock-based payments and awards under the fair value method.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based&#13;payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments&#13;issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees&#13;is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting&#13;period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments.&#13;Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based&#13;payments to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date,&#13;unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees&#13;will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their&#13;vesting period with a corresponding increase to additional paid-in capital.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the&#13;grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes&#13;in these assumptions can materially affect the fair value estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;l)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Fair&#13;    Value Measurements&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last&#13;unobservable, that may be used to measure fair value which are the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for&#13;identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable&#13;or whose significant value drivers are observable; and&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&#13;3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant&#13;to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the&#13;short-term maturity of those instruments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2018 and 2017, the Company did not have any Level 3 assets or liabilities.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2017-10-01to2018-09-30">&lt;table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;m)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif; color: #000000"&gt;Recent&#13;    Accounting Pronouncements&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recently&#13;Adopted Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;November 2015, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2015-17 &amp;#8220;&lt;i&gt;Income Taxes: Balance Sheet&#13;Classification of Deferred Taxes&lt;/i&gt;&amp;#8221; (&amp;#8220;ASU 2015-17&amp;#8221;). ASU 2015-17 eliminates the requirement to bifurcate deferred&#13;taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified&#13;as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15,&#13;2016, and for interim periods within those fiscal years. The Company adopted this standard on October 1, 2017. The adoption of&#13;this standard did not have any impact on the Company&amp;#8217;s financial position, results of operations or cash flows for any period&#13;presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2016, the FASB issued ASC 2016-09, &amp;#8220;&lt;i&gt;Compensation &amp;#8211; Stock Compensation (Topic 718) &amp;#8211; Improvements to&#13;Employee Share-Based Payment Accounting&lt;/i&gt;&amp;#8221;. These amendments are intended to simplify several aspects of the accounting&#13;for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities,&#13;and classification on the statement of cash flows. The Company adopted this standard on October 1, 2017. The adoption of this&#13;standard did not have a material impact on the Company&amp;#8217;s financial position, results of operations or cash flows for any&#13;period presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;November 2016, the FASB issued ASU 2016-18, &amp;#8220;Statement of Cash Flows (Topic 230): Restricted Cash&amp;#8221; (&amp;#8220;ASU 2016-18&amp;#8221;).&#13;ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents,&#13;and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted&#13;cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period&#13;and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after&#13;December 15, 2017. Early adoption is permitted. The Company early adopted this standard on October 1, 2017. The adoption of this&#13;standard did not have any material affect on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;SEC staff issued Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) 118, which provides guidance on accounting for the tax effects&#13;of the U.S. tax reform announced on December 22, 2017 by the U.S. Government commonly referred to as the Tax Cuts and Jobs Act.&#13;SAB 118 provides a measurement period that should not extend beyond one year from the U.S. tax reform enactment date for companies&#13;to complete the accounting under Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 740. In accordance with SAB 118, a company&#13;must reflect the income tax effects of those aspects of the U.S. tax reform for which the accounting under ASC 740 is complete.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Specifically,&#13;the Company was required to revalue its U.S. deferred tax assets and liabilities due to the federal income tax rate reduction&#13;from 35 percent to 21 percent. Since the Company has provided a full valuation allowance against its deferred tax assets, the&#13;revaluation of the deferred tax assets did not have a material impact on any period presented.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition&#13;from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition&#13;guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017.&#13;The new guidance is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard&#13;is not expected to have a material impact for any period presented and the Company will apply this standard to all future revenues.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued Accounting Standards Update No. 2016-02, &lt;i&gt;Leases&lt;/i&gt;. The guidance would require lessees to recognize&#13;most leases on their balance sheets as lease liabilities with corresponding right &amp;#8211;of use assets. The guidance is effective&#13;for annual and interim reporting periods beginning on or after December 15, 2018. The new guidance is effective for the Company&#13;on a prospective basis beginning on October 1, 2019. The Company is currently evaluating the impact this guidance will have on&#13;its financial condition, results of operations and cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2017, the FASB issued ASU No. 2017-09, &amp;#8220;Compensation&amp;#8211;Stock Compensation (Topic 718): Scope of Modification Accounting,&amp;#8221;&#13;clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The&#13;new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the&#13;same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for the Company&#13;on a prospective basis beginning on October 1, 2018, with early adoption permitted. The Company is currently evaluating the impact&#13;this guidance will have on its financial condition, results of operations and cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-based Payments&#13;(&amp;#8220;ASU 2018-07&amp;#8221;). This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring&#13;goods and services from nonemployees. The effective date for the standard is for interim periods in fiscal years beginning after&#13;December 15, 2018, with early adoption permitted, but no earlier than the Company&amp;#8217;s adoption date of Topic 606. The new&#13;guidance is effective for the Company beginning on October 1, 2019. The new guidance is required to be applied retrospectively&#13;with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the effect ASU 2018-07&#13;will have on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant&#13;impact on its results of operations, financial position or cash flow.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;The&#13;Company has entered into an office lease agreement expiring March 31, 2019. The Company is committed to lease commitments as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 80%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fiscal&#13;    year ending September 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70,022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of the Company&amp;#8217;s outstanding share purchase warrants is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 71%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,&#13;    October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,272,890&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,463,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September&#13;    30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,809,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,September 30,&#13;    2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,609,309&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(756,143&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(524,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,&#13;    September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2018, the Company had 678,379 share purchase warrants outstanding, with a weighted average exercise price of $2.87&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 41.75pt"&gt;&lt;/td&gt;&lt;td style="width: 0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&#13;    Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 67%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February&#13;    24, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;277,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 13, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 13, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June&#13;    30, 2021&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;678,379&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;At&#13;September 30, 2018, the following stock options were outstanding:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intrinsic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry&#13;    Date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Life&#13;    (yrs)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 30%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 5,&#13;    2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;565,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 7, 2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;125,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;125,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 8, 2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;176,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;618,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;618,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,119,938&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 8, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 15, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 18, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 30, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 2, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 16, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.90&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 31, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 27, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;June 30, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;379,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253,083&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 5, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;861,429&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;574,286&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;July 18, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;906,696&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;906,696&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 22, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,999&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 3, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 9, 2026&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 7, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 17, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;774,166&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;389,170&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 12, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,209&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;August 9, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;September 19, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;540,834&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;135,834&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 13, 2027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33,334&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 19, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;780,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;May 15, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;335,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;August&#13;    6, 2028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,108,028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,353,088&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These&#13;amounts have been included in general and administrative expenses and research and development expenses on the Company&amp;#8217;s&#13;statement of operations as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General&#13;    and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,699,557&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,017,199&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,208,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research&#13;    and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,817,447&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,118,371&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,854,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    share based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,517,004&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,135,570&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,062,267&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following&#13;weighted average assumptions:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free&#13;    interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.73&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options&#13;    (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;106.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;111.58&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;114.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;tax effects of the temporary differences that give rise to the Company&amp;#8217;s estimated deferred tax assets and liabilities are&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Assumed&#13;    Tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-style: italic"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net operating loss&#13;    carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,123,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,240,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,223,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&#13;    tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,605,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,344,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,036,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign exchange and&#13;    other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;13,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unpaid charges&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;72,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;28,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;152,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible asset costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;28,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;51,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,152,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,394,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation&#13;    allowance for deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(15,993,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(19,032,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,447,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;provision for income taxes differ from the amount established using the statutory income tax rate as follows:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 61%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income&#13;    benefit at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,215,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,577,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,010,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign income taxed&#13;    at other rates&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(173,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;132,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-deductible&#13;    finance and accretion expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-deductible&#13;    compensation costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;738,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&#13;    tax credit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(77,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(23,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;628,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry of foreign net&#13;    operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;333,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Adjustment and true&#13;    up to prior years&amp;#8217; tax provision&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;336,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(55,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;176,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effect of changes in&#13;    tax rates&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,166,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(11,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change&#13;    in valuation allowance related to current year provision&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,038,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,585,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,009,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income&#13;    Tax Recovery&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="From2017-10-01to2018-09-30" unitRef="Shares" decimals="INF">7185296</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="From2016-10-01to2017-09-30" unitRef="Shares" decimals="INF">6711339</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <avxl:FundingOfDeferredIncomeAwardedGrant contextRef="From2017-10-01to2018-09-30_custom_ClinicalStudyGrantMember" unitRef="USD" decimals="0">149055</avxl:FundingOfDeferredIncomeAwardedGrant>
    <avxl:FundingOfDeferredIncomeAwardedGrant contextRef="From2016-10-01to2017-09-30_custom_ClinicalStudyGrantMember" unitRef="USD" xsi:nil="true" />
    <avxl:FundingOfDeferredIncomeAwardedGrant contextRef="From2015-10-01to2016-09-30_custom_ClinicalStudyGrantMember" unitRef="USD" xsi:nil="true" />
    <avxl:FundingOfDeferredIncomeAwardedGrant contextRef="From2017-10-01to2018-09-30_custom_PreclinicalStudyGrantMember" unitRef="USD" xsi:nil="true" />
    <avxl:FundingOfDeferredIncomeAwardedGrant contextRef="From2016-10-01to2017-09-30_custom_PreclinicalStudyGrantMember" unitRef="USD" decimals="0">140942</avxl:FundingOfDeferredIncomeAwardedGrant>
    <avxl:FundingOfDeferredIncomeAwardedGrant contextRef="From2015-10-01to2016-09-30_custom_PreclinicalStudyGrantMember" unitRef="USD" decimals="0">141195</avxl:FundingOfDeferredIncomeAwardedGrant>
    <avxl:ValueOfSharesObligatedToPurchase contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:AgreementTerm contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">179598</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-10-01to2018-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">2398261</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-10-01to2017-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">7109956</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-10-01to2016-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">452437</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-10-01to2016-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">41687</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">89799</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2017-10-01to2018-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">2383580</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2016-10-01to2017-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">7060976</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4 contextRef="From2015-10-01to2016-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">450000</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2017-10-01to2018-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">8173920</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2016-10-01to2017-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">27270674</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3 contextRef="From2015-10-01to2016-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">1357800</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2017-10-01to2018-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">14681</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2016-10-01to2017-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">48980</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3 contextRef="From2015-10-01to2016-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">2437</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4 contextRef="From2017-10-01to2018-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">13197607</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:PercentageOfGrossProceedsFromSales contextRef="From2017-10-01to2018-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="Pure" decimals="INF">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:LegalFees contextRef="From2017-10-01to2018-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" unitRef="USD" decimals="0">101133</us-gaap:LegalFees>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">70022</us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsReceivable contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">70022</us-gaap:OperatingLeasesFutureMinimumPaymentsReceivable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2015-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">4272890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">1809309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2017-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">1609309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">678379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="From2015-10-01to2016-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-2463581</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="From2016-10-01to2017-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-200000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-756143</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">350000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">-524787</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">2.11</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">2.70</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">2.66</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">2.87</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice contextRef="From2015-10-01to2016-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">1.67</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice contextRef="From2016-10-01to2017-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.00</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">2.96</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">4.19</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.00</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">678379</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrants1Member" unitRef="Shares" decimals="INF">30000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrants2Member" unitRef="Shares" decimals="INF">277127</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrants3Member" unitRef="Shares" decimals="INF">1252</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrants4Member" unitRef="Shares" decimals="INF">12500</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrants5Member" unitRef="Shares" decimals="INF">7500</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_PurchaseWarrants6Member" unitRef="Shares" decimals="INF">350000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrants1Member" unitRef="USDPShares" decimals="INF">4.00</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrants2Member" unitRef="USDPShares" decimals="INF">1.20</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrants3Member" unitRef="USDPShares" decimals="INF">1.68</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrants4Member" unitRef="USDPShares" decimals="INF">1.24</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrants5Member" unitRef="USDPShares" decimals="INF">1.04</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrants6Member" unitRef="USDPShares" decimals="INF">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrants1Member">2019-02-24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrants2Member">2019-03-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrants3Member">2019-03-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrants4Member">2019-05-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrants5Member">2019-05-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrants6Member">2021-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_us-gaap_EmployeeStockOptionMember">2023-07-05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption1Member">2024-05-07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption2Member">2024-05-08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption3Member">2025-04-02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption4Member">2025-06-08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption5Member">2025-06-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption6Member">2025-09-18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption7Member">2025-09-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption8Member">2025-10-02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption9Member">2025-10-16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption10Member">2025-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption11Member">2026-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption12Member">2026-04-27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption14Member">2026-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption15Member">2026-07-05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption16Member">2026-07-18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption17Member">2026-09-22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption18Member">2026-10-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption19Member">2026-12-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption20Member">2027-02-07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption21Member">2027-02-17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption22Member">2027-05-12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption23Member">2027-08-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption24Member">2027-09-19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption25Member">2027-12-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption26Member">2028-03-02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption27Member">2028-03-19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption28Member">2028-05-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption29Member">2028-08-06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1822500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">4199000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">5092030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6506917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption1Member" unitRef="Shares" decimals="INF">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption2Member" unitRef="Shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption3Member" unitRef="Shares" decimals="INF">618750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption4Member" unitRef="Shares" decimals="INF">29167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption5Member" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption6Member" unitRef="Shares" decimals="INF">253750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption7Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption8Member" unitRef="Shares" decimals="INF">31250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption9Member" unitRef="Shares" decimals="INF">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption10Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption11Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption12Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption14Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption15Member" unitRef="Shares" decimals="INF">379625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption16Member" unitRef="Shares" decimals="INF">861429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption17Member" unitRef="Shares" decimals="INF">906696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption18Member" unitRef="Shares" decimals="INF">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption19Member" unitRef="Shares" decimals="INF">8750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption20Member" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption21Member" unitRef="Shares" decimals="INF">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption22Member" unitRef="Shares" decimals="INF">774166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption23Member" unitRef="Shares" decimals="INF">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption24Member" unitRef="Shares" decimals="INF">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption25Member" unitRef="Shares" decimals="INF">540834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption26Member" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption27Member" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption28Member" unitRef="Shares" decimals="INF">780000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption29Member" unitRef="Shares" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-10-01to2016-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">2401500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-10-01to2017-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1107500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">1730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2015-10-01to2016-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2016-10-01to2017-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">214470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">164280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">150833</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2017-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">3326223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">4108028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption1Member" unitRef="USDPShares" decimals="INF">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption2Member" unitRef="USDPShares" decimals="INF">1.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption3Member" unitRef="USDPShares" decimals="INF">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption4Member" unitRef="USDPShares" decimals="INF">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption5Member" unitRef="USDPShares" decimals="INF">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption6Member" unitRef="USDPShares" decimals="INF">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption7Member" unitRef="USDPShares" decimals="INF">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption8Member" unitRef="USDPShares" decimals="INF">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption9Member" unitRef="USDPShares" decimals="INF">8.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption10Member" unitRef="USDPShares" decimals="INF">5.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption11Member" unitRef="USDPShares" decimals="INF">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption12Member" unitRef="USDPShares" decimals="INF">5.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption14Member" unitRef="USDPShares" decimals="INF">6.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption15Member" unitRef="USDPShares" decimals="INF">6.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption16Member" unitRef="USDPShares" decimals="INF">7.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption17Member" unitRef="USDPShares" decimals="INF">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption18Member" unitRef="USDPShares" decimals="INF">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption19Member" unitRef="USDPShares" decimals="INF">4.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption20Member" unitRef="USDPShares" decimals="INF">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption21Member" unitRef="USDPShares" decimals="INF">5.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption22Member" unitRef="USDPShares" decimals="INF">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption23Member" unitRef="USDPShares" decimals="INF">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption24Member" unitRef="USDPShares" decimals="INF">4.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption25Member" unitRef="USDPShares" decimals="INF">3.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption26Member" unitRef="USDPShares" decimals="INF">2.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption27Member" unitRef="USDPShares" decimals="INF">2.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption28Member" unitRef="USDPShares" decimals="INF">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_EmployeeStockOption29Member" unitRef="USDPShares" decimals="INF">2.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-10-01to2016-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">5.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-10-01to2017-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">5.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-10-01to2016-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">14.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2016-10-01to2017-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">4.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">1.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2017-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-10-01to2016-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-10-01to2017-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">5.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member" unitRef="USDPShares" decimals="INF">2.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">4108028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption1Member" unitRef="Shares" decimals="INF">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption2Member" unitRef="Shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption3Member" unitRef="Shares" decimals="INF">618750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption4Member" unitRef="Shares" decimals="INF">29167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption5Member" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption6Member" unitRef="Shares" decimals="INF">253750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption7Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption8Member" unitRef="Shares" decimals="INF">31250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption9Member" unitRef="Shares" decimals="INF">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption10Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption11Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption12Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption14Member" unitRef="Shares" decimals="INF">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption15Member" unitRef="Shares" decimals="INF">253083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption16Member" unitRef="Shares" decimals="INF">574286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption17Member" unitRef="Shares" decimals="INF">906696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption18Member" unitRef="Shares" decimals="INF">39999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption19Member" unitRef="Shares" decimals="INF">8750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption20Member" unitRef="Shares" decimals="INF">16667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption21Member" unitRef="Shares" decimals="INF">23333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption22Member" unitRef="Shares" decimals="INF">389170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption23Member" unitRef="Shares" decimals="INF">5209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption24Member" unitRef="Shares" decimals="INF">6250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption25Member" unitRef="Shares" decimals="INF">135834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption26Member" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption27Member" unitRef="Shares" decimals="INF">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption28Member" unitRef="Shares" decimals="INF">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2018-09-30_custom_EmployeeStockOption29Member" unitRef="Shares" decimals="INF">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="USD" decimals="0">2353088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">565000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption1Member" unitRef="USD" decimals="0">57375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption2Member" unitRef="USD" decimals="0">176250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption3Member" unitRef="USD" decimals="0">1119938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption4Member" unitRef="USD" decimals="0">37625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption5Member" unitRef="USD" decimals="0">48500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption6Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption7Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption8Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption9Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption10Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption11Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption12Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption14Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption15Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption16Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption17Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption18Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption19Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption20Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption21Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption22Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption23Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption24Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption25Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption26Member" unitRef="USD" decimals="0">6500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption27Member" unitRef="USD" decimals="0">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption28Member" unitRef="USD" decimals="0">335400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-09-30_custom_EmployeeStockOption29Member" unitRef="USD" decimals="0">4500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_us-gaap_EmployeeStockOptionMember">P4Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption1Member">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption2Member">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption3Member">P6Y6M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption4Member">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption5Member">P6Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption6Member">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption7Member">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption8Member">P7Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption9Member">P7Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption10Member">P7Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption11Member">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption12Member">P7Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption14Member">P7Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption15Member">P7Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption16Member">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption17Member">P7Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption18Member">P8Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption19Member">P8Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption20Member">P8Y4M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption21Member">P8Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption22Member">P8Y7M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption23Member">P8Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption24Member">P8Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption25Member">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption26Member">P9Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption27Member">P9Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption28Member">P9Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-10-01to2018-09-30_custom_EmployeeStockOption29Member">P9Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">5517004</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">4135570</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">5062267</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-10-01to2018-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">2699557</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-10-01to2017-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">2017199</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-10-01to2016-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">3208220</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-10-01to2018-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">2817447</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-10-01to2017-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">2118371</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-10-01to2016-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">1854047</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-10-01to2018-09-30" unitRef="Pure" decimals="INF">0.0273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.0211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-10-01to2018-09-30">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-10-01to2017-09-30">P6Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-10-01to2016-09-30">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-10-01to2018-09-30" unitRef="Pure" decimals="INF">1.0645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">1.1158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">1.1475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-10-01to2018-09-30" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice contextRef="AsOf2018-09-30" unitRef="USDPShares" decimals="INF">2.87</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.00</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice>
    <avxl:ClassOfWarrantOrRighstExpirationDateWarrantsOrRights contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember">2018-07-05</avxl:ClassOfWarrantOrRighstExpirationDateWarrantsOrRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" unitRef="Shares" decimals="INF">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <avxl:RemainingAllocatedShareBasedCompensationExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">6827054</avxl:RemainingAllocatedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-09-30" unitRef="Shares" decimals="INF">678379</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2016-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">2421894</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2017-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2016-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">1979246</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2017-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">52562</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member">The exercise price will be determined by the board of directors at the time of &#13;grant shall be at least equal to the fair market value on such date. If the &#13;grantee is a 10% stockholder on the grant date, then the exercise price shall &#13;not be less than 110% of fair market value of the Company&amp;#226;&amp;#128;&amp;#153;s shares of common &#13;stock on the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2017-10-01to2018-09-30_custom_StockOptionPlan2015Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <avxl:AllocatedShareBasedCompensationExpenseRestrictedStock contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">0</avxl:AllocatedShareBasedCompensationExpenseRestrictedStock>
    <avxl:AllocatedShareBasedCompensationExpenseRestrictedStock contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">610000</avxl:AllocatedShareBasedCompensationExpenseRestrictedStock>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-10-01to2018-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">151405</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-10-01to2017-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">127993</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-10-01to2016-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">125317</us-gaap:LeaseAndRentalExpense>
    <avxl:NumberOfOptionsGrantedToConsultants contextRef="From2017-10-01to2018-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Shares" decimals="INF">350000</avxl:NumberOfOptionsGrantedToConsultants>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="USD" decimals="0">737393</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avxl:StockIssuedDuringPeriodValueStockOptionsExercised1 contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="USD" decimals="0">18750</avxl:StockIssuedDuringPeriodValueStockOptionsExercised1>
    <avxl:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2 contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">1.24</avxl:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2>
    <avxl:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">125748</avxl:StockIssuedDuringPeriodSharesNewIssues1>
    <avxl:StockIssuedDuringPeriodSharesNewIssues2 contextRef="From2017-10-01to2018-09-30_custom_PurchaseWarrantsMember" unitRef="Shares" decimals="INF">80981</avxl:StockIssuedDuringPeriodSharesNewIssues2>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2017-10-01to2018-09-30" unitRef="Pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2016-10-01to2017-09-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2015-10-01to2016-09-30" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">14240000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">11123000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">11223000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1344000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">1605000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">1036000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">25000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">-13000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">25000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <avxl:DeferredTaxAssetsUnpaidCharges contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">28000</avxl:DeferredTaxAssetsUnpaidCharges>
    <avxl:DeferredTaxAssetsUnpaidCharges contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">72000</avxl:DeferredTaxAssetsUnpaidCharges>
    <avxl:DeferredTaxAssetsUnpaidCharges contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">152000</avxl:DeferredTaxAssetsUnpaidCharges>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">51000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">28000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">57000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">3394000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">3152000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">2004000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">19032000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">15993000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">14447000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2016-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-4215000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-4577000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-5010000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-173000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">68000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">132000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <avxl:IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-5000</avxl:IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense>
    <avxl:NonDeductibleCompensationCosts contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:NonDeductibleCompensationCosts contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:NonDeductibleCompensationCosts contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-738000</avxl:NonDeductibleCompensationCosts>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">1000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">2000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-77000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-23000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">628000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <avxl:ExpiryOfForeignNetOperatingLossCarryforwards contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:ExpiryOfForeignNetOperatingLossCarryforwards contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <avxl:ExpiryOfForeignNetOperatingLossCarryforwards contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">333000</avxl:ExpiryOfForeignNetOperatingLossCarryforwards>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">336000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-55000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">176000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectOfExchangeRateOnCash contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">7166000</us-gaap:EffectOfExchangeRateOnCash>
    <us-gaap:EffectOfExchangeRateOnCash contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectOfExchangeRateOnCash contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">-11000</us-gaap:EffectOfExchangeRateOnCash>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2017-10-01to2018-09-30" unitRef="USD" decimals="0">-3038000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">4585000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">3009000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2017-10-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2016-10-01to2017-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2015-10-01to2016-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-09-30_us-gaap_DomesticCountryMember" unitRef="USD" decimals="0">50557000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-09-30_us-gaap_DomesticCountryMember" unitRef="USD" decimals="0">41000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2016-09-30_us-gaap_DomesticCountryMember" unitRef="USD" decimals="0">33000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-09-30_custom_ForeignCountry1Member" unitRef="USD" decimals="0">638000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-09-30_custom_ForeignCountry1Member_currency_EUR" unitRef="USD" decimals="0">549000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-09-30_custom_ForeignCountry1Member" unitRef="USD" decimals="0">13000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2016-09-30_custom_ForeignCountry1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-09-30_us-gaap_ForeignCountryMember" unitRef="USD" decimals="0">986000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-09-30_us-gaap_ForeignCountryMember_currency_AUD" unitRef="USD" decimals="0">1365000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-09-30_us-gaap_ForeignCountryMember" unitRef="USD" decimals="0">850000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2016-09-30_us-gaap_ForeignCountryMember" unitRef="USD" decimals="0">250000</us-gaap:OperatingLossCarryforwards>
    <avxl:OperatingLossCarryForwardsExpirationYear1 contextRef="From2017-10-01to2018-09-30">2027</avxl:OperatingLossCarryForwardsExpirationYear1>
    <avxl:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious contextRef="From2017-10-01to2018-09-30" unitRef="Pure" decimals="INF">0.35</avxl:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious>
    <avxl:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised contextRef="From2017-10-01to2018-09-30" unitRef="Pure" decimals="INF">0.21</avxl:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">167415</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2015-10-01to2016-09-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="0">6162</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2015-10-01to2016-09-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_ConvertibleDebtMember" unitRef="Shares" decimals="INF">6162</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationDescription contextRef="From2015-10-19to2015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park&#8217;s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.</us-gaap:UnrecordedUnconditionalPurchaseObligationDescription>
    <avxl:SharesIssuedPursuantToEmploymentAgreementInShares contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1000000</avxl:SharesIssuedPursuantToEmploymentAgreementInShares>
    <avxl:SharesIssuedPursuantToEmploymentAgreementInShares contextRef="From2016-10-01to2017-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <avxl:SharesIssuedPursuantToEmploymentAgreementInShares contextRef="From2017-10-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <dei:EntitySmallBusiness contextRef="From2017-10-01to2018-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityExTransitionPeriod contextRef="From2017-10-01to2018-09-30">false</dei:EntityExTransitionPeriod>
    <dei:EntityEmergingGrowthCompany contextRef="From2017-10-01to2018-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2017-10-01to2018-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2017-10-01to2018-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityShellCompany contextRef="From2017-10-01to2018-09-30">false</dei:EntityShellCompany>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2017-10-01to2018-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A&#13;summary of the status of Company&amp;#8217;s outstanding stock purchase options is presented below:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&#13;    of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&#13;    Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 54%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at October 1, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,822,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,401,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at September 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,199,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,107,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(214,470&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.09&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,092,030&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,730,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.09&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(164,280&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(150,833&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,506,917&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    at September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,108,028&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    at September 30, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,326,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2015-10-01to2016-09-30" unitRef="USD" decimals="0">4452267</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2015-10-01to2016-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2015-10-01to2016-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4452267</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2015-10-01to2016-09-30_custom_CommonSharesToBeIssuedMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2015-10-01to2016-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2015-10-01to2016-09-30" unitRef="Shares" decimals="INF">4</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2016-09-30" unitRef="USDPShares" decimals="INF">1.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2018-12-12" unitRef="Shares" decimals="INF">46586162</dei:EntityCommonStockSharesOutstanding>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>avxl-20180930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Created by S2 Filings, LLC- http://www.s2filings.com -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:avxl="http://anavex.com/20180930" elementFormDefault="qualified" targetNamespace="http://anavex.com/20180930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" id="ConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" id="ConsolidatedStatementOfChangesInStockholdersEquityParenthetical">
	  <link:definition>00000007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000008 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000010 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreements" id="EquityOfferingAgreements">
	  <link:definition>00000011 - Disclosure - Equity Offering Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/Commitments" id="Commitments">
	  <link:definition>00000012 - Disclosure - Commitments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000013 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SupplementalCashFlowInformation" id="SupplementalCashFlowInformation">
	  <link:definition>00000014 - Disclosure - Supplemental Cash Flow Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsTables" id="CommitmentsTables">
	  <link:definition>00000016 - Disclosure - Commitments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000017 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000019 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative" id="LincolnParkPurchaseAgreementDetailsNarrative">
	  <link:definition>00000020 - Disclosure - Equity Offering Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails" id="CommitmentsDetails">
	  <link:definition>00000021 - Disclosure - Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails1" id="CommitmentsDetails1">
	  <link:definition>00000022 - Disclosure - Commitments (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails2" id="CommitmentsDetails2">
	  <link:definition>00000023 - Disclosure - Commitments (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails3" id="CommitmentsDetails3">
	  <link:definition>00000024 - Disclosure - Commitments (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails4" id="CommitmentsDetails4">
	  <link:definition>00000025 - Disclosure - Commitments (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails5" id="CommitmentsDetails5">
	  <link:definition>00000026 - Disclosure - Commitments (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails6" id="CommitmentsDetails6">
	  <link:definition>00000027 - Disclosure - Commitments (Details 6)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Commitments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000029 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000030 - Disclosure - Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative" id="SupplementalCashFlowInformationDetailsNarrative">
	  <link:definition>00000032 - Disclosure - Supplemental Cash Flow Information (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
    <element id="avxl_GeneralSalesTaxRecoverable" name="GeneralSalesTaxRecoverable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GainOnSettlementOfDebt" name="GainOnSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GainOnSettlementOfAccountPayable" name="GainOnSettlementOfAccountPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GainOnSettlementOfAccountsPayable" name="GainOnSettlementOfAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncreaseDecreaseInGrantsPayables" name="IncreaseDecreaseInGrantsPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfWarrants" name="SharesIssuedPursuantToExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares" name="SharesIssuedPursuantToExerciseOfWarrantsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" name="SharesIssuedPursuantToCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" name="SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToEmploymentAgreement" name="SharesIssuedPursuantToEmploymentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit" name="SharesIssuedForRoundingInConnectionWithReverseSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares" name="SharesIssuedForRoundingInConnectionWithReverseSplitInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUponExerciseOfWarrantsCashless" name="SharesIssuedUponExerciseOfWarrantsCashless" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares" name="SharesIssuedUponExerciseOfWarrantsCashlessInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrantIncomePolicy" name="GrantIncomePolicy" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FundingOfDeferredIncomeAwardedGrant" name="FundingOfDeferredIncomeAwardedGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AgreementTerm" name="AgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" name="ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_RemainingAllocatedShareBasedCompensationExpense" name="RemainingAllocatedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock" name="AllocatedShareBasedCompensationExpenseRestrictedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfOptionsGrantedToConsultants" name="NumberOfOptionsGrantedToConsultants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" name="StockIssuedDuringPeriodValueStockOptionsExercised1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues2" name="StockIssuedDuringPeriodSharesNewIssues2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredTaxAssetsUnpaidCharges" name="DeferredTaxAssetsUnpaidCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" name="IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonDeductibleCompensationCosts" name="NonDeductibleCompensationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExpiryOfForeignNetOperatingLossCarryforwards" name="ExpiryOfForeignNetOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryForwardsExpirationYear1" name="OperatingLossCarryForwardsExpirationYear1" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" name="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" name="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToEmploymentAgreementInShares" name="SharesIssuedPursuantToEmploymentAgreementInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonSharesToBeIssuedMember" name="CommonSharesToBeIssuedMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalStudyGrantMember" name="ClinicalStudyGrantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PreclinicalStudyGrantMember" name="PreclinicalStudyGrantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveProgramMember" name="ResearchAndDevelopmentIncentiveProgramMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreementMember" name="PurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants3Member" name="PurchaseWarrants3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants4Member" name="PurchaseWarrants4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants5Member" name="PurchaseWarrants5Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants6Member" name="PurchaseWarrants6Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption1Member" name="EmployeeStockOption1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption2Member" name="EmployeeStockOption2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption3Member" name="EmployeeStockOption3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption4Member" name="EmployeeStockOption4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption5Member" name="EmployeeStockOption5Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption6Member" name="EmployeeStockOption6Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption7Member" name="EmployeeStockOption7Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption8Member" name="EmployeeStockOption8Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption9Member" name="EmployeeStockOption9Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption10Member" name="EmployeeStockOption10Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption11Member" name="EmployeeStockOption11Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption12Member" name="EmployeeStockOption12Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption14Member" name="EmployeeStockOption14Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption15Member" name="EmployeeStockOption15Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption16Member" name="EmployeeStockOption16Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption17Member" name="EmployeeStockOption17Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption18Member" name="EmployeeStockOption18Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption19Member" name="EmployeeStockOption19Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption20Member" name="EmployeeStockOption20Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption21Member" name="EmployeeStockOption21Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption22Member" name="EmployeeStockOption22Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption23Member" name="EmployeeStockOption23Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption24Member" name="EmployeeStockOption24Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption25Member" name="EmployeeStockOption25Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption26Member" name="EmployeeStockOption26Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption27Member" name="EmployeeStockOption27Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption28Member" name="EmployeeStockOption28Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption29Member" name="EmployeeStockOption29Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EmployeeStockOption30Member" name="EmployeeStockOption30Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ForeignCountry1Member" name="ForeignCountry1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsAbstract" name="EquityOfferingAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>avxl-20180930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
   <!-- Created by S2 Filings, LLC- http://www.s2filings.com -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20180930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20180930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:href="avxl-20180930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20180930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20180930.xsd#ConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:href="avxl-20180930.xsd#ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20180930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20180930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20180930.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20180930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20180930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SupplementalCashFlowInformation" xlink:href="avxl-20180930.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20180930.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20180930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20180930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative" xlink:href="avxl-20180930.xsd#LincolnParkPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20180930.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20180930.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20180930.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20180930.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20180930.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails5" xlink:href="avxl-20180930.xsd#CommitmentsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails6" xlink:href="avxl-20180930.xsd#CommitmentsDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20180930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20180930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20180930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20180930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:href="avxl-20180930.xsd#SupplementalCashFlowInformationDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GeneralSalesTaxRecoverable" xlink:label="loc_avxlGeneralSalesTaxRecoverable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_avxlGeneralSalesTaxRecoverable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfAccountPayable" xlink:label="loc_avxlGainOnSettlementOfAccountPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlGainOnSettlementOfAccountPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfDebt" xlink:label="loc_avxlGainOnSettlementOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlGainOnSettlementOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfAccountsPayable" xlink:label="loc_avxlGainOnSettlementOfAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlGainOnSettlementOfAccountsPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_IncreaseDecreaseInGrantsPayables" xlink:label="loc_avxlIncreaseDecreaseInGrantsPayables" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlIncreaseDecreaseInGrantsPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000010 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000011 - Disclosure - Equity Offering Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000012 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SupplementalCashFlowInformation" xlink:title="00000014 - Disclosure - Supplemental Cash Flow Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000016 - Disclosure - Commitments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000017 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000019 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative" xlink:title="00000020 - Disclosure - Equity Offering Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000021 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivable" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivable" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000022 - Disclosure - Commitments (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000023 - Disclosure - Commitments (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000024 - Disclosure - Commitments (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000025 - Disclosure - Commitments (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails5" xlink:title="00000026 - Disclosure - Commitments (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails6" xlink:title="00000027 - Disclosure - Commitments (Details 6)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000029 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000030 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000031 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:title="00000032 - Disclosure - Supplemental Cash Flow Information (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>avxl-20180930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by S2 Filings, LLC- http://www.s2filings.com -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20180930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20180930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:href="avxl-20180930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20180930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20180930.xsd#ConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:href="avxl-20180930.xsd#ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20180930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20180930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20180930.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20180930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20180930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SupplementalCashFlowInformation" xlink:href="avxl-20180930.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20180930.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20180930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20180930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative" xlink:href="avxl-20180930.xsd#LincolnParkPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20180930.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20180930.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20180930.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20180930.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20180930.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails5" xlink:href="avxl-20180930.xsd#CommitmentsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails6" xlink:href="avxl-20180930.xsd#CommitmentsDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20180930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20180930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20180930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20180930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:href="avxl-20180930.xsd#SupplementalCashFlowInformationDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommonSharesToBeIssuedMember" xlink:label="loc_avxlCommonSharesToBeIssuedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlCommonSharesToBeIssuedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapCommonStockSharesOutstanding_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrants_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsInShares_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToEmploymentAgreement" xlink:label="loc_avxlSharesIssuedPursuantToEmploymentAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToEmploymentAgreement_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToEmploymentAgreementInShares" xlink:label="loc_avxlSharesIssuedPursuantToEmploymentAgreementInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedPursuantToEmploymentAgreementInShares_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedForRoundingInConnectionWithReverseSplit" xlink:label="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplit_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares" xlink:label="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplitInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplitInShares_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedUponExerciseOfWarrantsCashless" xlink:label="loc_avxlSharesIssuedUponExerciseOfWarrantsCashless_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedUponExerciseOfWarrantsCashless_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfWarrantsCashlessInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_avxlSharesIssuedUponExerciseOfWarrantsCashlessInShares_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward_60" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000010 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000011 - Disclosure - Equity Offering Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000012 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SupplementalCashFlowInformation" xlink:title="00000014 - Disclosure - Supplemental Cash Flow Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000016 - Disclosure - Commitments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000017 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000019 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PreclinicalStudyGrantMember" xlink:label="loc_avxlPreclinicalStudyGrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlPreclinicalStudyGrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ResearchAndDevelopmentIncentiveProgramMember" xlink:label="loc_avxlResearchAndDevelopmentIncentiveProgramMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlResearchAndDevelopmentIncentiveProgramMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_FundingOfDeferredIncomeAwardedGrant" xlink:label="loc_avxlFundingOfDeferredIncomeAwardedGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlFundingOfDeferredIncomeAwardedGrant_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative" xlink:title="00000020 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAgreementTerm_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000021 - Disclosure - Commitments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000022 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_40" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000023 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants3Member" xlink:label="loc_avxlPurchaseWarrants3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants4Member" xlink:label="loc_avxlPurchaseWarrants4Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants4Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants5Member" xlink:label="loc_avxlPurchaseWarrants5Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants5Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants6Member" xlink:label="loc_avxlPurchaseWarrants6Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants6Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_140" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000024 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000025 - Disclosure - Commitments (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption1Member" xlink:label="loc_avxlEmployeeStockOption1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption2Member" xlink:label="loc_avxlEmployeeStockOption2Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption2Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption3Member" xlink:label="loc_avxlEmployeeStockOption3Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption3Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption4Member" xlink:label="loc_avxlEmployeeStockOption4Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption4Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption5Member" xlink:label="loc_avxlEmployeeStockOption5Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption5Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption6Member" xlink:label="loc_avxlEmployeeStockOption6Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption6Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption7Member" xlink:label="loc_avxlEmployeeStockOption7Member_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption7Member_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption8Member" xlink:label="loc_avxlEmployeeStockOption8Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption8Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption9Member" xlink:label="loc_avxlEmployeeStockOption9Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption9Member_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption10Member" xlink:label="loc_avxlEmployeeStockOption10Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption10Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption11Member" xlink:label="loc_avxlEmployeeStockOption11Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption11Member_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption12Member" xlink:label="loc_avxlEmployeeStockOption12Member_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption12Member_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption14Member" xlink:label="loc_avxlEmployeeStockOption14Member_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption14Member_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption15Member" xlink:label="loc_avxlEmployeeStockOption15Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption15Member_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption16Member" xlink:label="loc_avxlEmployeeStockOption16Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption16Member_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption17Member" xlink:label="loc_avxlEmployeeStockOption17Member_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption17Member_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption18Member" xlink:label="loc_avxlEmployeeStockOption18Member_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption18Member_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption19Member" xlink:label="loc_avxlEmployeeStockOption19Member_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption19Member_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption20Member" xlink:label="loc_avxlEmployeeStockOption20Member_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption20Member_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption21Member" xlink:label="loc_avxlEmployeeStockOption21Member_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption21Member_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption22Member" xlink:label="loc_avxlEmployeeStockOption22Member_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption22Member_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption23Member" xlink:label="loc_avxlEmployeeStockOption23Member_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption23Member_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption24Member" xlink:label="loc_avxlEmployeeStockOption24Member_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption24Member_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption25Member" xlink:label="loc_avxlEmployeeStockOption25Member_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption25Member_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption26Member" xlink:label="loc_avxlEmployeeStockOption26Member_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption26Member_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption27Member" xlink:label="loc_avxlEmployeeStockOption27Member_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption27Member_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption28Member" xlink:label="loc_avxlEmployeeStockOption28Member_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption28Member_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption29Member" xlink:label="loc_avxlEmployeeStockOption29Member_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption29Member_560" xlink:type="arc" order="561" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_600" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_600" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_600" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_600" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_600" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_600" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails5" xlink:title="00000026 - Disclosure - Commitments (Details 5)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails6" xlink:title="00000027 - Disclosure - Commitments (Details 6)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" xlink:label="loc_avxlClassOfWarrantOrRighstExpirationDateWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlClassOfWarrantOrRighstExpirationDateWarrantsOrRights_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:label="loc_avxlAllocatedShareBasedCompensationExpenseRestrictedStock_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAllocatedShareBasedCompensationExpenseRestrictedStock_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NumberOfOptionsGrantedToConsultants" xlink:label="loc_avxlNumberOfOptionsGrantedToConsultants_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfOptionsGrantedToConsultants_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" xlink:label="loc_avxlStockIssuedDuringPeriodValueStockOptionsExercised1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueStockOptionsExercised1_150" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="loc_avxlClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_150" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_150" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues2_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues2_150" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000029 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000030 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000031 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ForeignCountry1Member" xlink:label="loc_avxlForeignCountry1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlForeignCountry1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currencyEUR_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyEUR_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_OperatingLossCarryForwardsExpirationYear1" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear1_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" xlink:label="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" xlink:label="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:title="00000032 - Disclosure - Supplemental Cash Flow Information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SecuritiesPurchaseAgreementMember" xlink:label="loc_avxlSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_30" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>avxl-20180930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Created by S2 Filings, LLC- http://www.s2filings.com -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommonSharesToBeIssuedMember" xlink:label="avxl_CommonSharesToBeIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonSharesToBeIssuedMember" xlink:to="avxl_CommonSharesToBeIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonSharesToBeIssuedMember_lbl" xml:lang="en-US">Common Shares to be Issued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClinicalStudyGrantMember" xlink:label="avxl_ClinicalStudyGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalStudyGrantMember_lbl" xml:lang="en-US">Clinical Study Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PreclinicalStudyGrantMember" xlink:label="avxl_PreclinicalStudyGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PreclinicalStudyGrantMember" xlink:to="avxl_PreclinicalStudyGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PreclinicalStudyGrantMember_lbl" xml:lang="en-US">Preclinical Study Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ResearchAndDevelopmentIncentiveProgramMember" xlink:label="avxl_ResearchAndDevelopmentIncentiveProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveProgramMember" xlink:to="avxl_ResearchAndDevelopmentIncentiveProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveProgramMember_lbl" xml:lang="en-US">Research &amp; Development Incentive Program (Australian Government) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseAgreementMember" xlink:label="avxl_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreementMember_lbl" xml:lang="en-US">2015 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">First Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Second Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants3Member" xlink:label="avxl_PurchaseWarrants3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants3Member" xlink:to="avxl_PurchaseWarrants3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants3Member_lbl" xml:lang="en-US">Third Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants4Member" xlink:label="avxl_PurchaseWarrants4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants4Member" xlink:to="avxl_PurchaseWarrants4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants4Member_lbl" xml:lang="en-US">Four Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants5Member" xlink:label="avxl_PurchaseWarrants5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants5Member" xlink:to="avxl_PurchaseWarrants5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants5Member_lbl" xml:lang="en-US">Five Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants6Member" xlink:label="avxl_PurchaseWarrants6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants6Member" xlink:to="avxl_PurchaseWarrants6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants6Member_lbl" xml:lang="en-US">Six Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">First Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption1Member" xlink:label="avxl_EmployeeStockOption1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption1Member" xlink:to="avxl_EmployeeStockOption1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption1Member_lbl" xml:lang="en-US">Second Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption2Member" xlink:label="avxl_EmployeeStockOption2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption2Member" xlink:to="avxl_EmployeeStockOption2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption2Member_lbl" xml:lang="en-US">Third Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption3Member" xlink:label="avxl_EmployeeStockOption3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption3Member" xlink:to="avxl_EmployeeStockOption3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption3Member_lbl" xml:lang="en-US">Four Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption4Member" xlink:label="avxl_EmployeeStockOption4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption4Member" xlink:to="avxl_EmployeeStockOption4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption4Member_lbl" xml:lang="en-US">Five Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption5Member" xlink:label="avxl_EmployeeStockOption5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption5Member" xlink:to="avxl_EmployeeStockOption5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption5Member_lbl" xml:lang="en-US">Six Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption6Member" xlink:label="avxl_EmployeeStockOption6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption6Member" xlink:to="avxl_EmployeeStockOption6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption6Member_lbl" xml:lang="en-US">Seven Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption7Member" xlink:label="avxl_EmployeeStockOption7Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption7Member" xlink:to="avxl_EmployeeStockOption7Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption7Member_lbl" xml:lang="en-US">Eight Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption8Member" xlink:label="avxl_EmployeeStockOption8Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption8Member" xlink:to="avxl_EmployeeStockOption8Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption8Member_lbl" xml:lang="en-US">Nine Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption9Member" xlink:label="avxl_EmployeeStockOption9Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption9Member" xlink:to="avxl_EmployeeStockOption9Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption9Member_lbl" xml:lang="en-US">Ten Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption10Member" xlink:label="avxl_EmployeeStockOption10Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption10Member" xlink:to="avxl_EmployeeStockOption10Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption10Member_lbl" xml:lang="en-US">Eleven Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption11Member" xlink:label="avxl_EmployeeStockOption11Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption11Member" xlink:to="avxl_EmployeeStockOption11Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption11Member_lbl" xml:lang="en-US">Twelve Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption12Member" xlink:label="avxl_EmployeeStockOption12Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption12Member" xlink:to="avxl_EmployeeStockOption12Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption12Member_lbl" xml:lang="en-US">Thirteen Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption14Member" xlink:label="avxl_EmployeeStockOption14Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption14Member" xlink:to="avxl_EmployeeStockOption14Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption14Member_lbl" xml:lang="en-US">Fifteen Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption15Member" xlink:label="avxl_EmployeeStockOption15Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption15Member" xlink:to="avxl_EmployeeStockOption15Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption15Member_lbl" xml:lang="en-US">Sixteen Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption16Member" xlink:label="avxl_EmployeeStockOption16Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption16Member" xlink:to="avxl_EmployeeStockOption16Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption16Member_lbl" xml:lang="en-US">Seventeen Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption17Member" xlink:label="avxl_EmployeeStockOption17Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption17Member" xlink:to="avxl_EmployeeStockOption17Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption17Member_lbl" xml:lang="en-US">Eighteen Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption18Member" xlink:label="avxl_EmployeeStockOption18Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption18Member" xlink:to="avxl_EmployeeStockOption18Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption18Member_lbl" xml:lang="en-US">Nineteen Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption19Member" xlink:label="avxl_EmployeeStockOption19Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption19Member" xlink:to="avxl_EmployeeStockOption19Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption19Member_lbl" xml:lang="en-US">Twenty Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption20Member" xlink:label="avxl_EmployeeStockOption20Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption20Member" xlink:to="avxl_EmployeeStockOption20Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption20Member_lbl" xml:lang="en-US">Twenty One Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption21Member" xlink:label="avxl_EmployeeStockOption21Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption21Member" xlink:to="avxl_EmployeeStockOption21Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption21Member_lbl" xml:lang="en-US">Twenty Two Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption22Member" xlink:label="avxl_EmployeeStockOption22Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption22Member" xlink:to="avxl_EmployeeStockOption22Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption22Member_lbl" xml:lang="en-US">Twenty Three Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption23Member" xlink:label="avxl_EmployeeStockOption23Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption23Member" xlink:to="avxl_EmployeeStockOption23Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption23Member_lbl" xml:lang="en-US">Twenty Four Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption24Member" xlink:label="avxl_EmployeeStockOption24Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption24Member" xlink:to="avxl_EmployeeStockOption24Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption24Member_lbl" xml:lang="en-US">Twenty Five Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption25Member" xlink:label="avxl_EmployeeStockOption25Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption25Member" xlink:to="avxl_EmployeeStockOption25Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption25Member_lbl" xml:lang="en-US">Twenty Six Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption26Member" xlink:label="avxl_EmployeeStockOption26Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption26Member" xlink:to="avxl_EmployeeStockOption26Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption26Member_lbl" xml:lang="en-US">Twenty Seven Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption27Member" xlink:label="avxl_EmployeeStockOption27Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption27Member" xlink:to="avxl_EmployeeStockOption27Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption27Member_lbl" xml:lang="en-US">Twenty Eight Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption28Member" xlink:label="avxl_EmployeeStockOption28Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption28Member" xlink:to="avxl_EmployeeStockOption28Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption28Member_lbl" xml:lang="en-US">Twenty Nine Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption29Member" xlink:label="avxl_EmployeeStockOption29Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption29Member" xlink:to="avxl_EmployeeStockOption29Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EmployeeStockOption29Member_lbl" xml:lang="en-US">Thirty Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">United States [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ForeignCountry1Member" xlink:label="avxl_ForeignCountry1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ForeignCountry1Member" xlink:to="avxl_ForeignCountry1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ForeignCountry1Member_lbl" xml:lang="en-US">Germany [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="currency_EUR" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US">Euro Member Countries, Euro</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Australia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SecuritiesPurchaseAgreementMember" xlink:label="avxl_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SecuritiesPurchaseAgreementMember" xlink:to="avxl_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Senior Convertible Debentures Due March 18, 2044 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_DocumentAndEntityInformationAbstract" xlink:label="avxl_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DocumentAndEntityInformationAbstract" xlink:to="avxl_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GeneralSalesTaxRecoverable" xlink:label="avxl_GeneralSalesTaxRecoverable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GeneralSalesTaxRecoverable" xlink:to="avxl_GeneralSalesTaxRecoverable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GeneralSalesTaxRecoverable_lbl" xml:lang="en-US">Sales tax recoverable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Deferred costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 45,933,472 common shares (2017 - 43,330,817)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Capital shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Capital shares, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Capital shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Capital shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfAccountPayable" xlink:label="avxl_GainOnSettlementOfAccountPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GainOnSettlementOfAccountPayable" xlink:to="avxl_GainOnSettlementOfAccountPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GainOnSettlementOfAccountPayable_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfDebt" xlink:label="avxl_GainOnSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GainOnSettlementOfDebt" xlink:to="avxl_GainOnSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GainOnSettlementOfDebt_lbl" xml:lang="en-US">Gain on settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xml:lang="en-US">Financing related charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange loss, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Loss per share Basic and diluted (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares outstanding Basic and diluted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Amortization and depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US">Accretion of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfAccountsPayable" xlink:label="avxl_GainOnSettlementOfAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GainOnSettlementOfAccountsPayable" xlink:to="avxl_GainOnSettlementOfAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_GainOnSettlementOfAccountsPayable_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xml:lang="en-US">Unrealized foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Sales tax recoverable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_IncreaseDecreaseInGrantsPayables" xlink:label="avxl_IncreaseDecreaseInGrantsPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInGrantsPayables" xlink:to="avxl_IncreaseDecreaseInGrantsPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncreaseDecreaseInGrantsPayables_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Deferred financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents during the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Balance Beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Shares issued under purchase agreement - purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued under purchase agreement - purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement_lbl" xml:lang="en-US">Shares issued under purchase agreement - commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement_lbl" xml:lang="en-US">Shares issued under purchase agreement - commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Capital stock issued pursuant to debt conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Capital stock issued pursuant to debt conversions (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pursuant to the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares_lbl" xml:lang="en-US">Shares issued pursuant to the exercise of warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToEmploymentAgreement" xlink:label="avxl_SharesIssuedPursuantToEmploymentAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToEmploymentAgreement" xlink:to="avxl_SharesIssuedPursuantToEmploymentAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToEmploymentAgreement_lbl" xml:lang="en-US">Shares issued pursuant to employment agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToEmploymentAgreementInShares" xlink:label="avxl_SharesIssuedPursuantToEmploymentAgreementInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToEmploymentAgreementInShares" xlink:to="avxl_SharesIssuedPursuantToEmploymentAgreementInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToEmploymentAgreementInShares_lbl" xml:lang="en-US">Shares issued pursuant to employment agreement (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedForRoundingInConnectionWithReverseSplit" xlink:label="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit" xlink:to="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit_lbl" xml:lang="en-US">Shares issued for rounding in connection with reverse split</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares" xlink:label="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares" xlink:to="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares_lbl" xml:lang="en-US">Shares issued for rounding in connection with reverse split (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedUponExerciseOfWarrantsCashless" xlink:label="avxl_SharesIssuedUponExerciseOfWarrantsCashless" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfWarrantsCashless" xlink:to="avxl_SharesIssuedUponExerciseOfWarrantsCashless_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUponExerciseOfWarrantsCashless_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares" xlink:label="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares" xlink:to="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock option compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Balance Ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Shares issued for rounding, reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Share price of capital stock issued pursuant to debt conversions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="us-gaap_OtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Component of Operating Income [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EquityOfferingAgreementsAbstract" xlink:label="avxl_EquityOfferingAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsAbstract" xlink:to="avxl_EquityOfferingAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsAbstract_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="us-gaap_RevenueRecognitionIncentives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionIncentives" xlink:to="us-gaap_RevenueRecognitionIncentives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionIncentives_lbl" xml:lang="en-US">Research and Development Incentive Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GrantIncomePolicy" xlink:label="avxl_GrantIncomePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncomePolicy" xlink:to="avxl_GrantIncomePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrantIncomePolicy_lbl" xml:lang="en-US">Grant Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of statement of operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ProductOrServiceAxis_2_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_FundingOfDeferredIncomeAwardedGrant" xlink:label="avxl_FundingOfDeferredIncomeAwardedGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FundingOfDeferredIncomeAwardedGrant" xlink:to="avxl_FundingOfDeferredIncomeAwardedGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FundingOfDeferredIncomeAwardedGrant_lbl" xml:lang="en-US">Awarded grant funding amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_AgreementTerm" xlink:label="avxl_AgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AgreementTerm_lbl" xml:lang="en-US">Agreement term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xml:lang="en-US">Description of purchases price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross sale proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and accounting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable_lbl" xml:lang="en-US">Operating leases, future minimum payments receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Balance, at end</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Balance, at end</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Total Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Vested Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Remaining Contractual Life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of warrant exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" xlink:label="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" xlink:to="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of common shares called</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of grant option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:label="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:to="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock_lbl" xml:lang="en-US">Share based compensation with the vesting of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NumberOfOptionsGrantedToConsultants" xlink:label="avxl_NumberOfOptionsGrantedToConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfOptionsGrantedToConsultants" xlink:to="avxl_NumberOfOptionsGrantedToConsultants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfOptionsGrantedToConsultants_lbl" xml:lang="en-US">Number of options granted to consultants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Number of options converted to warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Number of share purchase warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercised price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" xlink:label="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" xlink:to="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1_lbl" xml:lang="en-US">Number of share purchase warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:to="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_lbl" xml:lang="en-US">Exercised price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Number of common stock to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues2" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues2" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues2_lbl" xml:lang="en-US">Number of additional common stock to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Assumed Tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US">Foreign exchange and other</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xml:lang="en-US">Unpaid charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible asset costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign income taxed at other rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" xlink:label="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" xlink:to="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense_lbl" xml:lang="en-US">Non-deductible finance and accretion expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NonDeductibleCompensationCosts" xlink:label="avxl_NonDeductibleCompensationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonDeductibleCompensationCosts" xlink:to="avxl_NonDeductibleCompensationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_NonDeductibleCompensationCosts_lbl" xml:lang="en-US">Non-deductible compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ExpiryOfForeignNetOperatingLossCarryforwards" xlink:label="avxl_ExpiryOfForeignNetOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExpiryOfForeignNetOperatingLossCarryforwards" xlink:to="avxl_ExpiryOfForeignNetOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExpiryOfForeignNetOperatingLossCarryforwards_lbl" xml:lang="en-US">Expiry of foreign net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Adjustment and true up to prior years' tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="us-gaap_EffectOfExchangeRateOnCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCash" xlink:to="us-gaap_EffectOfExchangeRateOnCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCash_lbl" xml:lang="en-US">Effect of changes in tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance related to current year provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry-forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_OperatingLossCarryForwardsExpirationYear1" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryForwardsExpirationYear1" xlink:to="avxl_OperatingLossCarryForwardsExpirationYear1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear1_lbl" xml:lang="en-US">Operating loss carry-forwards, expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" xlink:label="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" xlink:to="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious_lbl" xml:lang="en-US">Previous corporate income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" xlink:label="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" xlink:to="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised_lbl" xml:lang="en-US">Revised corporate income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Amount of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_AgreementTerm_doc" xml:lang="en-US">Terms of the agreement under agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:to="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_AllocatedShareBasedCompensationExpenseRestrictedStock_doc" xml:lang="en-US">Represent information about the share based compensation in connection with the vesting of restricted stock in exchange for services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" xlink:to="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights_doc" xml:lang="en-US">Information related to class of warrant or righst expiration date warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:to="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_doc" xml:lang="en-US">Information related to class of warrant or righst expiration date warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ClinicalStudyGrantMember_doc" xml:lang="en-US">Information by clinical study grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement_doc" xml:lang="en-US">Value of stock issued pursuant to commitment under terms of purchase agreement during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement_doc" xml:lang="en-US">Number of stock issued pursuant to commitment under terms of purchase agreement during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonSharesToBeIssuedMember" xlink:to="avxl_CommonSharesToBeIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommonSharesToBeIssuedMember_doc" xml:lang="en-US">Represents information related to common shares to be issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_doc" xml:lang="en-US">It represents as a deferred tax assets unpaid charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" xlink:to="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious_doc" xml:lang="en-US">Represents information related to effective income tax rate reconciliation state and local income taxes previous.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" xlink:to="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised_doc" xml:lang="en-US">Represents information related to effective income tax rate reconciliation state and local income taxes revised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption10Member" xlink:to="avxl_EmployeeStockOption10Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption10Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption11Member" xlink:to="avxl_EmployeeStockOption11Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption11Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption12Member" xlink:to="avxl_EmployeeStockOption12Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption12Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption14Member" xlink:to="avxl_EmployeeStockOption14Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption14Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption15Member" xlink:to="avxl_EmployeeStockOption15Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption15Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption16Member" xlink:to="avxl_EmployeeStockOption16Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption16Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption17Member" xlink:to="avxl_EmployeeStockOption17Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption17Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption18Member" xlink:to="avxl_EmployeeStockOption18Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption18Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption19Member" xlink:to="avxl_EmployeeStockOption19Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption19Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption1Member" xlink:to="avxl_EmployeeStockOption1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption1Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption20Member" xlink:to="avxl_EmployeeStockOption20Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption20Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption21Member" xlink:to="avxl_EmployeeStockOption21Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption21Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption22Member" xlink:to="avxl_EmployeeStockOption22Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption22Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption23Member" xlink:to="avxl_EmployeeStockOption23Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption23Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption24Member" xlink:to="avxl_EmployeeStockOption24Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption24Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption25Member" xlink:to="avxl_EmployeeStockOption25Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption25Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption26Member" xlink:to="avxl_EmployeeStockOption26Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption26Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption27Member" xlink:to="avxl_EmployeeStockOption27Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption27Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption28Member" xlink:to="avxl_EmployeeStockOption28Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption28Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption29Member" xlink:to="avxl_EmployeeStockOption29Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption29Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption2Member" xlink:to="avxl_EmployeeStockOption2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption2Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption30Member" xlink:label="avxl_EmployeeStockOption30Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption30Member" xlink:to="avxl_EmployeeStockOption30Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption30Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption3Member" xlink:to="avxl_EmployeeStockOption3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption3Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption4Member" xlink:to="avxl_EmployeeStockOption4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption4Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption5Member" xlink:to="avxl_EmployeeStockOption5Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption5Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption6Member" xlink:to="avxl_EmployeeStockOption6Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption6Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption7Member" xlink:to="avxl_EmployeeStockOption7Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption7Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption8Member" xlink:to="avxl_EmployeeStockOption8Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption8Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EmployeeStockOption9Member" xlink:to="avxl_EmployeeStockOption9Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EmployeeStockOption9Member_doc" xml:lang="en-US">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingAgreementsTextBlock_doc" xml:lang="en-US">Represents information related to equity offering agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExpiryOfForeignNetOperatingLossCarryforwards" xlink:to="avxl_ExpiryOfForeignNetOperatingLossCarryforwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ExpiryOfForeignNetOperatingLossCarryforwards_doc" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ForeignCountry1Member" xlink:to="avxl_ForeignCountry1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ForeignCountry1Member_doc" xml:lang="en-US">Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FundingOfDeferredIncomeAwardedGrant" xlink:to="avxl_FundingOfDeferredIncomeAwardedGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_FundingOfDeferredIncomeAwardedGrant_doc" xml:lang="en-US">Information related to funding of deferred income awarded grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GainOnSettlementOfAccountPayable" xlink:to="avxl_GainOnSettlementOfAccountPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_GainOnSettlementOfAccountPayable_doc" xml:lang="en-US">The amount represents gain on settlement of account payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GainOnSettlementOfAccountsPayable" xlink:to="avxl_GainOnSettlementOfAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_GainOnSettlementOfAccountsPayable_doc" xml:lang="en-US">The amount represents information about gain on settlement of account payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GainOnSettlementOfDebt" xlink:to="avxl_GainOnSettlementOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_GainOnSettlementOfDebt_doc" xml:lang="en-US">Represents information related to gain on settlement of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GeneralSalesTaxRecoverable" xlink:to="avxl_GeneralSalesTaxRecoverable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_GeneralSalesTaxRecoverable_doc" xml:lang="en-US">Information related to general sales tax recoverable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncomePolicy" xlink:to="avxl_GrantIncomePolicy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_GrantIncomePolicy_doc" xml:lang="en-US">Represents information related to grant income policy.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" xlink:to="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense_doc" xml:lang="en-US">It represents as a income tax reconciliation nondeductible finance and accretion expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInGrantsPayables" xlink:to="avxl_IncreaseDecreaseInGrantsPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_IncreaseDecreaseInGrantsPayables_doc" xml:lang="en-US">It represents as a increase decrease in grants payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonDeductibleCompensationCosts" xlink:to="avxl_NonDeductibleCompensationCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NonDeductibleCompensationCosts_doc" xml:lang="en-US">It represents as a income tax reconciliation nondeductible compansation cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NonOperatingIncomeFromGrant_doc" xml:lang="en-US">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfOptionsGrantedToConsultants" xlink:to="avxl_NumberOfOptionsGrantedToConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfOptionsGrantedToConsultants_doc" xml:lang="en-US">Represents the number of options granted to consultants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryForwardsExpirationYear1" xlink:to="avxl_OperatingLossCarryForwardsExpirationYear1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear1_doc" xml:lang="en-US">The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_OtherIncomeDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of other income disclosure.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PreclinicalStudyGrantMember" xlink:to="avxl_PreclinicalStudyGrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PreclinicalStudyGrantMember_doc" xml:lang="en-US">Information by preclinical study grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreementMember_doc" xml:lang="en-US">Terms of the purchase agreement under purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrants1Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrants2Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants3Member" xlink:to="avxl_PurchaseWarrants3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrants3Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants4Member" xlink:to="avxl_PurchaseWarrants4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrants4Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants5Member" xlink:to="avxl_PurchaseWarrants5Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrants5Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants6Member" xlink:to="avxl_PurchaseWarrants6Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrants6Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xml:lang="en-US">It represents as a remaining stock based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_doc" xml:lang="en-US">It refers to amount of research and development incentive income during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveProgramMember" xlink:to="avxl_ResearchAndDevelopmentIncentiveProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ResearchAndDevelopmentIncentiveProgramMember_doc" xml:lang="en-US">Information by category of arrangement,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SecuritiesPurchaseAgreementMember" xlink:to="avxl_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Information related to type of arrangement and non-arrangement Transactions of securities purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xml:lang="en-US">The number of exercised in period made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_doc" xml:lang="en-US">Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xml:lang="en-US">Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Refers to the weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_doc" xml:lang="en-US">Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average expired price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_doc" xml:lang="en-US">Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average issued price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit" xlink:to="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedForRoundingInConnectionWithReverseSplit_doc" xml:lang="en-US">Value of stock issued during the period upon the for rounding in connection with reverse split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares" xlink:to="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares_doc" xml:lang="en-US">The number of shares issued during the period upon the for rounding in connection with reverse split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_doc" xml:lang="en-US">Value of stock issued during the period upon the pursuant to cashless exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_doc" xml:lang="en-US">The number of shares issued during the period upon the pursuant to cashless exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToEmploymentAgreement" xlink:to="avxl_SharesIssuedPursuantToEmploymentAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedPursuantToEmploymentAgreement_doc" xml:lang="en-US">Value of stock issued during the period upon the pursuant to employment agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToEmploymentAgreementInShares" xlink:to="avxl_SharesIssuedPursuantToEmploymentAgreementInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedPursuantToEmploymentAgreementInShares_doc" xml:lang="en-US">Represents information related to shares issued pursuant to employment agreement in shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrants_doc" xml:lang="en-US">Value of stock issued during the period upon the pursuant to the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares_doc" xml:lang="en-US">The number of shares issued during the period upon the pursuant to the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfWarrantsCashless" xlink:to="avxl_SharesIssuedUponExerciseOfWarrantsCashless_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedUponExerciseOfWarrantsCashless_doc" xml:lang="en-US">It represents amount of shares issued upon exercise of cashless warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares" xlink:to="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares_doc" xml:lang="en-US">It represents number of shares issued upon exercise of cashless warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues2" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues2_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" xlink:to="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1_doc" xml:lang="en-US">Represents information related to stock issued during period value stock options exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GainOnSettlementOfAccountsPayable" xlink:to="avxl_GainOnSettlementOfAccountsPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GainOnSettlementOfAccountsPayable_3_lbl" xml:lang="en-US">GainOnSettlementOfAccountsPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_2_lbl" xml:lang="en-US">Foreign Currency Transaction Gain, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Deposit Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_3_lbl" xml:lang="en-US">Number of shares issued for commitment [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" xlink:to="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueStockOptionsExercised1_3_lbl" xml:lang="en-US">Operating loss carry-forwards, expiration year [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:to="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_2_lbl" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" xlink:to="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense_3_lbl" xml:lang="en-US">IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonDeductibleCompensationCosts" xlink:to="avxl_NonDeductibleCompensationCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonDeductibleCompensationCosts_3_lbl" xml:lang="en-US">NonDeductibleCompensationCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>avxl-20180930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
   <!-- Created by S2 Filings, LLC- http://www.s2filings.com -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/DocumentAndEntityInformation" xlink:href="avxl-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20180930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20180930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:href="avxl-20180930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20180930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20180930.xsd#ConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:href="avxl-20180930.xsd#ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20180930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20180930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20180930.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20180930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20180930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SupplementalCashFlowInformation" xlink:href="avxl-20180930.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20180930.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20180930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20180930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20180930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative" xlink:href="avxl-20180930.xsd#LincolnParkPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20180930.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20180930.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20180930.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20180930.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20180930.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails5" xlink:href="avxl-20180930.xsd#CommitmentsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails6" xlink:href="avxl-20180930.xsd#CommitmentsDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20180930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20180930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20180930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20180930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:href="avxl-20180930.xsd#SupplementalCashFlowInformationDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_DocumentAndEntityInformationAbstract" xlink:label="loc_avxlDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GeneralSalesTaxRecoverable" xlink:label="loc_avxlGeneralSalesTaxRecoverable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_avxlGeneralSalesTaxRecoverable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfAccountPayable" xlink:label="loc_avxlGainOnSettlementOfAccountPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlGainOnSettlementOfAccountPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfDebt" xlink:label="loc_avxlGainOnSettlementOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlGainOnSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GainOnSettlementOfAccountsPayable" xlink:label="loc_avxlGainOnSettlementOfAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_avxlGainOnSettlementOfAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_IncreaseDecreaseInGrantsPayables" xlink:label="loc_avxlIncreaseDecreaseInGrantsPayables" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlIncreaseDecreaseInGrantsPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommonSharesToBeIssuedMember" xlink:label="loc_avxlCommonSharesToBeIssuedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlCommonSharesToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsInShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfWarrantsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToEmploymentAgreement" xlink:label="loc_avxlSharesIssuedPursuantToEmploymentAgreement" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToEmploymentAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedPursuantToEmploymentAgreementInShares" xlink:label="loc_avxlSharesIssuedPursuantToEmploymentAgreementInShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedPursuantToEmploymentAgreementInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedForRoundingInConnectionWithReverseSplit" xlink:label="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares" xlink:label="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplitInShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedForRoundingInConnectionWithReverseSplitInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedUponExerciseOfWarrantsCashless" xlink:label="loc_avxlSharesIssuedUponExerciseOfWarrantsCashless" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedUponExerciseOfWarrantsCashless" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfWarrantsCashlessInShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_avxlSharesIssuedUponExerciseOfWarrantsCashlessInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInStockholdersEquityRollForward" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000010 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000011 - Disclosure - Equity Offering Agreements">
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EquityOfferingAgreementsAbstract" xlink:label="loc_avxlEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlEquityOfferingAgreementsAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000012 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SupplementalCashFlowInformation" xlink:title="00000014 - Disclosure - Supplemental Cash Flow Information">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="loc_us-gaapRevenueRecognitionIncentives" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionIncentives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_GrantIncomePolicy" xlink:label="loc_avxlGrantIncomePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlGrantIncomePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000016 - Disclosure - Commitments (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000017 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000019 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PreclinicalStudyGrantMember" xlink:label="loc_avxlPreclinicalStudyGrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlPreclinicalStudyGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ResearchAndDevelopmentIncentiveProgramMember" xlink:label="loc_avxlResearchAndDevelopmentIncentiveProgramMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlResearchAndDevelopmentIncentiveProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_FundingOfDeferredIncomeAwardedGrant" xlink:label="loc_avxlFundingOfDeferredIncomeAwardedGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlFundingOfDeferredIncomeAwardedGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative" xlink:title="00000020 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000021 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivableInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000022 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000023 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants3Member" xlink:label="loc_avxlPurchaseWarrants3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants4Member" xlink:label="loc_avxlPurchaseWarrants4Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants5Member" xlink:label="loc_avxlPurchaseWarrants5Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrants6Member" xlink:label="loc_avxlPurchaseWarrants6Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000024 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000025 - Disclosure - Commitments (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption1Member" xlink:label="loc_avxlEmployeeStockOption1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption2Member" xlink:label="loc_avxlEmployeeStockOption2Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption3Member" xlink:label="loc_avxlEmployeeStockOption3Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption4Member" xlink:label="loc_avxlEmployeeStockOption4Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption5Member" xlink:label="loc_avxlEmployeeStockOption5Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption6Member" xlink:label="loc_avxlEmployeeStockOption6Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption7Member" xlink:label="loc_avxlEmployeeStockOption7Member" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption7Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption8Member" xlink:label="loc_avxlEmployeeStockOption8Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption8Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption9Member" xlink:label="loc_avxlEmployeeStockOption9Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption9Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption10Member" xlink:label="loc_avxlEmployeeStockOption10Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption10Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption11Member" xlink:label="loc_avxlEmployeeStockOption11Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption11Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption12Member" xlink:label="loc_avxlEmployeeStockOption12Member" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption12Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption14Member" xlink:label="loc_avxlEmployeeStockOption14Member" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption14Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption15Member" xlink:label="loc_avxlEmployeeStockOption15Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption15Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption16Member" xlink:label="loc_avxlEmployeeStockOption16Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption16Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption17Member" xlink:label="loc_avxlEmployeeStockOption17Member" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption17Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption18Member" xlink:label="loc_avxlEmployeeStockOption18Member" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption18Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption19Member" xlink:label="loc_avxlEmployeeStockOption19Member" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption19Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption20Member" xlink:label="loc_avxlEmployeeStockOption20Member" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption20Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption21Member" xlink:label="loc_avxlEmployeeStockOption21Member" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption21Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption22Member" xlink:label="loc_avxlEmployeeStockOption22Member" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption22Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption23Member" xlink:label="loc_avxlEmployeeStockOption23Member" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption23Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption24Member" xlink:label="loc_avxlEmployeeStockOption24Member" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption24Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption25Member" xlink:label="loc_avxlEmployeeStockOption25Member" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption25Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption26Member" xlink:label="loc_avxlEmployeeStockOption26Member" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption26Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption27Member" xlink:label="loc_avxlEmployeeStockOption27Member" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption27Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption28Member" xlink:label="loc_avxlEmployeeStockOption28Member" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption28Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EmployeeStockOption29Member" xlink:label="loc_avxlEmployeeStockOption29Member" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlEmployeeStockOption29Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails5" xlink:title="00000026 - Disclosure - Commitments (Details 5)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails6" xlink:title="00000027 - Disclosure - Commitments (Details 6)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000028 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights" xlink:label="loc_avxlClassOfWarrantOrRighstExpirationDateWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlClassOfWarrantOrRighstExpirationDateWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:label="loc_avxlAllocatedShareBasedCompensationExpenseRestrictedStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlAllocatedShareBasedCompensationExpenseRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NumberOfOptionsGrantedToConsultants" xlink:label="loc_avxlNumberOfOptionsGrantedToConsultants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNumberOfOptionsGrantedToConsultants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodValueStockOptionsExercised1" xlink:label="loc_avxlStockIssuedDuringPeriodValueStockOptionsExercised1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueStockOptionsExercised1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="loc_avxlClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000029 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedCurrencyLosses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="loc_avxlDeferredTaxAssetsUnpaidCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlDeferredTaxAssetsUnpaidCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000030 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" xlink:label="loc_avxlIncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="loc_avxlIncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_NonDeductibleCompensationCosts" xlink:label="loc_avxlNonDeductibleCompensationCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="loc_avxlNonDeductibleCompensationCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ExpiryOfForeignNetOperatingLossCarryforwards" xlink:label="loc_avxlExpiryOfForeignNetOperatingLossCarryforwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlExpiryOfForeignNetOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="loc_us-gaapEffectOfExchangeRateOnCash" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000031 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_ForeignCountry1Member" xlink:label="loc_avxlForeignCountry1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlForeignCountry1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currencyEUR" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyEUR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_OperatingLossCarryForwardsExpirationYear1" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" xlink:label="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" xlink:label="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative" xlink:title="00000032 - Disclosure - Supplemental Cash Flow Information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20180930.xsd#avxl_SecuritiesPurchaseAgreementMember" xlink:label="loc_avxlSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!4P'T P$1  (1 0,1 ?_$ 1X  0  !@,!
M       $!08'" D! @,* 0$   <! 0$              0,$!08'" ()"A
M  8! @(""@L&#@H+"@T% 0(#! 4& !$'$@@A$S'3%!65%E:6%PE!42+45=76
M5Y<8&6%2(U.46'&1T3)"DM(S=;4V=C=9@;%TM"4FMB?7./"AP7)#<R14-;<Y
M8K+"@[/#-$2$1?&"HF-DQ&6%I<5&1W=FIR@I"A$  0," P,"#@L(# <,"@,
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M/JP<5/TO:V_R'53UOZ+]!=.^W-VRM-OA0-U=H]M9Z_1W,ANC,/8-:)%&/?\
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MH&A^QI[ ![0#[/3[/8S8ML@>V/>/!&(6(UDS9'X,[%3/+JJ),(I+9/Y.S_\
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MV7X(4<["[/$^/8XEV&&;'#+MPPV+/:,14;1L>W6 "K(,6B*I0,!@*HD@F0X
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MSQR.(!Z"AV.VVST8NU=1W.;&LEV,6G",U&U1GTQ;1"*XN4HY$H2? 1JFY'K
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M=\U@',..FILW3\-=C[?@ZLQU)QI<"UW#FU%IZ!IFX>UG7(4OED#H+SDWOL:
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M'4?O#:]&G8Z,PVN:['D*V);7# ;1_P"A64]2(<>I_!J#V.GJS^T&@=C3,/K
M=JSBWN;LVCE_PK**IIJZ)_@E>S^*/][_ +W,0JQM/W%F="=H63=416$4P!%8
M=1+H )*"(] :?L<Q:LZ)]A9C1X;,5E!7&2C=H553H,J!3::]'" >Y /8']'V
M?8Z.D<2JW@R91T%F-&QS69G##%5+E(JQ,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3"*B]R/Z.[[_,NT_Q&^ROM7]:4WYQ'_'"M=\_J6L_-9?Q
M;EKW]39_V;W+9_!%T_ZQ[?FS^._]ZUV_"1?B(EI_FU_W+67]Y/\ TF9;,)%N
MX>1[]HT?+1CMTS=-VTDW2067CW"Z!TD7R"+I-5LJLT4,"A2J%,0QB@!@$-0S
M4*WHM9E4]5#R[TQ_2E(B=W&=P<- P,1N'5+)95[9 [SR$'%;BQ1['=D+)WS6
MC)27)NO.J.4X8\:SZQV I(I"DGH16^VE]6;RK5,^VO>O?;<C<._;0V6ET_:V
MW6;<]A,SL.PV&?VQW9-K'U=8 RJMY&89WJRM;8,C&NY)1.9=F.HB<I1(14_6
M^47E%V]@>7J$VZYR*?%SNP.X.[LE"VN]3VP.[%DM=EW.LU1F)"-EE+PQ?)L+
M=18RH0T)#/8TK64CXIHDB8QS&$PD64NS?+ERV<LC/<:0<[I0\_5+=?:[8-S6
M^[EDH\M!+<TJKE9:R[M/GLLD@C7]XMT%Y>/-(M$S(IBJU:':-T!,/6$5"PG*
MERNM-_=V]V=SMX:YN;>K%;-O(60J[N1V_HZ=/L+:Y/IW:QE=X_;9*M2=SW!)
M,2Q8V&D;*+A^I'II,DBG R@JD5=WGD53LNU9]N*QOGN!0Y.:YBQYFK[N$Q@:
M//VJ^WYK>6E\@&<NG8(-Y"LX"NO82'8-D&K9,P1,,V:\>@',8BSV2*<B29%5
M.N4*F0JBO 5/K3E* '4X"^Y)QF#70.@-<(M7OKF/^SOWQ_NS;;_K-J6;CX!?
MWJ6W][4?T>5: YS_ /<I=OWU+_2H5LCI_P#)&K?S<A/XL:YJ:M_GDWX5_P#&
M*WE;?ZNI_P "S^*%4>4JK4PBT:^MDYT=FN5W<39^!W/Y/MN>99]:Z;9)>*G;
ML:M@[JS2/F6C1S%,._E2L:O<[Y50%C\"B1>(H:E$>G.B."N@;]K"UU]3:+[5
MVB*&HC:YD.\PD+F$ASLDL>T<@Q!_87*?.'XFZ8T'>+;2W[3=!?)JBFD>Q]1N
M\T0:\ M;G@EV$[3M;T-A6IS[7?E'$.(/56[!B44Q5 04V_$!3 =!/J&V/ZT!
MZ-<W3ZD=:^F=S]J;Y0N>/K%\.OT?V;VX/DBZE];SRB'*)B^JOV",4H:F$%-O
M]"AKPZC_ )L>CW0Z9$\$-;#_ .\[G[4WRA/K&<.OT?V;VX/DB!ZWKE$'BT]5
M?L#[GBXOPNWV@<(&$VH^C'3W(%'7]#'J1UMZ9W/VIOE"?6,X=<GJ_LV/W8/D
MBY-ZW?E&( "?U5VP10,3K"B97;X ,GJ <9==LNDNHAT_=R X(ZU.P:SN?M3?
M*$^L7P[_ $?V;VX/DB%];QRC'.5,GJK=A#J' !33(:@'54U_6E33+M@)U#F'
ML%* B/L!D?4CK4#$ZSN>'W)OE"B.<5P[<<&\/K,2?9@^1KG[7?E'XE"_96[!
M@='7KB&/0"G2X>@P*D-MB!DQ(/08! !*/0/3D/4EK7 'SSN>!]B;Y0GUBN'8
M.!X?6;$>S!\C74/6]<H8EXP]5AL )/=!Q==M]H E !, CZ,N@0 0Z!]O(^I'
M6V.'GG<\?N3?*%#ZQ?#K]']FV^S!\D0OK>>44Q@(7U5^P1C&+Q 4%-OQ$2AK
MJ/1MCT '"/Z6/4CK8#$ZSN>'W)OE"#G%\.CR</[-[<'R1/M>>43W'_\ JPV!
M#K $4_PVWP<8 (AJ7_-ETAJ&GZ./4AK;TSN?M3?*$^L7PZ_1_9O;@^2+NGZW
M7E(5+Q)>JLV$.773B*>@"&N@#IKZ,?:'('@EK4;#K.Y^U-\H41SBN'9Y.'UF
M]N#Y&N_VN/*9_54[#?MJ!_HQR'J3UIZ9W/VIOE"?6)X>?H^LWMP?(T^UQY3/
MZJG8;]M0/]&./4GK3TSN?M3?*$^L3P\_1]9O;@^2)]KCRF?U5.PW[:@?Z,<>
MI/6GIG<_:F^4)]8GAY^CZS>W!\D62?*GZQGU=N]^[D1MAO#R);";"1UJZF-J
M]]?US;ZQUKQH<."(LH2S*#2(?Q?:2O6 1!^<YVZ:_"1;JR'ZTN*:SX6<4=/V
M1]WL.I+G<I8<720A\T<F[ Q+X_AGYRWE+  XC:W$C YQP^XT<&-5:BCL6I=)
M6:T0U&#8IS'3RQ[TG8R4^#Q[MKN02$EH=@'Y6G,-_@<E_*"8 $.6'8(0$ $!
M#:>C" @/2 @(0F@@(9S1Y_:Y\L7/QF;MUU_ZK^&WD&S^*0=HN?J7<H7YL&P?
MT34?XDQY_P"N?+%S\9F[=1]5_#?R#9_%(.T3ZEW*%^;!L']$U'^),>?^N?+%
MS\9F[=/5?PW\@V?Q2#M%=G;W:?:_:2.?1&UNW=)VZBY-[WQDH^DUB&K#.0?@
MD5 'CUO#,V:;IR5$@$ YP,8"AH Z99+I>KQ>Y6SWFJJ*J9C<K72R/D+6XXX
MO)P&.W +(K-IZPZ<@?36"BI:*GD=F<V")D37.PPS.#&M!.&S$[<%2UOY<.7[
M<"QN[A>MDMJKA:WR31![9+-0JS-SCM%@@5JR2<RDC&N'JR;1L0J:8&.($(
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M! 4(J/1$!U#JVB)-!#_>D#)9J:AW92//[)4YM+3,[&-@_8"FP     &@!T
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MGI/5]U/R)/JG^H-_/0W&\^W?^B;'GASE?1^E[DWY2GF'S1/2>K[J?D2?5/\
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MJ.9]Q=!#A-: X<A\)EV?<^ V<I77[$OF@Z/\\G*R'"H"Q0#>N8 "+%$# N0
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MR8%=KF4\1UXR%5.MQ2#J#,H("A2%NGJ2*@(&<<1V_"F)^(BVM81,(N!^Y_\
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M!!#L"IL]VGW 8S[:N'FF"CUW#3DRBN,K(LVO!7U>Y73!0)!JU<E?/GXE;L!
M@HOE5"]4<P"(A20:RL,]O=<FQ2B!DT49&[8YV,PS->,A<W(UF+Y=N:)H.=H*
MK:CAY?J>YLM3I(#4/IYI0=Y(UN$!RN9UX:[.]^#(=F29Q&1Q&U406'LAY6K0
MP29RO+>UA7D9QOG14D$YYPLV9DD!$O&@LBH@;KBE W#[&HY?77"@;25=:6?
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M%E9FI5NM8H0?/+REV5+:U>!WRITJEO7/;S5;:H[3OL<+M9.7LLZIO%!0X#&
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M=>NF<)%+C444.H=3C-J/2&E?!:+?"8Y'3F6H94/G+WRL+I)9&&-SGX8 C(<
M  !@,%;*F]W2H;+$RF$5+)31TXC9#(&1PQ2"5C8\<2.O&+G.+B[$XJ8.;Q9W
M%L1NA:ZV:S($D"/2MH>>[BE.^B"K5\=TBX=KK-E%6ZQBE,T4;BB(\2?"8 '*
M>/3]LCM#K(:ESZ+%A;C+#F9D(<S*0T!P! )$@?FY'8C8JJ;4MWEO;=0"E:RX
M8/#\L,V63> M?F#G$M):2 8W,R\K<",5WF[]<)^=:6)[#(I23.N.ZH0S. DD
M$%(=VT=, *NB)E.L?(-7B@ XU!510>L4$Z@B884.G;1;Z!]M@F)I7U+9SFFC
M)$C7-?L.S!I<T8L[$#K6X-P"]7'5-\N=Q9=:BG:*ME(ZF&6"0 Q.:YFT;<7M
M:YV#^R+CG>7.Q)]Y7<:Z3K%=E.0R,H99I MBOEH69;OT'%;C#Q,9*E58KMDG
M$IW.?C5.N14BJP <Q-==9=)IFRT$[9Z&8Q!KY3E$L181,\2/CP<'$,Q&#0TM
M+6]:#@IE9JZ_7*F=3W*G$Q<R$9S#,UX=!'NHY,6%H=)EVN+PX.=UQ;CBNKO<
M6[+BN=G%)P2[L)-P]=P$%)QKMY,S QXR%B5<$.=5.85",2 HIB1!,.( 3]T.
M1ATS98PULTIJ(V9 ULLT;VMCCSY(0#@#&,[L<V+CLQ=L4)]6Z@DS.IX132/W
MCGNAAEC<Z67)GG+AB1*=VT#+@P;<&[2O1QN/;G*AW8UJ)1E1(JT2FFU5?(R+
M:(<2??=U!MC%-W,G&N'AE $>K%8J*RB13@0V@>8],6F)HA%5*ZDQ#C$:AA8Z
M0,W;97?NB\-P_=92YK7%I(7N75][F>9S20MK2"T2MIGB1L3I-ZZ%O[D1N=FQ
MZW,&.<P.#2NJ6YVY*(R $6DSHS4M.2\^V<1<B\0L"D^Q/&.&$QW6595Q$,8\
MYDFC<IR%;D,(!KD7Z5TV\1YFQ!\$,4<3A(QIA$3LX?'E( D<\!TCR"7D#%09
MK/5D9ERNF,=1/-+,UT4CFSF9AC<R7,"71,82V)@(# =B@D[S=$78/46;A%;O
M]7[&/4Q,HD11_6HDL+&I*E3$@K,3,B_ADC"(*']UT=C)[M/V5\.X>]KF>#RP
M[9(R0R:3>O(QQP?F[%PV@;%3,U-?XY_"(XWMD\)AGV12@%]/%NHP<,,69.R:
M>R.U<K7:R/6!XR5K$;,M2@D>-"3K4@N>$=IQI(D[Z*,0Z0)KNF:1.M*H"J1E
M4RG @&+D&6&W05 JJ2JD@E..?).P"5I>9 V3''$-<3E+<K@TEN.!49-1W6HI
M31UE)%/",-WO*>0F%PC$9?'AA@YS0,P=F:7-:[+B%X,+M>XMO'MXTTLS")K3
MVK1:B4?)":.92+Q5V_?M$E"':I3;LJYT#NNKXQ;G$GW<F5%AL57)))4B%^^J
M6SR OCZ]S&AK&.(.8Q-P#@S'#.,RETVI-1T4445(9XQ!2/IXR(Y/@V2.+GO:
M""T3.Q+#)EQR$M]E39YN=N$]62>*(*HR*2S-V,FV@GJ+Y9^TDX^7&0<* 02*
MNWCR.(+@>'A5*<Y1+H8<I(=*:>@886N:ZF+7-R.F86ACF/CR 8XAK6O.3;BT
MAIQV*NJ-9ZGJ9&U#FEM6'-=O&P/#R]LC)<[CA@7/>P9]F#@7##KEUKU-ON]N
MX;AK$PAQGK3*NI:25+'.8R$BR.EP4?/E>)(4V$8T%3H(7B'30A $1 ,C<+O8
M-#:<;-6S@6VDB;&P9VR2R91@U@P.+Y'8;2<!RN<0 5+MMDU+Q#U4^GMU,3=:
MZ9TCSNW1PQ!QQ?([$8,C;CL:,2=C6@DA;L-D]E:SLE50@8,.[)1^*#FR3ZR8
M)NYN013,0BAR 8_4,VI5#%;H@(@F01Z1,8QAXAUSKBZ:YNWA]=UE)'BV"$'%
ML3"<<!TW.P!>[E<>D  /H1P[X>V?AW9/FRW?"5LI#JB<C!\T@&&)&W*UN)#&
M#8T=,DDWDS"EGR81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(I3--IETR%*"E&<._ZY(P/'T4:80! HCUR7<1)
M&+$3J%Z /UON?:'"+'VP[K,ZI,O*_/[X4Z/F(\4P>L3;;S+A1N99(BR9%#M+
M*NB!Q24*(EXM0 0UTS![OQ)T/8:]]KN]QA@KX\,S"'DMQ (QRL(Y"#RJQ5FI
M;%05#J2LJ6,J&X8M.;9B,>@".12;T[5SY^Z;]&%B^/\ +;ZX>&OE:G][+WM4
MWGCIG\KC]IW:IZ=JY\_=-^C"Q?'^/7#PU\K4_O9>]IYXZ9_*X_:=VJ>G:N?/
MW3?HPL7Q_CUP\-?*U/[V7O:>>.F?RN/VG=JGIVKGS]TWZ,+%\?X]</#7RM3^
M]E[VGGCIG\KC]IW:IZ=JY\_=-^C"Q?'^/7#PU\K4_O9>]IYXZ9_*X_:=VJ>G
M:N?/W3?HPL7Q_CUP\-?*U/[V7O:>>.F?RN/VG=JGIVKGS]TWZ,+%\?X]</#7
MRM3^]E[VGGCIG\KC]IW:IZ=JY\_=-^C"Q?'^/7#PU\K4_O9>]IYXZ9_*X_:=
MVJX].U<^?RF_1A8OC_'KAX:^5J?WLO>T\\=,_ED?M.[571K+ZUW&':V"L[H5
M:7AW@J@V>M]OG9"*&14,DJ44U[<DLF<BA1 0,4!S-[/>;9?Z!ETL\S)Z"3'*
M]N.!P)!Y0""""," KY1UM+<*=M51O$E.['!PY#@<#R^RI_WEW*\O:[Y@+?+/
M+FJI.\NY7E[7?,!;Y9X16WW)O$QM9'1\E<MQH9!I)O#,FG<NV;IZ<ZZ:77&X
MB$N8 0I2Z=(CKJ/1[.8KJK6EDT5315=[?*R*:0L9D8YY+@,QV-Y!@.4JT7>\
MV^S1,EN!=NWNP&#2[;ABK._6FJOSG-/HA>?+3,(]?.@_C:SN+U8//G37^,[F
M4^M-5?G.:?1"\^6F/7SH/XVL[B]//G37^,[F4^M-5?G.:?1"\^6F1]?.@_C:
MSN+T\^=-?XSN93ZTU5^<YI]$+SY:9#U\Z#^-K.XO3SYTU_C.YE/K353V-SF8
M_H;0O/EICU\Z"^-K.XO3SYTU_C.YE/K357YSFGT0O/EICU\Z#^-K.XO3SYTU
M_C.YE/K357YSFGT0O/EID?7SH/XVL[B]//G37^,[F4^M-5?G.:?1"\^6F0]?
M.@_C:SN+T\^=-?XSN93ZTU5^<YI]$+SY:8]?.@_C:SN+T\^=-?XSN97HES1U
M115)(=TF"0*JII"JKM$]!)(%#@3K51)<CF!)/74P@ B !V!STSCQH%SPTSU;
M02!B87X#'HGEP Y2>DHC7&FB0"9 ">4QG >R=G(LF&49>9)FVD(_<*I/6+U!
M-RT=MJ"*S=PW6(!TED527,Q%$U"" @(#TYMRGJXZJ!E332"2GD:'-<TXM<TC
M$$$;""-H*R^/<2L$L65T;AB",""#R$%17B_N+Y<UGZ/5/ECDW._IGVU[W<?N
M1[2>+^XOES6?H]4^6.,[^F?;3=Q^Y'M+L6!W')KPWNMEU[/#M\J&NG8UTN0:
MY N<>4DKT&M;V( 7;O+N5Y>UWS 6^6>044[R[E>7M=\P%OEGA$[R[E>7M=\P
M%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7
MM=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R
M[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEG
MA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P
M%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7
MM=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R
M[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEGA$[R[E>7M=\P%OEG
MA$[R[E>7M=\P%OEGA%/()A:F:S@U@L<9-H'2(5LBPK:D&=!4#B)U%%CSLL"Y
M3DT "\)-!Z=1[&$5381,(F$3"+%G;:+BY+?+F#"1C(^0ZN0I@I"^9-G9DN*&
M6X@3,NDH9,#Z!Q &@#H&O8#-0:4I:6IXB:H%3%'(!)289FM=A\">3$'#V>FL
M.M,44NHKJ)6M=@^'E /[CV5D1XJU?R;@? \?[WS9_P TVO\ )J?N;.HLI\#I
M/BH_>MZB>*M7\FX'P/'^]\?--K_)J?N;.HG@=)\5'[UO43Q5J_DW ^!X_P![
MX^:;7^34_<V=1/ Z3XJ/WK>HGBK5_)N!\#Q_O?'S3:_R:G[FSJ)X'2?%1^];
MU$\5:OY-P/@>/][X^:;7^34_<V=1/ Z3XJ/WK>HGBK5_)N!\#Q_O?'S3:_R:
MG[FSJ)X'2?%1^];U$\5:OY-P/@>/][X^:;7^34_<V=1/ Z3XJ/WK>HGBK5_)
MN!\#Q_O?'S3:_P FI^YLZB>!TGQ4?O6]1>+BKU@K=<P5R U*BJ(:PT<(:@0P
MAJ MA 0^X.>7VJUACB*:GQP/_)LZ7W% TE)@?@H^3W+>HK(<IH &RT(    $
MQ9@      "<>    :   &:[X+@#04 ')X34_CWK'-%?U!'^%E_&.62>;666)
MA%@ESXZ^)-*T[/C([T_1[WAIG/'.'_J2W8?E;_Q96NN(W\QIOPQ_BK#B/JL,
MJ:KKJPM=)1&<+%6:>NKV053?2;AHS7>SL \.@^4<E!S*$!@+5%H*J"0 H7I-
MQ#I>FL]"\TCWP4HT\R".>:J<\YWEK2Z6%Q#RX!TGP1C;&7,;@X;3BL)BHZ=V
MY<8XOFT1MD?*7;7$ E[#@<=KNLRAN+1M'+BJC;4C;HP@U.>&.NYD[M:(1^63
M4%E*5)O6D9&/KHE552.1S&*N^M9"H5-9=9JHD8!$P!ETBL.F''<N,!D?+53Q
M/$ARR4X@#V0[2#F879HLP:YSHW-.)("J64%K/6'=YBZ61CLVQT89F#/NMQQ9
MC@26D'E4''U:&&0D4CTR#6@VM?,XI\PW(2>D;2<2PHD?.8Y2Q1Y)A<Z3E54X
MCW/W,8QB:#P<.2::TT7A,K'4-.;>RFS4TK0)GU!^"P>YAF8)20YSCV&0DMPZ
MW!>(Z2'?/:8(S3B+&)PZ]TG8;2,XS':3T,IQ'0P5,W"%J"=/KQXMLQ:3Z3BK
M$LRK0AF;B-:SK5Z*Z[D3OW:,SUSI$0_!II#'&1ZLW&!P'+1?*"RMLE,ZD9&R
MXAU.)RWK2QLS78EV+W"3%PZ ;N2W*<P<"J2NIZ$4,1B:UM4#'O"-A:'@XD[2
M'XD= #)A@<<56"T1MNUE8>(F(.+1D)>^342FS;MW**S:.A[%',V[B3DBR"+-
MM#*09%0,V,D"KI98%04*&HY?7T.EXJR"BK:>)M1-<98PT-<"UD4S&M,C\X:V
M+=!V+"W-(YV<. VJN=!:F31P3QL$CZE[< ""&M>T N=B &Y,>MPQ<3CB%P-8
MISAZT>5NN5Z>BI*6A"3JKQPI%(0%06C5#25ECHQ29Z^O*&DDG)#B=5R9NHT*
M4 X5@ 8&U6.6H9-:Z6FJ:.6:+>EQ,;8:8L.>=C#+C"<X>#BYY88P!L>,1I*%
MT@DI8HI(7/;GQ.4,B+3F>UN;%G7!V.UV4M'NE!!$52/-7W1:I6U8M]$V5NDP
MLB!U)Q^[A()63C[*F_9S?<TI#3S@$^K4,FW534.9L8@Z:Y3^!6BF--,VCI32
M20SM#)P3*]T41>R</;+EDCE.7 D,<'$Q%NS%2]Q1QF)XAB,3F2#+(.O)8PN:
M_$.P<UYPP. ()+<-BB3P5)C6B3EO'4.=?Q-;L+2W,5%'[E%M;&U>6LT0];(J
M.F9$4Q>J*QQD6YW"*A&I XN(PZS7VZPTD+98HK=45,-+,VI:2YP;4-A,\;F@
MN: ,V:$M87M(C:,<3M]&FH(8P]C*>21D3Q(,2<) S>-(&(Z.+,&D@AHVXE4G
M:X"&%WMJA&Q,3$LYXE94DGYFP1D6NYDFD<XDVZ\^25?KN&I5%E"G 4&XM1'A
M#734+->+=0F:U14D,,,%0(#(_+DC<Y[6&0.F$CW%N)<#UK-WR;>545934Y?2
M,B8QD<@CS'#*TEP:7 OS$D<H.QN7DVIO/5X>"E8J3KK1G'PTNBY;(QK5))NY
M9J1J@!U\VR0=O$XF7?E7_P#10,8.H0(OQF%8=&NK10VZKAJ[8R.*@F:YH8T!
MKFEAY96!SA'(\'[V">M:'XG.HWZCIZ:9DM*&M@>" T;",O1> 3E<<>QZ0#L=
MJNARW\R#O;!VC5+8NY?T)\X J)_=+KU5PN?W;MJ7I.I%*'-Q+H%Z2"(J$#7B
M*;)>&'$^;1TXM%X<^33,CO9+J9Q/9,'*8B=KV#L>R:.4&YZ6U3)9GBCK"76M
MQ^Z8B>B/_4]T.ARCH@[:F3UG),VTA'N4'K%Z@FY:.VRA5F[ANL0#I+(JD$2'
M3.00$! <[-IZB"J@94TSVR4\C0YKFD%KFD8@@C801R%;JCD9*P2Q$.C<,01M
M!!Y""HK)R]IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3"+&C:G^G+F&_N^E_Q,MFI]'?WBZH_"4GX
MDK$K+_M'=?WT/\19+YMA9:L!V'K)>6)\-)44D[O%QU]YI+AR@PTU,TB6C8=K
MNO4XZ?DV\A-/E]"Q.W-U:P.M?L*@=[I07K/@. ."#A%UE_61<N4%WD"12W*2
M/-\OY>9<A"T)^H6.VP3ND339%65<%<BS:6:&))*S+N+!0SM.O1KY^4IDFQ\(
MIQ-\_&U+#>&0V0KU)W8OUSC)FRP2ZM2A:>C!NI"GLJLXLZ,)(V^\U12SN(5[
M<63!9O&)/'8/C'3!(2IG.!%C)NSZ[#E!VG8[.S#F&WIM=>WHWPK7+] 6.L;>
M=9$16XDQ'QCJR0\TK*2\8X(_VRDIEO%61H@DLZC9?KF@D.LW7*0BR5L'K MG
MX-.^MV])WNL%EH.\DYLDO1(?;9=O=K-8:QML&[MAL=2A+%*0'?2B1FWI%9$)
M-51N5V1$4VI%U56Y%B)%<_FU]GG++7*/MWO/>IF$V[J.[L*QK=<J +WK:ZXR
M+6,8WJM)SE[A3Q<,T6=E45)8 A'B[8IUFB#E),YRD62NR6[<!OSM+0-Y*K$6
MF"K6X];8VJ!B[K#E@;.WB9(#*,%)6)3=OTVBCML!5D^!94AT5"'*80,&$5S'
M7_HSC_B%O_)FSQ+][=^]/[2@[L3]Q8Y\IO\ 0M"_PS9_X\>9JW@O_L%!^<U/
MX^18IHK^H&?A9?QCEDGFU5EB818)<^'\BJ3_ #E=_P!X!G/'.'_J6W?G;_Q9
M6N>(W\QIOPQ_BK#*&V41FDZPN2>=M3S46TEY 585!R9!F]8+KIN8-!F\5?R*
M#&1!!FZ.LDB!3N"F()@*(!I2AT%'7MI)!4/8:B)LK\8@[!KF$AT0:XO>&/#(
MY"YK<"\$$@%8/!I]LXA>)"-XP/.+ < 03BP XNP=@UQ('*",5+6NS<B\BF#U
M.11"172DDIF)49B4T!-M; ,)$M7BW$(K1DP9)90KDI0%-5$R?")A#6DAT/4S
MT<=0V4>$N:\21EOWF5LVZC:XX[628.(>!B'-+,,<%*CL4DD+7APWI#LS<.P>
M'Y&@GW+MIS<H((P7,#M?5;4K:DH2TRRH54#(R+A]7HUJB#]$)<R[PZ8RPN58
M4I(@YN%$JCXO6!^"'0<C;M)6>\/K&6^LF<*/8]SX6- >-YBXC>9C%\&3@T.E
MV]@<"E-:*.L=,*:9YW.QQ+&C;UV)PS8EO6GDQ?M[%>K':-K)SL!7V4P^,I)U
MPMAEG_>^-?-X]%[&1[A@@UCXJ0=2O"[E)-!J87:3<W";K0*)0'/5/HN*KN%-
M;J>>3-+2B:1^1CPP.C8Y@:R-[I.NDD9&=XUAP.< A>H[*R:HCIHWNS/BSN.#
M2 "UI #6N+MKG!IS!O3"\U-OF<T=BDC/V-Q:Y>-D'+AO8(QBFT1=P4TWJB\>
MZD$'SAVL!'IOP9^ 1[G(&H<71D'Z:@KC&UE35.O$T3R6S1M#0Z*5M.6.>'N<
M<'=B<.P')BH&V1SY0)9362,<2'M&&+'B,M)!)Y>0X<@Z:I1_6:L=G:%J_-2L
MNXJBK,C\9.(:1B*@GESPKU1J5%T[4.GW3U2B7&)% ((@<O$ 99ZFU6AT%7);
M)YII*(MS[R-L8.,AB=EP<XD9LI;C@0,0X8JBEI*,LF=32/>^ C-F:&CLLAPV
MGHX$<APV%4.!"!KH0H<0@(] =(@.H:_H#F/Y6](;5;\ N> O1[DON?UO0'N=
M!U#3VM!QE'2"8!< 0@"80(4!/^OT*'NM>SQ>WKK@-:,2 -J8!"ID)KP$*773
M7A  UT[&NG9TP&M;R#!, .17(VOVOL^[-G0K=:0 .'JUY:67*<8^$CA/PG>O
M#ET$3#H()) /&L?W)?9$,ETKI6[:QNS;3:6]=L,DA["%GNW^S[EG*\[!LQ(N
M=IM-9>:P4=&-O*YQ[%C?='_ .4E;KMNJ'$[:T^(IT,L\<LHI$Q1=/EC+.'+E
M8PJNG @)A3;D66,(E23 $TP'0 ]D>[M+Z<HM)V."Q4#GNIX0>N>27.<3BYW2
M:"22&MP:T; M^6JVP6FA904Y<8V#E)Q))VD^QB>@-@Z"K?,@5P3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$6-&U/].7,-_=]+_B9;-3Z._O%U1^$I/Q)6)67_:.Z_OH?XBOO;(5
MU9*M9:ZRG).L/9^OS,*TLL+W/WXKSJ5CG+%O.1/=B+AIWSB55P<(=:F=/K4R
M\13%U =L++5K@@/5-<M%6.C$P$AN*UV]>4(M+MNW4A;7EAAK?();4V;9QO>G
MDG8^^L]#7!I3K$D""L:X:-V[N,9N$D4U$N(Q%#43U3>P=.<4B=D[INQ?;U1B
MT^O-+M<[2+]W-[553:1WL>XVELM<:H,Z9+5FU;=S,HWE'1HXLHNZDUG!7)#@
MF!"*9U'U9]4VX:\O'H^WFO+*=Y>Z3;Z9&W&\4_:S=2W6M:ZVE&Y3-WDYV\4Z
M2=P>XBT^@4YI>+%HY50*")^(@  $5_N7;DUVOY;HF>K-6=3-IJ<O;66Y3* O
MP1=G)7=V'C553<3<V"DGL>,DRM6[%I76L$T<%.J[]NW3AL1 '*A,(K+SWJ^7
ML_;MR[^KS,;IQ]TO>Z:VY\+.155VL:C0SR^UK[8ZU5B&:*5!="5AK!M,Y18
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MD&(Q/10</+N2 9Z<-Q_]?9^QAM6PK;';&L;4UEO6ZTVT#W*\I*+%)WPFI#@
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M0PB0P &I1T(IF^E(V,[C[Y2#*/[X/F\6P[M=(->[9)V)@:Q[3KSD[I>N> W
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M&X4;9.ZRJ]_W,K5&92=VD6K^^Q$+696QK;E[E1T6BHT<&!RHP%XHNY%P_62
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381,(F$3")A$PB81,(F$3"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img002_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!I@)8 P$1  (1 0,1 ?_$ /D  0 !! (# 0
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M!P"V:MGGU*H2PP9[2BQ+*+5HLLP-/I1AS@F214AP<#(D8G.8 !84P3$1Z=<
MFQ,!0$QA I0[1$1  #ZHCV!@'G & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M5+NI@0A0-?-WKVN!\J?A19+E3-T;DV>ML/3>Z:L_B8[<&[K0E=V>Z:3==G;
MFT8Z3D4CN8ZF1\@JT]Y =JU*!D6")#F H 4N2I;*^<AVAOJ#UY>HF.=7'>=M
MAHV7U;9HRR4JKNN)Z]8K/)U?DW(@A'3&J[4[B4&;#5#A,#0LO*).12*Z8G
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MY0:XVQ%TO?7G.Z\CHBTTQQ,2'(+;>W=1W5P\8PKQ^P)KYW;X1!XZKJR:PA*
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M 'SO/FA_I\<J/SQ7#\)8 ^=Y\T/]/CE1^>*X?A+ 'SO/FA_I\<J/SQ7#\)8
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MI\<J/SQ7#\)8 ^=Y\T/]/CE1^>*X?A+ 'SO/FA_I\<J/SQ7#\)8 ^=Y\T/\
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MDX6(D8YBIG6/W>@#TP#M$X P#\(#E/\ ZSO(O_/KMO\ R^G\ L-@# & , 8
MP!@# & , 8 P!@# & , 8Y@\]T<]HX]V2ZDN!Q5#NCCR+J:BUQ8JCZ%14-Z
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MKV"&2_-TSRVTXN/Q.\9U./E..+BZ,]AG &=E)I47(#.H/U _^"__ -V)M_\
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MB/7Z ?1RK=,V7K.KW(V\&U*<G[$W^@\+F3;M_:=$5]6]8VVQ.$T8ZO2CH5!
M %-FN)!Z_#WA)W>F7VV=Z?=Q:ADQ6?A7(6_;*+I^=%(ZUO?;^CV7=S,RQ;2]
MLXU_)4RKJ?"S9<ZDD*E>5;@H3O%$[98P]![?C#W0#J 9DYH'IQTA6W9SL.'!
M4ZG!4?P;18W7/4?M#3[CA9R5-ITX-+ZV41M7BGL+6J974A NU61@Z>LMFBH@
M4WIZ'3$!-V!\(=F4IO7TUPQ++R--Q>*Y1C#B_>DN95&R.^6U-W77BX^7;CE+
M]64DJ_!F.+RIS#1+QG$>Z02$>@&6;J) /]DQ #,>]9[)[BPK#O7L:<;=>3C1
M_47>QM?T[(N>79O6Y3]BDG]3*76;BD8Q3!W1 >F61U?0IZ=?E9NQ<)KVD\A=
M4U5.J..(=,IV=N4.9ZUJ>,\SD8 P!@# & >0Z9WBH-?,<'T*(=@9-,>Y%I6U
M3])T:\3Z@ ^GIDTMV9+YZ?*=&RHH*//(/FS=),ZBBZI$DBE*)N\H<P%*4  !
MZB(CEZ>V^W(:UJV/94)N=R22]E62C5,R.'BSO3:4(Q;=?8EQ.R1P6\O$;#2&
M5QM,"Z54>)IN" X0$ %,Q.\'<*=(?B#](>W-DVD:;MS8N/9TS<&5CVKLX*E)
M)->]FHOU'>IZ>%N*YHVE9,(X\&XKIES?MX,R<W=Y5["[5:2>5Z$%N[1;J*)"
M5+NF Q$Q$.X8J/4!*(9X:IN3MGN#(_LQ<U+$^]RX1K*/$M!V]]8F5MS6[-G/
MR^J$I*JE*J:_*=6G>VGK!J"Z3-3G6:[=U&NUT@,JF8@+)D4,4JA>I2]?H#]/
M,$_4#VEN;>N2R\"/79;<E*/%27.JHN7Z#=!VRW]IN^]OX^LX%R$K=VW%M)UZ
M6TG0L+F'+BUS3+HC. , 8 P!@# & , 8!Y HCGM:L3N_9.&Z'V*@8_0"_LA^
M#)MC:%DY<X6K']-)\J'25V,55E:UZE3<ZX30CF#EZJ<0 4VR1E3 'T1[H" !
M]7,AMC=F-<U&=N]*#E:=.JBY?E*8UC<NF:59=W,NPM07C)T1DU7^--FDX]11
M5FY;K@3XJ0MC&'O=.OQC=WIVYECI_9?3K.%'&NVY>;*/L7#A\"RFK]Z=#PLJ
M*A=A.VWQ?5R1CY>*%-5:1682#%PV62.8!!1,2@<H?WY.H!U 0S'3NIVBU+3K
MDIX-N;@J\:>!=O:^Z],U[#CEXEV$[<DN3K3W,MJLB<AOV)@+]$?_ &] S%34
M-*S;%VD[4XVUS;5.)6\;D)<8\CY=SZN0JP*\>-#GJ/ E /ASSNXUF'!-U.4V
MSTR!=$Z+D=C]0/\ X+__ '8FW_\ :[O7^C?5F< [>N , _" Y3_ZSO(O_/KM
MO_+Z?P"PV , 8 P!@# & , 8 P!@# & , 8 SF+I),'V+DWQHQIR1YR.:V:*
MN5"D1(*AC=.@ '7IV].W*JT3;&J;AR[>-IEOK4G27#CQ/"]D6\>/F3:21M.X
M=>53R"Y4HIV2$BD:Y44UB$7FYXJB":I#=HF:HB'>4$ 'L',GK6R^SW972K>]
M^[^KXVFVE!-6[TE'JCXRI+AP? PP[Y^M#MSVCNRT6[<GG:_.+<;&.NN3:\*1
MJV_:D=A[0GEA*\<F#8DDWCK 9%(AG3MBF*@&, ?&.<AR@H/;U'+^=IO4]Z;=
MR686=BZ]A9"F_EC&<9<OAX&JSN9ZN+G<S.N1F\O!R)3^6S?C*TZ>Y22Y&52F
MHZ&_2]6<5]OXI2>&<I6P=.HAT^$O7X?[>7PR]]2M9TLFY.S/2IPJG1?9IX%F
MX[TW#C3\^WD/I;KQ9B%O7RKJSO2.<.(./2BWBH'41743!$"*]!$HD,  ;L'X
M,MCNKO!V3C;EA[GU'%PWX^:XKZR]7;GUDZIVVS(V\V]YD:I.*;=5[T=?/EMY
M7&\^,R+NQ2T866JH*G%&39 ;O$2 !, J$#L.'=]/H'+)ZWV@V%W"Q9;L[:ZM
MC:AC1CU2A:DG[_U3:1V.]:/;CNQT:+9GY.MNBHWPZN5/=7V,U<.F*C90X*%,
M40$0Z&ZAZ!Z>@<Q/U_9F5HN;=G>C**3Y.O\ =0S.LY4+\$XM-$8?_GRW&=%-
M\5PJ1L3XY)'S/08 P!@# & 3$0Q5?N4FZ*9U5%3E3*5,!$QCG'NE*4  1$1$
M<NCVXVM>W-J$,;'@Y)RI+@^9+M0RX8=F5ZY)1C%5;?*BYG; \H7RO-57VNL]
MD[BK)[#-.72",3"2I!3CB"X[HIJJI*)]%2% >W+^>L#OIH7H$]/\-[:;I-O4
M=S7+75Q2E)-I_2J4-/?JA]1O<?=G<W"[+=J\ZU@RU"^K2R5+EQHY2HZT5>1V
M5+CY8>EJ9733#37]()Z@BE[P0A&Z2#B.*JGWT@.44_08@]0_Z6:*>RW_ *AO
MNKNSN'A[9W+H-G%TK+OJ$)J-6ZRIR_207?+T1^JSL[VR?<K)W=:UFQ8M^9?A
M*,HQ4:5?3*O%I<.!BQ(:.UU57(-$6,<@U( "B0R2 * 0W02D$I2]0].?2%L?
MU!;R[D[?Q]6Q+'E^;CJY%*-%1JO,UJZ?W*W3N+'^^3E==]M]5*J-5P=/R%<1
M'#O5.V',8RDJBSL"CTO5%L9-,&H%[/C*F AA$!$?0';F"7J]_%3UOTIZ1+(U
MK'M7,^2E"S%QZFYK@E[E[^16O:'*[X=T-[_V [9S5K4Y23G>FY/RT_'AQ?P,
M5/,&\NWC]0]-6D7&N(F FXZ-\=JXBD^Z/0Q1Z%[4^]W^]VY#_AF?B7Z]Z]-:
MU/;FYM)A9GBVKDN$52JITT?O3XF4MR'J,].G>W3-E;]UJ&=++L^:J=4:)-5Z
MDWQ2KXG1-VI4%:W9)5D#-PW;-GBY6YEDC)BHW\4P(F#J4 -U*&9%]^]A>1E7
ML_%QYVK%N;3K%I5]B]O$W7;#W##6]%Q\GS(3O3MIR476DJ+J1:,Y1 >@AF(6
M7C7K<W&:I(N#&29\\EIW& , 8 P!@# /H0 [1$>G3)A@VX5=Z;:4>7O.DF^2
M*PJU5FKA+,8. CW<G)2"R;=JS9(G7<K+*#W2$33(!C#U'X?@R_';SMWK&_\
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M0Z?5^IE@9Q<'TOF5/PI[SQG4# & , 8 P!@# .8S1.X5*DD43G,( !0 1_N
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M\/QE2$$3 !P[0 <^SK8V\=Z=TO3+<W-W4Q'A;C4U)*XDIRX)^''B1?X<N_\
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MMRC*_-W*R5.+Y\3#_,OW;^1/+<7%795]S?C0]5&[8IE%4B)E<*D$HJ'-U.<
M_O2=X<A]>S=<UK;=[3='3^ZQM.,GQ:;IR.T,G*NPC;NN4L:$JT2X+XE$;$<2
MZ5)L"D&H"<BE%.#-CF$1\$Q$S"?H'I X!V]G;E(>A["V9I'>JSI6[M-Q[NH7
MK\E%W(KBVU2E5S+MZ;D6-2W#I;U"Y*YH=8QZ*UBI^QKE7XG07Y^V6ZV3==L3
MN$TXDG#-PJ#<JZQCD;)@LJ7N% W[$#=.SX<W,]\;-NQIM_1\11Q]-BU*,(\(
M^[@CZ3?2QI.@:9L'$O[?QXV8SC\[HOF=$:Y'"8@81S6_N73[L,J4JU29EO9F
MNDXF4@1 P!@# & , 8Y@DH\@"X3 WH[P?0_L>G+D]O\ %MO7K#R%U*,D0>7)
MJR^D[IWDI<\-;:ITS6]?SSQM&3<0^5]4.Z,3P5BN.Z4Y% $Q3@8PE#T!E:?B
M&^@+)]>_:C2=.VOJ%O3]5TRPH)7)-*?'JX**;9IQ[SX?<;LMZE'WTV;A6M0?
MDN%RW-2XVVZM1=.FOQ=#LD2/,!>W1K=W'1M<=IIID4CI,\:A(.&A.G4JC<RY
M% 3$!Z" AT$,T*:+^ YO/9^XONF]];N6=*E.C\N4TI.O!4Z:T:KSX'GNK\7S
MU%6-+R-M[4TRQHM^<';5SJ^9+DT^E\C%R_7G^LLL@28<N7CER/[[7= '=43)
MZ$B)@(]TH#Z,W:>D+TA:!Z.;5F]L6VKF5?Z5=N3JV_:ZT1K3WMW![D=R=Z_[
MP.X>;]\UV4.F,E7Y:\>%2RE M<#0I9>-\'U%HX5$2J)]TO<4[WQ5.HB'4W7T
M]<S7]3W8C5_4?VP>FZA"W=M3MT:?4^#^"9Y:]@;@U2./KFF7FM7Q9*<)<>#1
ME&><"S(HKE?)2;($^XH!5>\()G)T$50$?B!W1S1]V_\ 2/G^F#N#'5=MZ?=C
ME2R:*D75OJYK@N'L*$[A]RM][N6/A[JG<^]8U.ANK3<>":K]1UM/.9V%J.IU
MA:IP23!_:'YS^(1(Z1E6YU# !SF$IA'L[?[6?0=LK<6[L3M-#4=]M?O*<9=$
M'7J5OI70G7]!LQ] NVM]:WJ]K5]64K>GVX\VG2B7#Z6=2*36%9RJ?IV"8W3^
MWZ<UR=Q=4N:CK=^?0U:ZG3\IO+PK7E68QKQ2(K+8$<, 8 P!@# & , V(^6K
MOU+CUR2J%U>J-D8H[@K"24<]P"IM5CAWC@<_4""&9P^F;*T[5- U3:FLW79P
M=0QIVDX.C4I*E77P,4/5[VSEW0[3YN@6(SEDJ+E%*M6Z4:X<3O8U+S(M:QU<
M;#4;AZU[S034%I%BDNL!UB@(I"8B@"'41_L!FLW>?X!.T.X7<7.W=D:O'*LY
MV5*Y3JN/IC-MM/Y7X,U#[&[D^K#M%H3V+M>YCZ?H^.G;\R<91FX+@J\%QH6,
MW=N>X[-A%'<0W<@R=]Y58ZY#"Z6 P=0%0WQAZ=!'IFY+T<^AGM%Z.MLQT/:L
M+3U%6_FDN,I3]M71OB6KLK4-;WI>W-O[.GG;FO/YKDI52X\HJO!&"U+(Z3M'
M[8X(R='<!T,L84P W>[>WLZ=OIS,[%M8URQ&SFJ2N1E.3]Z=:4+K:[*T]+;M
MKS+/2N7'P-B]=M]_KT>T59G:RK%,"'43(4R@@F0 _8'+U[OH[.@YBMW>["=B
M>\MB[I&^\2/WZ=8JY)1I\W#])C'J&C;>S=1=SJO8FH1E\LXR<)*5:IU3]IQ-
MG^8=6M:5M5"U-)HKA!(PI-%!(+?QBE'NCU4Z&[G>^GFM#"_ U]/FD=PH=PK>
M12S8R8WK5FW*27ROJI)42+XZ#A=^M^:7'9<=>^\;6E\LHSCU7'!\**7'C0Z3
M?F%\@7/(C?=HO2@"FU57!NP3#IT303,/9V"/;TZ9FAWZO8FC:%I^U=(AT:7@
M8\;4(^R,50W1^E/MC8[6=M,70HU>33JD_?[_ 'FOM0_?.8P^D1[?JY@YE7K3
MNS5'P?$RJE*4WUOFSCB(#Z,D5Z<)<(IKB=DF?J _\%__ +L3;_\ M=WK_1OJ
MS/ Y.WK@# /P@.4_^L[R+_SZ[;_R^G\ L-@# & , WC[W\Q:$K/#+@?H'4D%
MQKVH[K7$B[T+<#_8FB*Y=]D:RN5KVYLMXM7X2]VF.]YQ"K>L2;*09#'J"@U7
M<>(4?%Z]!R9/UKS":O9;_K_4++ERYUY7XCRH=:\>^.6RY5]:(G6G&3EHOJVK
MQEUF%5(Y@J_U_9K W9S%5>WB-:*R$824*L5?P$2B0<$IN_S!:KKCC3OFAZWY
MBK6KF0RXF<--*7KDCK*9MJ,[OV^T;DI:=AV1M2-O&815MLJ6HM8OXZ(=6MRJ
MS?3::'@)J+-D2=\"\FQ.:G&#=MOV Q?\ZU=7:X4\R;AWR6O,A7HR?4DKG45.
M-6N:ALK9E'H+^!<TFWW.I;VKSF0GTY1B<P*G-*E2=&*)3@3FW.9O%5KJF$JU
MDY'ZWM&Q:_6/,SA/$B-T[GY23"$3OWBI'U754>[W=LJLQ+B44ONP8@Y5(R)1
M;PT2[73,*22AUA #35P8V-IR^\2>9' K:FVJIQZL.^[#I/<FF=P;#),):K<;
M"T<]M*3G5VT9N CI>4J4)=:[<%U(V7,T<LF4HS(#DI$U04*!E-QV)Q#X@2NQ
M-,:NYR5<W*_<G#VZ4L>7< :PQG&W0.\9K9=5L;'6^JMKM:ZA?8Y.X:G@GD-.
M7QLP0;,I!X#=H86JKA? +N;T\Q&O:UT'R)J&F>74A,\KG.AN NEMB<AM9R5G
MB9_D9;]6V[;DOMB:J>S2,XNT6".IU3G(&ON[&]4:OK*@Q,H85D5C=\#- W.S
MCM=;AO\ -6^6.JW6U-R2W!7<M.W+LW?N^='>H:>U?Q^CZ'>]$S^TZ-7Y&Z0=
MTUCNMFO8GM+5$T1843 Y0.Y=&31$"S&ON?/%U%QS%92W)?6>OI[EUR*WQ(\0
M;1K?44RRHW .V.:+^+%OY7QT;/1[JV4"-Y>I+FJIF,8 3,3&'4GEB(."D1P#
MJ=2"1T'[U%1VB_41=N4E'S=8SEN].FL<AG:#@Y2G71<&#OE.( )BB B';@'%
M#TAGI:;5R+CSJ</D9>4S:G$^+K-?B[;Q&L5OM+"-1;3]K;<DK+6F]ADB&.*T
MFC76M"?MH5-8!  ;D75*3I^R'KE4Z1AW[^<DHTJ^=?T57Y#QN22B7PH^SN&D
MG*,6Y>%-G3!1PD3O#RKM1OV1NP.[_5VF)@_LYF1VET#6<KI5C.A8E'DG8C<^
MNXBA]T:C9PL&[>:;:@W^;V]+.W]Y.59XHUF_U?:TKQM?5FM1D?-D>EF-A/=J
MM5DW\,Z:(MQJTS68]G)*+JJ@4ICF(")A!3J E#+G>H#4MP;"[39$Y:Y'[_DN
MVUY>,K%U0A.,FX7H77./+BDOF7RO@V:IM]^I7M'L;NGBY/<S2;E_:EJ.0K[4
MOO?7U6IPA;6'*U&%UW)244I3C&+?6VNDVP;&G-<V*T.9#5]#7UU4Q(";:O+S
M"LKWE"F$3/")G[R<454/_P"5345(G\!LU*9>L8.Z<V>KWIW+V3<FW.4W3J?B
MZ+AQYU-/G>W=G;7>G<#*W!VEVS=VIM*\N&'<RI94IW&ZROTDFL;K7^S6YW(0
M?*9;94ZBJAR()@<B91$WQ>OH#J(=?HY8O?G<?1M#U=:9<E:5J7RT:5?RE%Z-
MMW4M6LSOXEN4E!-MKW<3R51,6Q?$!),!-T*14X$ QP'IT !$.H@.79VAFZWE
MZ M0VWBS;I5=*JOS$H\G)MY+C;4W<CP=$VU[:F/W(W7T+>=3W%B]BTUG*,4Y
M62\,A1$_1$X%Z=@]1[P_!F7'HT[P[JAW/6QMQS<=/O)U@XTDG[.IEX.SFZ]3
MT+>^%T7I>3.ZE1NE'5'YYG(ZNGK.S[C#F;F;%:33HI$C$$@E(90QO0/P".7^
M]2VFRQM2O-12M.58_P GP/JC[.ZJM7V5I^;U=4YX\:OWK@8[&#J/9]#,)<FR
MYWNF'"21=]/@>HE'X1R&EBW%&LVNE'/4CYCD#-)2HN1W&=0, 8 #TAG:"K)+
MVL$^S;=Y1,.S]D CU[ Z!]/X,OQM[;JN7;4714N1;;]SJ2J]D*$7)JO!G9#\
MCG35/GK\\N\NFV=OF8B5!)8"F%(Q! "]"G+Z3&#X,S:U13V7V*U?<6W/V>JR
MM--K@^,6J\.-/?R-1WXC&_\ 7]-VXM!P)2A8Z*\*\:\WP]QVMK4ZEHR,*I$M
MB*/#JE03(0O7PD2]"E!, #H =!S6-V!VMI6Y=SY6X.XU+N8FY5E2G-OFS2/M
MC&TS4-0DM4N/R%'J;?C)\VV3$*#Y1@S3<!W9%T4JKOX1()@Z@4?H997U6=U=
M-V7FY&%H32P+=WI@DU]FGN?MK4C,/0%N;<KTW37_ *G!TBURH<YXQ5+WFCCJ
M CT4;KCU#N']'3O=G7ZF4#Z=^]N'J65/&UEQGBW7RJGX>RIZ;DVUF;-U&*N1
MF\22X\'1^[V5/DHT\1 6SHY5040527^$AP.F8HF$!]/Q1[<NO8OZ9I7=?"W7
MH,/+=G*C.E$GS*5MZA..1&>)U1M1NQG%5Y-,Z4OG!ZLJU,W6]E8=1#UB8,L=
MT@D)>G>$YS@(@ !^Q'-U._L;&UG9>!K&8OVV;A*XZ\./3[SZ)?0CO+5]=V)#
M"S.KR[*BU6O#@E^<T>R*::9A H?!]7X,U_[XQ,.Q;?2DVD^7P-CV'.<TFR"R
MQA-1@# & , 8!Y .HYZ6HN4TEQXG#Y%30K<JBR9OA 2C_9Z_V<R&[:Z)C9-Z
MWDR_I'1DFU#(E:BZ>!M!X(:XL%JV;!*) N6)(_0,KW3"9,0 P"(B7T= _M#F
MQ'MOI%ZWT^9%RG&WU1?6XQ4??[V84>IO=>EZ3M2_!]/W^472JXH[E$$]&J4-
MC'L&H""3 B/?*(@<#$1  'H/PB;KEN=5VU;W;W&ZYRN.Q;;ZHRE6WP?A[7[#
M1#J>+'7-RW,O*FZ^8VEX4J6ZJ-CG3RKL[Y P-SG-W3 )C ("/I,'3L[/3E[=
MZ;2T.QMZ%C"=N.0K=*NBXT\"J=;TK3XX<%9?[1)$/MJ,?/6WK44F=-8#$'HD
M?N]>G;U 0^ /HY&=MLY8^'#2K]_K:5*/BB/V;EV+%WR<MIVO?Q+B:K7LR=3<
MMC*'37.S.F<>^/?*84Q#K],>GPY:WO'H>TLK?6%<U24(QBXM=,4_FKXE+;TM
M:/=UJU?<4X1N)KA[SJ;^:;2K!#[7?RDJ]<NTG2[CN N!NZF"AQ$G='J(>C^U
MD?W9QY9>W+=ZU*+QH68QBHO]5+A4W4^C/<&F9FTXX.);C"<4G5<&Z+B:9790
M!0P?3$,UF;KL6EFSK2K;_N9L(QY-P3(PP=!RU^3;5NZXQ^R1R=4>N0YR, 8
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MVGW#CXNIVO.:BG)4]Y(M6QI7K$HKV,[?'E&VV)F**CZT!"]QN4G[8(#W5"%
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M#447RS=HI5+C[;)K=?&&ICR2KBNPZ)5[?N&/K]QB-/MD[D9WMJ\0;N/_ /\
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MMLPVKOBY>LVKCPYM]3X\2SFUYR3JNN;/..'#57U:,<IKKD+T$">$<PE,(_1
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M)!?+;MQBOH5"CE#]!]'TLL3J>7&,TNFK2I6I44(G%,/;E)W[T?,K3C7D>Z7
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M@# & , Y394B0B)Q$.WX ZY5FU]6P=+N.>9*2^;P3?"AX7K<IKY2H&DNT2Z
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@'Z=_P#P6W^[9WG_ +6MI_T:ZVP#N$X P#\'
MCDY_K)<@O\]NU/\ +F=P"QV , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@'Z=__!;?[MG>?^UK:?\ 1KK; .X3
M@# /P>.3G^LER"_SV[4_RYG< S8BO)OYW3]$IUTKU#U_/RNPM41>[Z-J6'W3
MJI]OBVZRF8Q_-QECKVF$[7^/\N+Z%BG+M%H@R.]500.8B)NG3 -7BK=P@==-
M9!9%1LJ*#@BJ1TSMURF.445RG*!DE0,F8!*;H/4H_0' /F)#@4IQ*8"'$P$.
M)1 IA)T[X%-TZ&$O>#KT]'7 !B')W>^0Q>^4#D[Q1+WR"(@!R]0#O%$0'M#L
M[,  0PE,<"F$A1*!C  B4HFZ]T#&Z= $W='I]'I@%_=U<9]J<?8#4$]M)E7H
M)7=U C]H4ZLM[7 RUS94:<;,9"L3MQJL8]<R],2ML1)(O8Q.1306>,S^*0G=
MP"M;_P &^3NKV/%.2O>M'==8\UX!A9N.#AY*PIBWN)DK8A2VBBA49!52NN3S
M;QOU0D0:KE;.D' E!%9,Y@.9;.!?*NB[RWWQPM^JI"O[BXS4Z[; W'4I"3A2
M'K=,U^VCWMCL;23)(*1-AB2Q\JV<M%H]=RF^;K$4;BH0P#@$74^$W)2Z:)J/
M)B#UVX-HZ\;ZB^-4!L)]*P\;"J;:F&"$@PAWWKKU%S&0ZB;@J1I5PFG&$<]4
M#+@J DP".CN'?(>1WMMGC<37SMGMW133;\CMNN2LA%Q3>BQ6B(Z:EMHS$Y,O
MWB$0A$UMA .%!<%6,DX#P_!%3Q4^\!E#=_*,Y=ZTI+R[;!<<?J86/UG%;;>4
MZP\EM*Q^R4*=.U-M=X-0^OE;C^-'OF8K3U%PVC_5_7%?%*0$^^/=P"Q[7@!R
MJ?;!U]KEEK87,GM#1B?)BFV%*?KXT%_H0M<D+1*[3=WT9$*K$U.LQ\0\1E5G
M3I$T<_:JLURD=%\(0)Y[Y;O+R.T%_P"HYWK5JG12ZY:;H4@/QMJQMJH:/D)1
M2%8;N<ZC++#L)MJ5W(I&*2</'E9^$7QQ,#<05$"VW&?B'MOEB[N3+53W6+)6
MB1T;*3Q]E;9U]JM S66<N&K0(E>^S\$G-N 5:F\1)J*JB1>@F  ,'4#)ASY/
MG/=AL/:6K9+4\%%W+44[3Z;964GL[7#!C*;%O]3;7FGZMI4RYLZ<3=MFSE6=
MINR0<:LX?)%,!52)G,4I@-:DI%R4')R,+,L'D5,1#]W%RL7(MEF<A&R4>X4:
M/F#YFX(FX:/&;I(R:J9RE.F<HE, " A@'!P!@# ,ON,/!3DKS 86N6TA2HV6
MA:C*5ZL/)VTV^JT&"E[]<C.DZ5K"K3%SEX2/M&S;DJR5+&0;)19^Y$H""8 8
MHF Q5G(28K4U+UNPQCZ%GX"4?PDW#2;95G)1,O%NE6,E&2#-<I%VKYB\0.DJ
MF< ,10HE$ $, C!*8.O4I@Z&[H]0$.ANWXH_0-V>C /(D,!2F$I@*?KW#" @
M4W='H;NB(=#=T?3T]& 9)<>>)&]^4Q[*EI2HHVE6J/*]&RR:\W#0IO>EJ96F
M3@HQF,P]9E>OWT92)9R":8B((,%3#T .T#'#P5>_X8)G,?OF3 I2B83'(/0Q
M2]T![PA]+ /E@# & , 8 P!@%_..O%_??+&].=<\?-9V39EJCJ[/VZ:;033J
MPKE5K$4\FIRQ6::<F0B*]#,F+%3]\/%D4U%A(D03*J$(8"PRB9DE%$C@ '3.
M9,X (" &(82F !#L$.H8!X[IN@CW3="]!,/0>A>]^QZ_0Z_!@ 2'*4AS$,4J
MG42&$H@4X%'NF$@B'0W=,'0>GH' ,E=O\1-]:)H=7V3LVG)P%1M\Q&5V(?EF
M8=^N%AE-;4K;2,'(1[)XN^C9-"C;!B72Z2R9!1.Y\(W10ARE QJ$AP*)A(<"
M@82"82B!0.':)!$0Z=X ^#TX!ZX P!@# & , 8![%*8YBD(4QSG,!2E* F,8
MQAZ%*4H=1,8PCT  ]. 9B/\ R_N8<5?>.VK971%VB=D<K*VSN.C:-+,THNSV
MZJOY.2BVEA<Q$@LV=5N(5-#N7(KR96A",$A=F$K?HH(%!\D>*^YN*5HKU9V]
M!Q#=*YUEO<Z%<*?:*_?M=;!JCEVZC??]&OU1D):KV>/:RC!=JX%JY.=LY1,F
MJ4AN@"!CN4AS=WND,;OF[A.Z41[Q^SXA>@?&-\8.P.WMP !3"!A IA H=3"
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MM%<B='[FOT=QP7A)%)E!4JOZ H=6A:)QDD'7NY:O1MG<&L;-VB*94$TRN#&
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M^XJ]^-QQ\P +$M(M>36^KB]8OY'9FN-Z1<B,M4;S-H/:]4GR[6/.5@E'E55
MU4><66[KTSRX)K;%BTY>-Q6/B5:)K9.P=+-J@K!W>44Y%;=9QDQ8;12&+.O7
MRXMXEDDTDIEL9RW>.6YA275( '$#2-@# & ?IW_\%M_NV=Y_[6MI_P!&NML
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M$G,SLY+NU7\I+2LB[45=/I"0>KG5654,8YSF$1$1' (/ & , 8 P!@# & ,
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MDN07^>W:G^7,[@%CL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# /T[_\ @MO]VSO/_:UM/^C76V =PG & ?@\
M<G/]9+D%_GMVI_ES.X!8[ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P#]._\ X+;_ ';.\_\ :UM/^C76V =P
MG & ?CV<A/(7\WZP;\W?/0? [=,M"S6W=CRT1*L$*TNPDXR2N$P]82#%P%A
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M_*+ 'S 'G)_J_MZ>QUK\HL ?, ><G^K^WI['6ORBP!\P!YR?ZO[>GL=:_*+
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!Z]XO3O=XO3KTZ]0Z=>
MO3IU]'7KV8![8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M, >%._+8WV%?[LP#BH'G5EWB/K487U15)/O>I.!$_B-TEQ$0];#N]!4Z?V,
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M1 .X#=NHB(&Z]HF$ZZH"'3Z08!S< 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , T8<L^1_)S1'++:;C3>WUK1JH*5J>4VM49?B_
MM+=E.XM> C.IK7&9NU"N-;)$,+W#&%\]BV[22>M&[ 'RA2(G #@;MZ](IS$!
M!RR,C&RZ4I#QDBE+0Q_%B)--\R0<DD8I3Q%?$C7I5040-WC=4C%'J/IP"8P!
M@'Q%NW%(4!01% 1$PHBD3PA,*GBB84^[W!$51[W7I^R[?3@'VP"G*_\ X^Q_
M^87/VDPP"H\ 8 P!@# (F-_A$Q_XE_V-I@$M@# & , 8!%L?X=,?QIO]HML
ME, 8 P!@# (>._ATW_'D?M%K@$Q@# & , 8!$LOY3F?^L8_:9, EL 8 P!@#
M (:/_E&<_C+3[22P"9P!@# & , AV7\JS?\ A1WVI@$Q@# & , 8 P!@# &
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M9P!@# & , AV7\JS?^%'?:F 3& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MNG@'8)J8SYJK636ME$QMI&OPPV6.@%55H)A/C'-AF&4*LN4BZL2UD?$3;&.
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MI4''U)\PCWC^ M$E-/'LF_K\+-LO"9.HQH1LT+'R($4$Q@-XI!  $.W ,@<
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M?[/=R-L:78UC6-,NQP<AI1Z'&[.+DJQ5R%OJE!M<JIKP;3X&0)]E4OOF2;3
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M_E#G'W+NS_\ L-!_^BR?_O!Y^S/_ );4?_;VOZ@\@WV<7_ZM1SA_[T'.$_\
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M /Q;4O\ N\F=3M#:\9M^7J>E2_TTU^7JM1H2(;&9_P#S*O>DOH]ZJOC_ /Y
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MREC8NXJ:@WM@$TEW/'13:E36;'=$4# -D> , 8 P!@# & , 8!X,'>*)?^D
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M8Z=I.I:O>\C3;-R]<\>E<$O;)\HKWMI%*%M-HG.OXK519LT, ^'-W!16$:G
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MWWM..VK.#'!NW'!Y%Z-UR=SH:=+:2BX1E))RJVZ?*N%38:FDDD4"I)IIE*
M4J9"D* !V   4    ,S_ +=JU9BH6HQC%>"22_,8URG.;K-MM^UU/IGH=1@#
M & 1$< @]FNP>U\CT^G^\6V 2^ , 8 P!@$2R_E.9_ZQC]IDP"6P!@# & ,
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M#O5UNTGQ9T%J:_.F[JYZ_P!75.LV06;L\@S:RD?&(IN(MF^. >N,X81!HDH
M 0Z: "4 *(  %WXB/!R[L:@O9!'K8' >&W<^$D'1DP#J!.X/:/P]N 3?N<OW
MQEO;1^QX ]SE^^,M[:/V/ 'N<OWQEO;1^QX ]SE^^,M[:/V/ 'N<OWQEO;1^
MQX!&L(H#KRH>\)4.[(=WL>=!,/JC0>\;]K[1_P"; /:4)%PC!Q*2]@>1L>T)
MWW#MY)E003+UZ  G.0 $YS" %*'4QC"   B(!DMU?6-*T#3KNK:UD6L73;,:
MSN7)*,(KXOQ;X12JY-I)-M(BL+!S-2R88>!:G>RIND8P3;?T+P7-ODEQ? H-
M)>V6\!"K'EZO JAT"UV'O'EWB(]?VR!K+A(OA)JAT$KA]X8]!ZE2-\-N(;BW
MMOB/3L_'_<^VY_\ ]AFVF\F['_"P\&33C&7ZM[+Z.#ZHV)4*JEI6W]ONNN7?
MOVJ1_P!EQYTM0?LOY$:U:\;=GJXJCN(J2'UO!0[DTF#J9DYU0!!:P3,@,E+G
M 0Z&*BLND*$>F/\ T&J:)?I94VW]A[?T#(_>71<S=P27S9N7+S\EUK7IG+Y;
M,77[%B%J%/U24ZGN/4]3M_=>J./IBY8]A>795/;&/&X_?<E-^\JCW.7[Y2WM
MH_8\K,D)\7$4=-!=1!W+.5TT5#HM_>((^L*E(8R:/BG3$B7BG "]X>PO7J.
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MSD3IR8@H&]-ZG'2\\[82UAL 5B/:,S,X\[.6 LP51%95JJLB@HB<BARG+W<
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M (\C]HM< F, 8 P!@# (EE_*<S_UC'[3)@$M@# & , 8!#1_\HSG\9:?:26
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MA4*]'U\)I)H"R[IQ*>+(RKY3UF4E70LVHG=/W9@*94XB8>X4 *FD7H4A2E
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MF'GVEJBH]V\;)KK-8VR,46[.=9)F/T2=)$(18G0P  #TP"J\ 8 P!@# & ,
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MES/SYNYE7)5E)_D22Y**5%&*HHI))))(DLFI!D3&_P (F/\ Q+_L;3 ); &
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MGG9DJWI4225(QBE2,(17",(JBC%<$D2^3H@!@$3&_P (F/\ Q+_L;3 ); &
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MDD8_0.C=>1/)9LZ<PB$M+M]9A=G,@\[_ (+JZK6XS%S9"QI3^IMW2B:A^XF
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M]F1^LP!Z@Q^1-/9D?K, >H,?D33V9'ZS 'J#'Y$T]F1^LP!Z@Q^1-/9D?K,
MB63)F,I-%%HV$H&CQ HH)= ZM.H] [G0.HX!-I-VZ B**"*(F#H(I)$3$0 >
MH (D*'4.N ?; & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# .MOSUV6TU=S=V3-T:^;IUE)N]5P+K:1:MRFHVE(V[RNN-9["V;3D
MJOKZX:QNJ<EZU5X!_%*SYG38CB2<(QR93&*8Q .Q%2IAO8:;4I]H69(UG*Q
MS#8EB0!K8"-Y.*:/42SK4H%!M,E37 '28  $7[P?!@%38 P!@# +0Q1?>6RW
MS8_4R%9+*3(EZ]A9*>(RBF"HA]$D<R>E#_K,MWFQ_>O<["QI<<;2=+N9+7@K
M^9<>/9E\8V;64E_+*GQW]SVE?NKA=S<R-K_1V(^;-?3<G9?_ !2CDE[J;D2I
M.GUC:TZD-%"CDM@R-,-&F?%LI9GWF+ MG]^$B!:"8.]ZJ*_B  >$ #WLN(4P
M9'X P!@# (F-_A$Q_P")?]C:8!+8 P!@# & 1;'^'3'\:;_:+; )3 & , 8
MP"'COX=-_P >1^T6N 3& , 8 P!@$2R_E.9_ZQC]IDP"6P!@# & , AH_P#E
M&<_C+3[22P"9P!@# & , AV7\JS?^%'?:F 3& , 8 P!@# & , 8 P!@# &
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M/^X6X !B)$1  Z.>HAW4P]/7MP#[>[+?_2AG_,2'W3@#W9;_ .E#/^8D/NG
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M1R4#9>U:H,FK9FU3!)LT01:MT@,8P)H()E213 QS&.8")D .HB(CT[1P#[X
MP!@%J]SZ[GMHT"3J=6V;<=/V91W%2M?V#1_=RLS!2\+(MY-F+B-F&KR)GH)Z
MHV\"0CW)/">LU%$A,03 <H&NU;RH*:LP?))[RV(QE-I.K(/*F4C8.I,DN0D3
M;-@,=E2\*E$)LAB]3-"3[ &K88$A/"B%W#8Y5%5C.< VOM6K=BU;,FB14&K-
MNBU;($Z]Q%NW3*DBD3J(CW4TR  ?2# /O@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@&O6^^9CQTU]LZRZE>PVZK%:ZS?E-2.5:;J&TV. D=P&I)-C1^JH:?:I$CG
MUTF*,"DDV3$Y&@MT%?$<)G+W! CYKS3.*<17ZC;V[K9UCI]DJVO+9.6FK:OL
M\Y"ZN8[6LZ]+U^PVNLV;@XIDW8;6P>,BM5$U5&YV+A1QX2) 5,!0;GS*X^I<
MD)756QZY"1%"G5]BUW2CNNNY*P[5W%?=<[-K^KI&IT>AM2'7M;QW,2#]P/J
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M,=?)WF7F&<7JR_O;%'1*%IO#&)CTGRTO7DU(,P*F0'PE2D!0#8I@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# / >D?J_\P8!YP!@# / >D?J_P#,& >< 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M]UI58RZ!I^I7K83MK+R].NSS<%5UG7;+=:6SF@D6\;:F$A+OTF;]M' R"/0
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M]EC[FWIR$,NSW)K\:D@\8RY&9F4;74EP>JJJG0.B0#>9@# & , 8 P!@# /
MEZ_"(?4' / AT 1[QNSM]. >V , \!Z1^K_S!@'G & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & 0KW\7?4''O+W+[L]6?^M^N^H^H>J?_4_6/'_>_JW[OWOB_P#3
MP"W%?#38;*F1KYJ\.Q1UU6?72MN]XI=7A)S/XO>Z.I0B_P 51F?7>OJ0BCZS
MWO%^/W< JV+_ *N_%A?<OXE^-UD?Q<]U^X_%[W_U;W+ZI\;K\H\#_P"/ )1E
M^*OOZ5]W?B_^,_@-O??J7N[W]ZMT_>?O7P/^\/ Z?XOQOB_]' .";\1/&G^]
M^*/K'CL_QH[WN;QO6N^G[O\ ?_7X_C^)W/!]8^-WNG=[>F 2;G\6_>[+USW)
M[^]65]W>L^H>]_4^]^W>I>+^_?5N_P#LNY\3KZ< I6B?U7^Z9+^K[\5/=7XX
M3?OCW)ZEW/QZ]>'WW[T[G[;^,GK?=\3QOV_N]SI\3N8!7*?N_P!><>%ZE[R\
M!#UOP_ ]>]7ZG]6]8[O[X\#O=[N=[XO7KT^' (63_$[W:G[Y_%GW1ZZAX7O/
MW7[M]X]GJWA^M?O7UWT=SI\?Z& >LM^)7KL9[\_%?WCW4O<_O;W3Z[W?'2\'
MW9ZY^W]WUKN=WPO_ )G=Z=O3 /BX_$/P)SUK\4?5?>"?XR>L>YO ]Z_M?@^_
M/$_:_>'['N^L?MGHZ?!@'V9_B5[QB_4/Q7][>ZQ]R^I^Z?>/N7M[WNOP?WS[
MK]/7POVK *HP!@# & , 8 P!@# / ^@?J#@#M^@']L?_ &8 [?H!_;'_ -F
M ^'ZO_,'U, \X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
B@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860744560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 12, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,432,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,586,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860716064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,930,638<span></span>
</td>
<td class="nump">$ 27,440,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GeneralSalesTaxRecoverable', window );">Sales tax recoverable</a></td>
<td class="nump">40,171<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,251,798<span></span>
</td>
<td class="nump">335,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred costs</a></td>
<td class="nump">101,133<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">52,396<span></span>
</td>
<td class="nump">52,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">24,323,740<span></span>
</td>
<td class="nump">27,785,933<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">24,376,136<span></span>
</td>
<td class="nump">27,838,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,884,626<span></span>
</td>
<td class="nump">3,584,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Liabilities</a></td>
<td class="nump">3,884,626<span></span>
</td>
<td class="nump">3,584,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 45,933,472 common shares (2017 - 43,330,817)</a></td>
<td class="nump">45,935<span></span>
</td>
<td class="nump">43,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">129,377,542<span></span>
</td>
<td class="nump">115,689,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(108,931,967)<span></span>
</td>
<td class="num">(91,478,558)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">20,491,510<span></span>
</td>
<td class="nump">24,253,995<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 24,376,136<span></span>
</td>
<td class="nump">$ 27,838,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GeneralSalesTaxRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to general sales tax recoverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GeneralSalesTaxRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6847318816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Capital shares, authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Capital shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Capital shares, issued</a></td>
<td class="nump">45,933,472<span></span>
</td>
<td class="nump">43,330,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Capital shares, outstanding</a></td>
<td class="nump">45,933,472<span></span>
</td>
<td class="nump">43,330,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6861188416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 5,989,170<span></span>
</td>
<td class="nump">$ 5,008,275<span></span>
</td>
<td class="nump">$ 8,334,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,344,421<span></span>
</td>
<td class="nump">10,672,086<span></span>
</td>
<td class="nump">7,254,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(19,333,591)<span></span>
</td>
<td class="num">(15,680,361)<span></span>
</td>
<td class="num">(15,589,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">149,055<span></span>
</td>
<td class="nump">140,942<span></span>
</td>
<td class="nump">141,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">1,629,513<span></span>
</td>
<td class="nump">2,022,902<span></span>
</td>
<td class="nump">571,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">255,092<span></span>
</td>
<td class="nump">88,098<span></span>
</td>
<td class="nump">11,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GainOnSettlementOfAccountPayable', window );">Gain on settlement of accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75,204<span></span>
</td>
<td class="nump">151,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GainOnSettlementOfDebt', window );">Gain on settlement of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">61,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Financing related charges</a></td>
<td class="num">(30,943)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss, net</a></td>
<td class="num">(49,789)<span></span>
</td>
<td class="num">(47,583)<span></span>
</td>
<td class="num">(48,445)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,952,928<span></span>
</td>
<td class="nump">2,279,563<span></span>
</td>
<td class="nump">881,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(17,380,663)<span></span>
</td>
<td class="num">(13,400,798)<span></span>
</td>
<td class="num">(14,707,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">72,746<span></span>
</td>
<td class="nump">59,607<span></span>
</td>
<td class="nump">29,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (17,453,409)<span></span>
</td>
<td class="num">$ (13,460,405)<span></span>
</td>
<td class="num">$ (14,736,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding Basic and diluted (in shares)</a></td>
<td class="nump">44,655,725<span></span>
</td>
<td class="nump">40,841,033<span></span>
</td>
<td class="nump">35,153,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GainOnSettlementOfAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents gain on settlement of account payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GainOnSettlementOfAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GainOnSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to gain on settlement of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GainOnSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to amount of research and development incentive income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6861142464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,453,409)<span></span>
</td>
<td class="num">$ (13,460,405)<span></span>
</td>
<td class="num">$ (14,736,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Amortization and depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,517,004<span></span>
</td>
<td class="nump">4,135,570<span></span>
</td>
<td class="nump">5,062,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(61,205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GainOnSettlementOfAccountsPayable', window );">Gain on settlement of accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(75,204)<span></span>
</td>
<td class="num">(151,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Unrealized foreign exchange</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Sales tax recoverable</a></td>
<td class="num">(30,423)<span></span>
</td>
<td class="nump">54,435<span></span>
</td>
<td class="num">(2,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(915,870)<span></span>
</td>
<td class="num">(155,804)<span></span>
</td>
<td class="num">(79,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(52,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">300,292<span></span>
</td>
<td class="nump">554,709<span></span>
</td>
<td class="nump">775,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_IncreaseDecreaseInGrantsPayables', window );">Deferred grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(70,532)<span></span>
</td>
<td class="num">(1,082)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,582,406)<span></span>
</td>
<td class="num">(9,017,231)<span></span>
</td>
<td class="num">(9,236,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">8,173,920<span></span>
</td>
<td class="nump">27,270,674<span></span>
</td>
<td class="nump">3,167,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing charges</a></td>
<td class="num">(101,133)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(34,759)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,072,787<span></span>
</td>
<td class="nump">27,270,674<span></span>
</td>
<td class="nump">3,132,661<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents during the year</a></td>
<td class="num">(4,509,619)<span></span>
</td>
<td class="nump">18,253,443<span></span>
</td>
<td class="num">(6,104,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">27,440,257<span></span>
</td>
<td class="nump">9,186,814<span></span>
</td>
<td class="nump">15,290,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 22,930,638<span></span>
</td>
<td class="nump">$ 27,440,257<span></span>
</td>
<td class="nump">$ 9,186,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GainOnSettlementOfAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents information about gain on settlement of account payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GainOnSettlementOfAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncreaseDecreaseInGrantsPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a increase decrease in grants payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncreaseDecreaseInGrantsPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862894272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Shares to be Issued [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Beginning at Sep. 30, 2015</a></td>
<td class="nump">$ 32,044<span></span>
</td>
<td class="nump">$ 74,060,999<span></span>
</td>
<td class="nump">$ 1,997,415<span></span>
</td>
<td class="num">$ (63,281,455)<span></span>
</td>
<td class="nump">$ 12,809,003<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2015</a></td>
<td class="nump">32,044,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued under purchase agreement - purchase shares</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="nump">3,041,619<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,042,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under purchase agreement - purchase shares (in shares)</a></td>
<td class="nump">740,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement', window );">Shares issued under purchase agreement - commitment shares</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement', window );">Shares issued under purchase agreement - commitment shares (in shares)</a></td>
<td class="nump">187,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Capital stock issued pursuant to debt conversions</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">173,404<span></span>
</td>
<td class="num">(167,415)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Capital stock issued pursuant to debt conversions (in shares)</a></td>
<td class="nump">173,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrants', window );">Shares issued pursuant to the exercise of warrants</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">125,020<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">125,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares', window );">Shares issued pursuant to the exercise of warrants (in shares)</a></td>
<td class="nump">41,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">$ 1,979<span></span>
</td>
<td class="num">(1,979)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares', window );">Shares issued pursuant to cashless exercise of warrants (in shares)</a></td>
<td class="nump">1,979,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToEmploymentAgreement', window );">Shares issued pursuant to employment agreement</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="num">(1,830,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToEmploymentAgreementInShares', window );">Shares issued pursuant to employment agreement (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplit', window );">Shares issued for rounding in connection with reverse split</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares', window );">Shares issued for rounding in connection with reverse split (in shares)</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,452,267<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,452,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,736,698)<span></span>
</td>
<td class="num">(14,736,698)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Sep. 30, 2016</a></td>
<td class="nump">$ 36,169<span></span>
</td>
<td class="nump">84,290,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(78,018,153)<span></span>
</td>
<td class="nump">6,308,156<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance Ending (in shares) at Sep. 30, 2016</a></td>
<td class="nump">36,168,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued under purchase agreement - purchase shares</a></td>
<td class="nump">$ 7,061<span></span>
</td>
<td class="nump">27,263,613<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,270,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under purchase agreement - purchase shares (in shares)</a></td>
<td class="nump">7,060,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement', window );">Shares issued under purchase agreement - commitment shares</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement', window );">Shares issued under purchase agreement - commitment shares (in shares)</a></td>
<td class="nump">48,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Capital stock issued pursuant to debt conversions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Capital stock issued pursuant to debt conversions (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrants', window );">Shares issued pursuant to the exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares', window );">Shares issued pursuant to the exercise of warrants (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares', window );">Shares issued pursuant to cashless exercise of warrants (in shares)</a></td>
<td class="nump">52,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToEmploymentAgreement', window );">Shares issued pursuant to employment agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToEmploymentAgreementInShares', window );">Shares issued pursuant to employment agreement (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplit', window );">Shares issued for rounding in connection with reverse split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares', window );">Shares issued for rounding in connection with reverse split (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfWarrantsCashless', window );">Shares issued pursuant to cashless exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares', window );">Shares issued pursuant to cashless exercise of options (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,135,570<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,135,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,460,405)<span></span>
</td>
<td class="num">(13,460,405)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Sep. 30, 2017</a></td>
<td class="nump">$ 43,332<span></span>
</td>
<td class="nump">115,689,221<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(91,478,558)<span></span>
</td>
<td class="nump">$ 24,253,995<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance Ending (in shares) at Sep. 30, 2017</a></td>
<td class="nump">43,330,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,330,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued under purchase agreement - purchase shares</a></td>
<td class="nump">$ 2,384<span></span>
</td>
<td class="nump">8,171,536<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,173,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under purchase agreement - purchase shares (in shares)</a></td>
<td class="nump">2,383,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement', window );">Shares issued under purchase agreement - commitment shares</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement', window );">Shares issued under purchase agreement - commitment shares (in shares)</a></td>
<td class="nump">14,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Capital stock issued pursuant to debt conversions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Capital stock issued pursuant to debt conversions (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrants', window );">Shares issued pursuant to the exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares', window );">Shares issued pursuant to the exercise of warrants (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares', window );">Shares issued pursuant to cashless exercise of warrants (in shares)</a></td>
<td class="nump">125,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToEmploymentAgreement', window );">Shares issued pursuant to employment agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToEmploymentAgreementInShares', window );">Shares issued pursuant to employment agreement (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplit', window );">Shares issued for rounding in connection with reverse split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares', window );">Shares issued for rounding in connection with reverse split (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfWarrantsCashless', window );">Shares issued pursuant to cashless exercise of options</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares', window );">Shares issued pursuant to cashless exercise of options (in shares)</a></td>
<td class="nump">78,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,517,004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,517,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,453,409)<span></span>
</td>
<td class="num">(17,453,409)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance Ending at Sep. 30, 2018</a></td>
<td class="nump">$ 45,935<span></span>
</td>
<td class="nump">$ 129,377,542<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (108,931,967)<span></span>
</td>
<td class="nump">$ 20,491,510<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance Ending (in shares) at Sep. 30, 2018</a></td>
<td class="nump">45,933,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,933,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to commitment under terms of purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued pursuant to commitment under terms of purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the for rounding in connection with reverse split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedForRoundingInConnectionWithReverseSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the for rounding in connection with reverse split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedForRoundingInConnectionWithReverseSplitInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the pursuant to cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the pursuant to cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToEmploymentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the pursuant to employment agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToEmploymentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToEmploymentAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to shares issued pursuant to employment agreement in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToEmploymentAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the pursuant to the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the pursuant to the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfWarrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUponExerciseOfWarrantsCashless">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount of shares issued upon exercise of cashless warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUponExerciseOfWarrantsCashless</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of shares issued upon exercise of cashless warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUponExerciseOfWarrantsCashlessInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6591696064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares issued for rounding, reverse stock split | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Share price of capital stock issued pursuant to debt conversions | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6851774320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px">
<tr style="vertical-align: top">
    <td style="width: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note
    1</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Business Description and Basis of Presentation</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Business</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which select patients that will receive the therapeutic benefit
for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX 2-73 is being
developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted
in the United States of America (&#8220;GAAP&#8221;).&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Liquidity</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these consolidated financial statements
are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain. The assumptions
upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the
Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design, timing and
duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of financial
resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical
trials.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development
programs. Such capital may not be available on commercially acceptable terms, if at all. The Company believes that it will be
able to obtain additional working capital to fund future operations through current financing commitments from third parties,
or through other arrangements; however, there can be no assurance that such additional financing, if available, can be obtained
on terms acceptable to the Company. If the Company is unable to obtain such additional financing, future operations would need
to be scaled back.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6851601792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px">
<tr style="vertical-align: top">
    <td style="width: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note&#160;2</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Summary of Significant Accounting Policies</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">a)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Use
    of Estimates</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with United States GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of
revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income
tax asset valuations, asset impairment, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions
on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">b)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Principles
    of Consolidation</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">c)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Cash
    and equivalents</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents</i>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">d)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Research
    and Development Expenses</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#8217;s proprietary research
and development efforts, including salaries, facilities costs, overhead costs and other related expenses, as well as costs incurred
in connection with third-party collaboration efforts. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard
Codification (&#8220;ASC&#8221;) 730, Research and Development, as these materials have no alternative future use outside of their
intended use.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks.
The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents
and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the
development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due
to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus
are expensed as incurred within general and administrative expenses.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">e)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Research
    and Development Incentive Income</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain a research and development tax credit from the Australian Tax Authority (the &#8220;ATO&#8221;)
for certain research and development activities undertaken in Australia. The tax incentive is available on the basis of specific
criteria with which the Company must comply. Although the tax incentive is administered through the ATO, the Company has accounted
for the tax incentive outside of the scope of ASC Topic 740, Income Taxes, since the incentive is not linked to the Company&#8217;s
income tax liability and can be realized regardless of whether the Company has generated taxable income in Australia. The Company
recognizes as other income the amount received for qualified expenses in the period they are received.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">f)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Basic
    and Diluted Loss per Share</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2018, loss per share excludes 7,185,296 (2017 &#8211; 6,711,339) potentially dilutive common shares related to
outstanding options and warrants, as their effect was anti-dilutive.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">g)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Financial
    Instruments</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the Company&#8217;s financial instruments, consisting of cash and equivalents and accounts payable and accrued
liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s
opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">h)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Foreign
    Currency Translation</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing at the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined
that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian
dollar.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">i)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Grant
    Income</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income is recognized when the research and development activities have been undertaken and the Company
has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income
at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government
and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized
in the consolidated statement of operations in the period they are earned and when the related research and development costs
are incurred.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">j)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Income
    Taxes</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (&#8220;ASC 740&#8221;)
which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax
assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">k)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Stock-based
    Compensation</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for all stock-based payments and awards under the fair value method.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based
payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees
is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting
period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments.
Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based
payments to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date,
unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees
will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their
vesting period with a corresponding increase to additional paid-in capital.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the
grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes
in these assumptions can materially affect the fair value estimates.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">l)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Fair
    Value Measurements</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level
1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level
3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2018 and 2017, the Company did not have any Level 3 assets or liabilities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">m)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Recent
    Accounting Pronouncements</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recently
Adopted Accounting Pronouncements</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
November 2015, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2015-17 &#8220;<i>Income Taxes: Balance Sheet
Classification of Deferred Taxes</i>&#8221; (&#8220;ASU 2015-17&#8221;). ASU 2015-17 eliminates the requirement to bifurcate deferred
taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified
as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15,
2016, and for interim periods within those fiscal years. The Company adopted this standard on October 1, 2017. The adoption of
this standard did not have any impact on the Company&#8217;s financial position, results of operations or cash flows for any period
presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
March 2016, the FASB issued ASC 2016-09, &#8220;<i>Compensation &#8211; Stock Compensation (Topic 718) &#8211; Improvements to
Employee Share-Based Payment Accounting</i>&#8221;. These amendments are intended to simplify several aspects of the accounting
for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities,
and classification on the statement of cash flows. The Company adopted this standard on October 1, 2017. The adoption of this
standard did not have a material impact on the Company&#8217;s financial position, results of operations or cash flows for any
period presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
November 2016, the FASB issued ASU 2016-18, &#8220;Statement of Cash Flows (Topic 230): Restricted Cash&#8221; (&#8220;ASU 2016-18&#8221;).
ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents,
and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted
cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period
and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after
December 15, 2017. Early adoption is permitted. The Company early adopted this standard on October 1, 2017. The adoption of this
standard did not have any material affect on the Company&#8217;s consolidated financial statements.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, which provides guidance on accounting for the tax effects
of the U.S. tax reform announced on December 22, 2017 by the U.S. Government commonly referred to as the Tax Cuts and Jobs Act.
SAB 118 provides a measurement period that should not extend beyond one year from the U.S. tax reform enactment date for companies
to complete the accounting under Accounting Standards Codification (&#8220;ASC&#8221;) 740. In accordance with SAB 118, a company
must reflect the income tax effects of those aspects of the U.S. tax reform for which the accounting under ASC 740 is complete.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Specifically,
the Company was required to revalue its U.S. deferred tax assets and liabilities due to the federal income tax rate reduction
from 35 percent to 21 percent. Since the Company has provided a full valuation allowance against its deferred tax assets, the
revaluation of the deferred tax assets did not have a material impact on any period presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition
from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition
guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017.
The new guidance is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard
is not expected to have a material impact for any period presented and the Company will apply this standard to all future revenues.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, the FASB issued Accounting Standards Update No. 2016-02, <i>Leases</i>. The guidance would require lessees to recognize
most leases on their balance sheets as lease liabilities with corresponding right &#8211;of use assets. The guidance is effective
for annual and interim reporting periods beginning on or after December 15, 2018. The new guidance is effective for the Company
on a prospective basis beginning on October 1, 2019. The Company is currently evaluating the impact this guidance will have on
its financial condition, results of operations and cash flows.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2017, the FASB issued ASU No. 2017-09, &#8220;Compensation&#8211;Stock Compensation (Topic 718): Scope of Modification Accounting,&#8221;
clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The
new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the
same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for the Company
on a prospective basis beginning on October 1, 2018, with early adoption permitted. The Company is currently evaluating the impact
this guidance will have on its financial condition, results of operations and cash flows.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-based Payments
(&#8220;ASU 2018-07&#8221;). This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring
goods and services from nonemployees. The effective date for the standard is for interim periods in fiscal years beginning after
December 15, 2018, with early adoption permitted, but no earlier than the Company&#8217;s adoption date of Topic 606. The new
guidance is effective for the Company beginning on October 1, 2019. The new guidance is required to be applied retrospectively
with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the effect ASU 2018-07
will have on the consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant
impact on its results of operations, financial position or cash flow.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6628560800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Component of Operating Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note
    3</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Other Income</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Grant
Income</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Clinical
Study Grant</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received
in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018 in exchange for
a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The
grant income is deferred when received and amortized to other income as the related research and development expenditures are
incurred. During the year ended September 30, 2018, the Company recognized $149,055 (2017: $Nil; 2016$Nil) of this grant on its
statement of operations within grant income.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Preclinical
Study Grant</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2015, the Company was awarded grant funding in the amount of $286,455. The grant was received in
exchange for a commitment to provide research and development for preclinical validation of Sigma-1 receptor agonism as potential
treatment for Parkinson&#8217;s disease.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The
grant income was deferred and amortized to other income over the related commitment period as the related research and development
expenditures were incurred. During the year ended September 30, 2018, the Company recognized $Nil (2017: $140,942; 2016: $141,195)
of this grant on its statement of operations within grant income.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development tax incentive</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2018, the Company received other income of $1,629,513 (2017: $2,022,902; 2016: $571,093) in respect
of a research and development incentive program offered by the Australian government.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other income disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6851660944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsAbstract', window );"><strong>Number of shares issued for commitment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offering Agreements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note
    4</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Equity Offering Agreements</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Controlled
Equity Offering Sales Agreement</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
July 6, 2018, the Company entered into a Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor
Fitzgerald &#38; Co., as agent (&#8220;Cantor Fitzgerald&#8221;), pursuant to which the Company may offer and sell shares of common
stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the &#8220;Offering&#8221;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company.
The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend
or terminate the offering of Shares upon notice to the other party, subject to certain conditions. Cantor Fitzgerald will act
as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable
state and federal law, rules and regulations and the rules of Nasdaq.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds
from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. During the year ended September 30, 2018, the Company incurred $101,133 in legal and
accounting fees associated with the Sales Agreement. This amount is included in deferred costs at September 30, 2018
and is expected to be reclassified to share capital upon issuance of shares under the Sales Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Purchase
Agreement</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &#8220;2015 Purchase Agreement&#8221;) with Lincoln
Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln
Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period
starting from the effective date of the respective registration statement, to September 6, 2019.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of
common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount
of a purchase may be increased under certain circumstances provided, however that Lincoln Park&#8217;s committed obligation under
any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will
be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2015 Purchase Agreement, the Company issued to Lincoln Park 179,598 shares of common stock
as a commitment fee and agreed to issue up to 89,799 shares pro rata, when and if, Lincoln Park purchases at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2018, the Company issued to Lincoln Park an aggregate of 2,398,261 (2017: 7,109,956; 2016: 452,437)
shares of common stock under the Purchase Agreement, including 2,383,580 (2017: 7,060,976; 2016: 450,000) shares of common stock
for an aggregate purchase price of $8,173,920 (2017 $27,270,674; 2016: $1,357,800) and 14,681 (2017: 48,980; 2016: 2,437) commitment
shares. At September 30, 2018, an amount of $13,197,607 remained available under the 2015 Purchase Agreement.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to equity offering agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635200448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note
    5</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Commitments</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000">a)</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000">Lease
    Commitment</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">The
Company has entered into an office lease agreement expiring March 31, 2019. The Company is committed to lease commitments as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal
    year ending September 30, 2019</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,022</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,022</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2018 the Company recorded rent expense of $151,405 (2017: $127,993, 2016: $125,317) which is included
in general and administrative expenses on the consolidated statement of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000">b)</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000">Litigation</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company&#8217;s consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000">c)</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif; color: #000000">Share
    Purchase Warrants</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 71%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance,
    October 1, 2015</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,272,890</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.11</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,463,581</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.67</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance, September
    30, 2016</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,809,309</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.70</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(200,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.00</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance,September 30,
    2017</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,609,309</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.66</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Issued</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(756,143</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.96</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(524,787</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.00</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance,
    September 30, 2018</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.87</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2018, the Company had 678,379 share purchase warrants outstanding, with a weighted average exercise price of $2.87
as follows:</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 41.75pt"></td><td style="width: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: justify"></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">30,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.00</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 67%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">February
    24, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">277,127</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 13, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,252</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.68</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 13, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.24</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.04</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2021</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 41.75pt"></td><td style="width: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: justify"></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2018, 350,000 options granted to a consultant to the Company were converted to 350,000 warrants with
the same exercise price.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2018, an aggregate of 737,393 share purchase warrants at $3.00 per share and 18,750 share purchase
warrants at $1.24 per share were exercised on a cashless basis, pursuant to which the Company issued 125,748 shares of common
stock and an additional 80,981 shares of common stock were to be issued. The remaining 524,787 share purchase warrants exercisable
at $3.00 per share until July 5, 2018 expired unexercised.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, 200,000 share purchase warrants were cashless exercised, resulting in the issuance of 52,562
shares of common stock.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2016, the Company issued 1,979,246 shares of common stock pursuant to the exercise of 2,421,894 share
purchase warrants on a cashless basis, and 41,687 shares of common stock pursuant to the exercise of warrants for cash.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">d)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Stock&#8211;based
    Compensation Plan</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;),
which provides for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will
be granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
2015 Plan provides that it may be administered by the board of directors, or the board of directors may delegate such responsibility
to a committee. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to
the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be
less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted
under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may
be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at October 1, 2015</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,822,500</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,401,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.22</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.38</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(25,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14.68</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at September 30, 2016</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,199,000</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.76</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,107,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.51</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.44</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(214,470</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.09</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at September 30, 2017</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,092,030</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.13</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,730,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.71</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.09</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(164,280</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.66</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(150,833</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.18</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at September 30, 2018</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable
    at September 30, 2018</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,108,028</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.75</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable
    at September 30, 2017</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,326,223</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.10</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2018, the following stock options were outstanding:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Value</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Life
    (yrs)</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.60</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 30%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">July 5,
    2023</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">565,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 7, 2024</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,375</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.32</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 8, 2024</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">176,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">618,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">618,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.92</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">April 2, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,119,938</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.51</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">29,167</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">29,167</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.44</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 8, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,625</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.69</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.76</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 15, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">48,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.71</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.04</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 18, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.97</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.64</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.68</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">October 2, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.01</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.98</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">October 16, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.04</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.57</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.25</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.90</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.50</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.66</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">April 27, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.57</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.11</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.75</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">379,625</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,083</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.26</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">July 5, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.76</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">861,429</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">574,286</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.06</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">July 18, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.80</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">906,696</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">906,696</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.28</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 22, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.98</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">39,999</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.63</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">October 3, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.01</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.35</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">December 9, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.19</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,667</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.39</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">February 7, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.36</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,333</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.26</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">February 17, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.38</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">774,166</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">389,170</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.92</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 12, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.61</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,209</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.42</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">August 9, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.86</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 19, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.97</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">540,834</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">135,834</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.30</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">December 13, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.20</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 2, 2028</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.42</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">33,334</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.72</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 19, 2028</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.47</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">780,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.30</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 15, 2028</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">335,400</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.62</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,500</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.70</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">August
    6, 2028</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,500</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.85</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,108,028</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,353,088</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money at September 30, 2018.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company recognized stock-based compensation expense of $5,517,004 during the year ended September 30, 2018 (2017: $4,135,570;
2016: $4,452,267) in connection with the issuance and vesting of stock options and warrants in exchange for services, and $Nil
(2017: $Nil 2016: $610,000), in connection with the vesting of restricted stock in exchange for services. These amounts have been
included in general and administrative expenses and research and development expenses on the Company&#8217;s statement of operations
as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,699,557</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,017,199</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,208,220</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research
    and development</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,817,447</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,118,371</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,854,047</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Total
    share based compensation</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,517,004</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,135,570</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,062,267</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $6,827,054 in stock-based compensation is expected to be recorded over the remaining term of such options
through June 30, 2021.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.73</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.11</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.28</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.86</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.88</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">106.45</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">111.58</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">114.75</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Dividend rate</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of restricted stock compensation charges recognized during the years ended September 30, 2018, 2017 and 2016 was determined
with reference to the quoted market price of the Company&#8217;s shares on the commitment date.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6851568448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note
    6</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Income Taxes</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">US
Tax Reform</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On
December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (&#8220;Tax Reform Act&#8221;).
The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a
territorial tax system and imposing a transition tax on deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act
permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued
its ending net deferred tax assets at September 30, 2018. The Company did not need to recognize any provisional tax expense for
the year ended September 30, 2018 as it has recorded a full valuation allowance against its deferred tax assets.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Tax Reform Act also provided for a one-time deemed mandatory repatriation of post &#8211; 1986 undistributed foreign subsidiary
earnings and profits (&#8220;E&#38;P&#8221;) as well as Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) and Base-Erosion
Anti-Abuse provisions. The Company had no adjustments related to these latter noted provisions at September 30, 2018.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
tax effects of the temporary differences that give rise to the Company&#8217;s estimated deferred tax assets and liabilities are
as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">Assumed
    Tax rate</font></td>
    <td style="width: 1%; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">34</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">34</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss
    carryforwards</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,123,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14,240,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,223,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development
    tax credits</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,605,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,344,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,036,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Foreign exchange and
    other</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Unpaid charges</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">72,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">28,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">152,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Intangible asset costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">28,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">51,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,152,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,394,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,004,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Valuation
    allowance for deferred tax assets</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(15,993,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(19,032,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(14,447,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Net
    deferred tax assets</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
provision for income taxes differ from the amount established using the statutory income tax rate as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Income
    benefit at statutory rate</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,215,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,577,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(5,010,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Foreign income taxed
    at other rates</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(173,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">132,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Permanent differences</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-deductible
    finance and accretion expenses</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-deductible
    compensation costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">738,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Other
    permanent differences</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development
    tax credit</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(77,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(23,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">628,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expiry of foreign net
    operating loss carryforwards</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">333,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Adjustment and true
    up to prior years&#8217; tax provision</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">336,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(55,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">176,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Effect of changes in
    tax rates</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,166,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(11,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Change
    in valuation allowance related to current year provision</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,038,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,585,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,009,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Income
    Tax Recovery</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2018, the Company had net operating loss carry-forwards of approximately $50,557,000 (2017: $41,000,000; 2016:
$33,000,000) in the United States, approximately $986,000 (Approximately AUD$1,365,000) (2017: $850,000; 2016: $250,000) in Australia
and approximately $638,000 (Approximately &#8364;549,000) (2017: $13,000; 2016: $Nil) in Germany, available to offset future taxable
income in those jurisdictions. The carry-forwards will begin to expire in 2027.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company evaluates its valuation allowance requirements based on projected future operations. When circumstances change, and this
causes a change in management&#8217;s judgment about the recoverability of deferred tax assets, the impact of the change on the
valuation allowance is reflected in current income. Because management of the Company does not currently believe that it is more
likely than not that the Company will receive the benefit of these assets, a valuation allowance equal to the deferred tax asset
has been established at September 30, 2018, 2017 and 2016.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Uncertain
Tax Positions</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company&#8217;s
tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities
until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation
years commencing on or after 2009.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain
of the Company&#8217;s net operating loss carryforwards <font style="background-color: white">in the United States may be subject
to limitations by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces
the Company&#8217;s ability to utilize net operating loss carry-forwards, under certain circumstances. The Company completed a
Section 382 analysis through the fiscal year ended September 30, 2018 and currently does not believe Section 382 will apply to
limit the utilization of these tax losses.</font></font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6628422896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0px">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note
    7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Supplemental Cash Flow Information</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Investing
and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2016;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">i)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">the Company issued
    6,162 shares of common stock upon conversion of $6,162 in principal amount of convertible debentures at a conversion price
    of $1.00 per share and 167,415 shares of common stock pursuant to the application of an incorrect conversion price for conversion
    notices received during the year ended September 30, 2015.</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641382560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">a)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Use
    of Estimates</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with United States GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of
revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income
tax asset valuations, asset impairment, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions
on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs
and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially
and adversely from the Company&#8217;s estimates. To the extent there are material differences between the estimates and the actual
results, future results of operations will be affected.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">b)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Principles
    of Consolidation</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and equivalents</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">c)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Cash
    and equivalents</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents</i>.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">d)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Research
    and Development Expenses</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#8217;s proprietary research
and development efforts, including salaries, facilities costs, overhead costs and other related expenses, as well as costs incurred
in connection with third-party collaboration efforts. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard
Codification (&#8220;ASC&#8221;) 730, Research and Development, as these materials have no alternative future use outside of their
intended use.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks.
The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents
and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the
development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due
to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus
are expensed as incurred within general and administrative expenses.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionIncentives', window );">Research and Development Incentive Income</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">e)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Research
    and Development Incentive Income</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain a research and development tax credit from the Australian Tax Authority (the &#8220;ATO&#8221;)
for certain research and development activities undertaken in Australia. The tax incentive is available on the basis of specific
criteria with which the Company must comply. Although the tax incentive is administered through the ATO, the Company has accounted
for the tax incentive outside of the scope of ASC Topic 740, Income Taxes, since the incentive is not linked to the Company&#8217;s
income tax liability and can be realized regardless of whether the Company has generated taxable income in Australia. The Company
recognizes as other income the amount received for qualified expenses in the period they are received.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">f)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Basic
    and Diluted Loss per Share</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2018, loss per share excludes 7,185,296 (2017 &#8211; 6,711,339) potentially dilutive common shares related to
outstanding options and warrants, as their effect was anti-dilutive.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">g)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Financial
    Instruments</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the Company&#8217;s financial instruments, consisting of cash and equivalents and accounts payable and accrued
liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s
opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">h)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Foreign
    Currency Translation</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing at the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined
that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian
dollar.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrantIncomePolicy', window );">Grant Income</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">i)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Grant
    Income</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income is recognized when the research and development activities have been undertaken and the Company
has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income
at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government
and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized
in the consolidated statement of operations in the period they are earned and when the related research and development costs
are incurred.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">j)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Income
    Taxes</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (&#8220;ASC 740&#8221;)
which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax
assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">k)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Stock-based
    Compensation</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for all stock-based payments and awards under the fair value method.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based
payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees
is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting
period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments.
Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based
payments to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date,
unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees
will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their
vesting period with a corresponding increase to additional paid-in capital.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the
grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes
in these assumptions can materially affect the fair value estimates.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">l)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Fair
    Value Measurements</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level
1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level
3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2018 and 2017, the Company did not have any Level 3 assets or liabilities.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; color: gray; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">&#160;</font></td>
    <td style="width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">m)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #000000">Recent
    Accounting Pronouncements</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recently
Adopted Accounting Pronouncements</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
November 2015, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2015-17 &#8220;<i>Income Taxes: Balance Sheet
Classification of Deferred Taxes</i>&#8221; (&#8220;ASU 2015-17&#8221;). ASU 2015-17 eliminates the requirement to bifurcate deferred
taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified
as noncurrent on the balance sheet. ASU 2015-17 is effective for public entities in fiscal years beginning after December 15,
2016, and for interim periods within those fiscal years. The Company adopted this standard on October 1, 2017. The adoption of
this standard did not have any impact on the Company&#8217;s financial position, results of operations or cash flows for any period
presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
March 2016, the FASB issued ASC 2016-09, &#8220;<i>Compensation &#8211; Stock Compensation (Topic 718) &#8211; Improvements to
Employee Share-Based Payment Accounting</i>&#8221;. These amendments are intended to simplify several aspects of the accounting
for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities,
and classification on the statement of cash flows. The Company adopted this standard on October 1, 2017. The adoption of this
standard did not have a material impact on the Company&#8217;s financial position, results of operations or cash flows for any
period presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
November 2016, the FASB issued ASU 2016-18, &#8220;Statement of Cash Flows (Topic 230): Restricted Cash&#8221; (&#8220;ASU 2016-18&#8221;).
ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents,
and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted
cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period
and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for fiscal years beginning after
December 15, 2017. Early adoption is permitted. The Company early adopted this standard on October 1, 2017. The adoption of this
standard did not have any material affect on the Company&#8217;s consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, which provides guidance on accounting for the tax effects
of the U.S. tax reform announced on December 22, 2017 by the U.S. Government commonly referred to as the Tax Cuts and Jobs Act.
SAB 118 provides a measurement period that should not extend beyond one year from the U.S. tax reform enactment date for companies
to complete the accounting under Accounting Standards Codification (&#8220;ASC&#8221;) 740. In accordance with SAB 118, a company
must reflect the income tax effects of those aspects of the U.S. tax reform for which the accounting under ASC 740 is complete.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Specifically,
the Company was required to revalue its U.S. deferred tax assets and liabilities due to the federal income tax rate reduction
from 35 percent to 21 percent. Since the Company has provided a full valuation allowance against its deferred tax assets, the
revaluation of the deferred tax assets did not have a material impact on any period presented.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition
from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede nearly all existing revenue recognition
guidance. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017.
The new guidance is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard
is not expected to have a material impact for any period presented and the Company will apply this standard to all future revenues.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, the FASB issued Accounting Standards Update No. 2016-02, <i>Leases</i>. The guidance would require lessees to recognize
most leases on their balance sheets as lease liabilities with corresponding right &#8211;of use assets. The guidance is effective
for annual and interim reporting periods beginning on or after December 15, 2018. The new guidance is effective for the Company
on a prospective basis beginning on October 1, 2019. The Company is currently evaluating the impact this guidance will have on
its financial condition, results of operations and cash flows.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2017, the FASB issued ASU No. 2017-09, &#8220;Compensation&#8211;Stock Compensation (Topic 718): Scope of Modification Accounting,&#8221;
clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The
new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the
same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for the Company
on a prospective basis beginning on October 1, 2018, with early adoption permitted. The Company is currently evaluating the impact
this guidance will have on its financial condition, results of operations and cash flows.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-based Payments
(&#8220;ASU 2018-07&#8221;). This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring
goods and services from nonemployees. The effective date for the standard is for interim periods in fiscal years beginning after
December 15, 2018, with early adoption permitted, but no earlier than the Company&#8217;s adoption date of Topic 606. The new
guidance is effective for the Company beginning on October 1, 2019. The new guidance is required to be applied retrospectively
with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the effect ASU 2018-07
will have on the consolidated financial statements.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Other
than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant
impact on its results of operations, financial position or cash flow.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrantIncomePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to grant income policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrantIncomePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sales incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining compensation cost for share-based payments by either estimating number of forfeitures expected to occur or by recognizing effect of forfeitures when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4549-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843336736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease commitments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">The
Company has entered into an office lease agreement expiring March 31, 2019. The Company is committed to lease commitments as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal
    year ending September 30, 2019</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,022</font></td>
    <td style="width: 1%; border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">70,022</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of share purchase warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 71%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance,
    October 1, 2015</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,272,890</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.11</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,463,581</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.67</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance, September
    30, 2016</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,809,309</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.70</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(200,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.00</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance,September 30,
    2017</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,609,309</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.66</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Issued</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(756,143</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.96</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(524,787</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.00</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Balance,
    September 30, 2018</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.87</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2018, the Company had 678,379 share purchase warrants outstanding, with a weighted average exercise price of $2.87
as follows:</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 41.75pt"></td><td style="width: 0.8pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="text-align: justify"></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">30,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.00</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 67%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">February
    24, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">277,127</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 13, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,252</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.68</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 13, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.24</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.04</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 31, 2019</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">350,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.19</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June
    30, 2021</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">678,379</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Exercise Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted
    Average Grant Date Fair Value</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at October 1, 2015</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,822,500</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,401,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.22</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.38</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(25,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14.68</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at September 30, 2016</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,199,000</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.76</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,107,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.51</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.44</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(214,470</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.09</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at September 30, 2017</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,092,030</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.13</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,730,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.71</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.09</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(164,280</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.66</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(150,833</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.18</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding
    at September 30, 2018</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.83</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable
    at September 30, 2018</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,108,028</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.75</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable
    at September 30, 2017</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,326,223</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.10</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of stock options outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2018, the following stock options were outstanding:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Value</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Life
    (yrs)</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.60</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 30%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">July 5,
    2023</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">565,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.20</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 7, 2024</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,375</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.32</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 8, 2024</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">176,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">618,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">618,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.92</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">April 2, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,119,938</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.51</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">29,167</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">29,167</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.44</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 8, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37,625</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.69</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.76</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 15, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">48,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.71</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.04</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 18, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.97</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.64</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">31,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.68</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">October 2, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.01</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.98</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">October 16, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.04</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.57</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2025</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.25</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.90</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 31, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.50</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.66</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">April 27, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.57</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.11</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.75</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">379,625</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253,083</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.26</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">July 5, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.76</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">861,429</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">574,286</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.06</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">July 18, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.80</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">906,696</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">906,696</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.28</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 22, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.98</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">39,999</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.63</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">October 3, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.01</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,750</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.35</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">December 9, 2026</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.19</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,667</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.39</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">February 7, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.36</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,333</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.26</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">February 17, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.38</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">774,166</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">389,170</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.92</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 12, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.61</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,209</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.42</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">August 9, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.86</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,250</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">September 19, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.97</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">540,834</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">135,834</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.30</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">December 13, 2027</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.20</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 2, 2028</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,500</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.42</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">33,334</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.72</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">March 19, 2028</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.47</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">780,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.30</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">May 15, 2028</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">335,400</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.62</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,500</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.70</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">August
    6, 2028</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,500</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.85</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,506,917</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,108,028</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,353,088</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of statement of operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">These
amounts have been included in general and administrative expenses and research and development expenses on the Company&#8217;s
statement of operations as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,699,557</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,017,199</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,208,220</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research
    and development</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,817,447</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,118,371</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,854,047</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Total
    share based compensation</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,517,004</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,135,570</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,062,267</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of weighted average assumptions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.73</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.11</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.28</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.60</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.86</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.88</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">106.45</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">111.58</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">114.75</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Dividend rate</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630238928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
tax effects of the temporary differences that give rise to the Company&#8217;s estimated deferred tax assets and liabilities are
as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">Assumed
    Tax rate</font></td>
    <td style="width: 1%; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">34</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">34</font></td>
    <td style="width: 1%; text-align: left; font-style: italic"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss
    carryforwards</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,123,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14,240,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,223,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development
    tax credits</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,605,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,344,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,036,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Foreign exchange and
    other</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(25,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Unpaid charges</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">72,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">28,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">152,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Intangible asset costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">28,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">51,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,152,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,394,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,004,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Valuation
    allowance for deferred tax assets</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(15,993,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(19,032,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(14,447,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Net
    deferred tax assets</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">The
provision for income taxes differ from the amount established using the statutory income tax rate as follows:&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 95%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Income
    benefit at statutory rate</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,215,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,577,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(5,010,000</font></td>
    <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Foreign income taxed
    at other rates</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(173,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">132,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Permanent differences</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-deductible
    finance and accretion expenses</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Non-deductible
    compensation costs</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">738,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in"><font style="font: 10pt Times New Roman, Times, Serif">Other
    permanent differences</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development
    tax credit</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(77,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(23,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">628,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Expiry of foreign net
    operating loss carryforwards</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">333,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Adjustment and true
    up to prior years&#8217; tax provision</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">336,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(55,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">176,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Effect of changes in
    tax rates</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,166,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(11,000</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Change
    in valuation allowance related to current year provision</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,038,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,585,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,009,000</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Income
    Tax Recovery</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6627437056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">7,185,296<span></span>
</td>
<td class="nump">6,711,339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862944000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">$ 149,055<span></span>
</td>
<td class="nump">$ 140,942<span></span>
</td>
<td class="nump">$ 141,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_ResearchAndDevelopmentIncentiveProgramMember', window );">Research &amp; Development Incentive Program (Australian Government) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">1,629,513<span></span>
</td>
<td class="nump">2,022,902<span></span>
</td>
<td class="nump">571,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember', window );">Clinical Study Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_FundingOfDeferredIncomeAwardedGrant', window );">Awarded grant funding amount</a></td>
<td class="nump">149,055<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avxl_PreclinicalStudyGrantMember', window );">Preclinical Study Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_FundingOfDeferredIncomeAwardedGrant', window );">Awarded grant funding amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 140,942<span></span>
</td>
<td class="nump">$ 141,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FundingOfDeferredIncomeAwardedGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to funding of deferred income awarded grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FundingOfDeferredIncomeAwardedGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_ResearchAndDevelopmentIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_ResearchAndDevelopmentIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avxl_PreclinicalStudyGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avxl_PreclinicalStudyGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863429408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 06, 2018</div></th>
<th class="th"><div>Oct. 21, 2015</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,173,920<span></span>
</td>
<td class="nump">$ 27,270,674<span></span>
</td>
<td class="nump">$ 3,167,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember', window );">2015 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription', window );">Description of purchases price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 50,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park&#8217;s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2015 Purchase Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,598<span></span>
</td>
<td class="nump">2,398,261<span></span>
</td>
<td class="nump">7,109,956<span></span>
</td>
<td class="nump">452,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,383,580<span></span>
</td>
<td class="nump">7,060,976<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,173,920<span></span>
</td>
<td class="nump">$ 27,270,674<span></span>
</td>
<td class="nump">$ 1,357,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,681<span></span>
</td>
<td class="nump">48,980<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,197,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald &amp; Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and accounting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms of the agreement under agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630238928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears', window );">2019</a></td>
<td class="nump">$ 70,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable', window );">Operating leases, future minimum payments receivable</a></td>
<td class="nump">$ 70,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future minimum rental payments in aggregate as of the balance sheet date under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164653&amp;loc=d3e41551-112718<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future rental payments receivable within the second year from the balance sheet date under an operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164653&amp;loc=d3e41551-112718<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860609776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 1) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, at beginning</a></td>
<td class="nump">1,609,309<span></span>
</td>
<td class="nump">1,809,309<span></span>
</td>
<td class="nump">4,272,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised</a></td>
<td class="num">(756,143)<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">(2,463,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod', window );">Issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired</a></td>
<td class="num">(524,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, at end</a></td>
<td class="nump">678,379<span></span>
</td>
<td class="nump">1,609,309<span></span>
</td>
<td class="nump">1,809,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, at beginning</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.96<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">1.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice', window );">Issued</a></td>
<td class="nump">4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice', window );">Expired</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, at end</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercised in period made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangement by share based payment award equity instruments other than options expired in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average expired price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to share based compensation arrangements by share based payment award equity instruments other than options exercised in period weighted average issued price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862935488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">First Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Feb. 24,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Second Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number</a></td>
<td class="nump">277,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar. 13,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants3Member', window );">Third Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number</a></td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar. 13,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants4Member', window );">Four Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May 31,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants5Member', window );">Five Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number</a></td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May 31,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants6Member', window );">Six Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember', window );">Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number</a></td>
<td class="nump">678,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6849402480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 3) - 2015 Omnibus Incentive Plan [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">5,092,030<span></span>
</td>
<td class="nump">4,199,000<span></span>
</td>
<td class="nump">1,822,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,730,000<span></span>
</td>
<td class="nump">1,107,500<span></span>
</td>
<td class="nump">2,401,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(164,280)<span></span>
</td>
<td class="num">(214,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(150,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">6,506,917<span></span>
</td>
<td class="nump">5,092,030<span></span>
</td>
<td class="nump">4,199,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at ending</a></td>
<td class="nump">4,108,028<span></span>
</td>
<td class="nump">3,326,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">2.71<span></span>
</td>
<td class="nump">5.51<span></span>
</td>
<td class="nump">5.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">3.66<span></span>
</td>
<td class="nump">4.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">1.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">3.83<span></span>
</td>
<td class="nump">4.13<span></span>
</td>
<td class="nump">3.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at ending</a></td>
<td class="nump">3.75<span></span>
</td>
<td class="nump">3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 5.44<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6868496992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">First Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Jul.  05,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">4 years 9 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption1Member', window );">Second Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May  07,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 57,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption2Member', window );">Third Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 176,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption3Member', window );">Four Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">618,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">618,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Apr.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,119,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">6 years 6 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption4Member', window );">Five Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">29,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">29,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Jun.  08,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 37,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption5Member', window );">Six Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Jun. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 48,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">6 years 8 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption6Member', window );">Seven Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">253,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">253,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Sep. 18,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">6 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption7Member', window );">Eight Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption8Member', window );">Nine Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">31,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">31,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Oct.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption9Member', window );">Ten Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Oct. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption10Member', window );">Eleven Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption11Member', window );">Twelve Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption12Member', window );">Thirteen Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Apr. 27,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption14Member', window );">Fifteen Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption15Member', window );">Sixteen Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">379,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">253,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Jul.  05,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 9 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption16Member', window );">Seventeen Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">861,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">574,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Jul. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption17Member', window );">Eighteen Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">906,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">906,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Sep. 22,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption18Member', window );">Nineteen Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">39,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Oct.  03,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption19Member', window );">Twenty Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Dec.  09,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption20Member', window );">Twenty One Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Feb.  07,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 4 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption21Member', window );">Twenty Two Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">23,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Feb. 17,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption22Member', window );">Twenty Three Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">774,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">389,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May 12,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 7 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption23Member', window );">Twenty Four Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">5,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Aug.  09,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 10 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption24Member', window );">Twenty Five Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Sep. 19,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption25Member', window );">Twenty Six Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">540,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">135,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Dec. 13,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption26Member', window );">Twenty Seven Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar.  02,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption27Member', window );">Twenty Eight Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">33,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar. 19,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption28Member', window );">Twenty Nine Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 335,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption29Member', window );">Thirty Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Aug.  06,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (in years)</a></td>
<td class="text">9 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares</a></td>
<td class="nump">6,506,917<span></span>
</td>
<td class="nump">5,092,030<span></span>
</td>
<td class="nump">4,199,000<span></span>
</td>
<td class="nump">1,822,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Vested Shares</a></td>
<td class="nump">4,108,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,353,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption11Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption11Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption14Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption14Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption17Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption17Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption18Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption18Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption21Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption21Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption22Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption22Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption24Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption24Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption25Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption25Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption26Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption26Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption27Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption27Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption28Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption28Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_EmployeeStockOption29Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_EmployeeStockOption29Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6849566208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 5) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 5,517,004<span></span>
</td>
<td class="nump">$ 4,135,570<span></span>
</td>
<td class="nump">$ 5,062,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">2,699,557<span></span>
</td>
<td class="nump">2,017,199<span></span>
</td>
<td class="nump">3,208,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 2,817,447<span></span>
</td>
<td class="nump">$ 2,118,371<span></span>
</td>
<td class="nump">$ 1,854,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6849394416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 6)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.73%<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 10 months 10 days<span></span>
</td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">106.45%<span></span>
</td>
<td class="nump">111.58%<span></span>
</td>
<td class="nump">114.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6868526864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_RemainingAllocatedShareBasedCompensationExpense', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 6,827,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants exercised</a></td>
<td class="nump">678,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 5,517,004<span></span>
</td>
<td class="nump">$ 4,135,570<span></span>
</td>
<td class="nump">$ 5,062,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AllocatedShareBasedCompensationExpenseRestrictedStock', window );">Share based compensation with the vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">2,699,557<span></span>
</td>
<td class="nump">2,017,199<span></span>
</td>
<td class="nump">3,208,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 151,405<span></span>
</td>
<td class="nump">$ 127,993<span></span>
</td>
<td class="nump">$ 125,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfOptionsGrantedToConsultants', window );">Number of options granted to consultants</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of options converted to warrants</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember', window );">Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number of warrant exercisable</a></td>
<td class="nump">678,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights', window );">Expiration date</a></td>
<td class="text">Jul.  05,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">2,421,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares called</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,562<span></span>
</td>
<td class="nump">1,979,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Number of share purchase warrants exercised</a></td>
<td class="nump">$ 737,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercised price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueStockOptionsExercised1', window );">Number of share purchase warrants exercised</a></td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2', window );">Exercised price (in dollars per share)</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues1', window );">Number of common stock to be issued</a></td>
<td class="nump">125,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues2', window );">Number of additional common stock to be issued</a></td>
<td class="nump">80,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">The exercise price will be determined by the board of directors at the time of
grant shall be at least equal to the fair market value on such date. If the
grantee is a 10% stockholder on the grant date, then the exercise price shall
not be less than 110% of fair market value of the Company&#226;&#128;&#153;s shares of common
stock on the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AllocatedShareBasedCompensationExpenseRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent information about the share based compensation in connection with the vesting of restricted stock in exchange for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AllocatedShareBasedCompensationExpenseRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to class of warrant or righst expiration date warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ClassOfWarrantOrRighstExpirationDateWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to class of warrant or righst expiration date warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfOptionsGrantedToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of options granted to consultants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfOptionsGrantedToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_RemainingAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a remaining stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_RemainingAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to stock issued during period value stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750880944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Assumed Tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 11,123,000<span></span>
</td>
<td class="nump">$ 14,240,000<span></span>
</td>
<td class="nump">$ 11,223,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">1,605,000<span></span>
</td>
<td class="nump">1,344,000<span></span>
</td>
<td class="nump">1,036,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Foreign exchange and other</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DeferredTaxAssetsUnpaidCharges', window );">Unpaid charges</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset costs</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,152,000<span></span>
</td>
<td class="nump">3,394,000<span></span>
</td>
<td class="nump">2,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(15,993,000)<span></span>
</td>
<td class="num">(19,032,000)<span></span>
</td>
<td class="num">(14,447,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredTaxAssetsUnpaidCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a deferred tax assets unpaid charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredTaxAssetsUnpaidCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6850958016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income benefit at statutory rate</a></td>
<td class="num">$ (4,215,000)<span></span>
</td>
<td class="num">$ (4,577,000)<span></span>
</td>
<td class="num">$ (5,010,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income taxed at other rates</a></td>
<td class="num">(173,000)<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract', window );"><strong>Permanent differences</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense', window );">Non-deductible finance and accretion expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonDeductibleCompensationCosts', window );">Non-deductible compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">738,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credit</a></td>
<td class="num">(77,000)<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
<td class="nump">628,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ExpiryOfForeignNetOperatingLossCarryforwards', window );">Expiry of foreign net operating loss carryforwards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">333,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment and true up to prior years' tax provision</a></td>
<td class="nump">336,000<span></span>
</td>
<td class="num">(55,000)<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCash', window );">Effect of changes in tax rates</a></td>
<td class="nump">7,166,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance related to current year provision</a></td>
<td class="num">(3,038,000)<span></span>
</td>
<td class="nump">4,585,000<span></span>
</td>
<td class="nump">3,009,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income Tax Recovery</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExpiryOfForeignNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExpiryOfForeignNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a income tax reconciliation nondeductible finance and accretion expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncomeTaxReconciliationNondeductibleFinanceAndAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonDeductibleCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a income tax reconciliation nondeductible compansation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonDeductibleCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of effect of exchange rate changes on cash balances held in foreign currencies. Excludes cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6844717776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OperatingLossCarryForwardsExpirationYear1', window );">Operating loss carry-forwards, expiration year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious', window );">Previous corporate income tax rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised', window );">Revised corporate income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry-forwards</a></td>
<td class="nump">$ 50,557,000<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=avxl_ForeignCountry1Member', window );">Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry-forwards</a></td>
<td class="nump">638,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=avxl_ForeignCountry1Member', window );">Germany [Member] | Euro Member Countries, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry-forwards</a></td>
<td class="nump">549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry-forwards</a></td>
<td class="nump">986,000<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Australia [Member] | Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry-forwards</a></td>
<td class="nump">$ 1,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to effective income tax rate reconciliation state and local income taxes previous.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesPrevious</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to effective income tax rate reconciliation state and local income taxes revised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxesRevised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryForwardsExpirationYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryForwardsExpirationYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=avxl_ForeignCountry1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=avxl_ForeignCountry1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860564928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of shares issued</a></td>
<td class="nump">$ 167,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Senior Convertible Debentures Due March 18, 2044 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of shares issued</a></td>
<td class="nump">$ 6,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued | shares</a></td>
<td class="nump">6,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !V%C$T?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ '86,32?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    "  =A8Q-CK!A0>X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/2@,Q$(=?17+?G<U62@G;7!1/"H(%Q5M(IFUP\X=D9+=O;W9M
MMX@^@)!+9G[YYAM(IZ/0(>%S"A$36<PWH^M]%CINV9$H"H"LC^A4KDO"E^8^
M)*>H7-,!HM(?ZH#0-LT:')(RBA1,P"HN1"8[HX5.J"BD,][H!1\_4S_#C ;L
MT:&G#+SFP.0T,9[&OH,K8((1)I>_"V@6XES]$SMW@)V38[9+:AB&>EC-N;(#
MA[>GQY=YW<KZ3,IK+*^R%72*N&67R:^KN_O= Y-MPS<5;\O9\;6X;42S>9]<
M?_A=A5TP=F__L?%%4';PZU_(+U!+ P04    "  =A8Q-F5R<(Q &  "<)P
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MT[\N[+L:>L9A8&0W]L/)U)2O_P%02P,$%     @ '86,39]>_SW^ @  @PL
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MPHT[\$]YFK*$N%UA0IXR2MD,$QY^0'RFU&4B[V5"A&\RX8$*?J(R-U%'S:L
MLX>,NT2(C%)*9GCP. 4_3[F;I^!')=B(%X*[ 9-A4N!)*@F!&2X\6\$/5^Z&
M*_BI^0'B5%*0B7#!$*T$9K^]?.Z@XRD+?CAR-V;!SUD2,PD<W$3!E(QP*B6?
MH<(3%_S(Y=2E$OX/,)XJF!*/E6AR&^JNI]_S9E_4;?"DC;U8]=>?G=9&V:KQ
MG>WR8&_$MT&I=J9[%?:]&:Z%P\#HXWCEC6[W[M4_4$L#!!0    ( !V%C$WG
MYJY ]P$  (D%   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC93;CILP
M$(9?!?$ ,6 .V0B0NJFJ5FJE:*MNKQT8 EJ#J>V$[=O7-BPBX+;+!3[]__@;
MC"<=&'\1-8!T7EO:B<RMI>P/"(FBAI:('>NA4RL5XRV1:L@O2/0<2&E,+46!
MY\6H)4WGYJF9._$\95=)FPY.W!'7MB7\]R-0-F2N[[Y-/#676NH)E*<]N<!W
MD#_Z$U<C-$<IFQ8ZT;#.X5!E[@?_<(RUW@B>&QC$HN_H3,Z,O>C!ES)S/0T$
M% JI(Q#5W. (E.I "N/7%-.=M]3&9?\M^B>3N\KE3 0<&?W9E++.W+WKE%"1
M*Y5/;/@,4SZ1ZTS)?X4;4"77)&J/@E%AWDYQ%9*U4Q2%TI+7L6TZTP[C2I1,
M-KLAF S!;/##?QKP9, K QK)3*H?B21YRMG@\/&P>J+_"?^ U<<L]*3Y=F9-
M92O4["V/PA3==)Q)\CA*@H4DN%<<MPJ<S!*D]I\A BM$8/QX"1'9_=CJQ\8?
M+OWQ*HE1$AE)9R2^-SVK9-ZCO&,*K4SAEBE9,8V29+&3M_,\?\7S/]4=2V1E
MB;8L^Q5+M,DZC!XP#I/U65N$&&-O[__EQ&,K4;PE>E@1Q>\EL@CM1&AQ*721
M^D;XI>F$<V92W2]S"RK&)*B@WD[%JU5=G <4*JF[B>KSL3J, \GZJ?"AN?KF
M?P!02P,$%     @ '86,34Z#[+_@ P  !1   !@   !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6R%E]F.XS8017_%T'M:W)>&;:!M8Y  "="8(,FSVJ87C!:/
MI&Y/_C[4,AZYJC1YL23Z%'E9(GE5RUM5?VG.(;2+;T5>-JODW+;7YS1M]N=0
M9,U3=0UE_.=8U476QL?ZE#;7.F2'/JC(4\&828OL4B;K9=_V6J^7U7N;7\KP
M6B^:]Z+(ZG\W(:]NJX0GWQL^7T[GMFM(U\MK=@I_AO:OZVL=G])[+X=+$<KF
M4I6+.AQ7R0M_W@G6!?3$WY=P:R;WBVXJ;U7UI7OX[;!*6*<HY&'?=EUD\?(1
MMB'/NYZBCJ]CI\E]S"YP>O^]]T_]Y.-DWK(F;*O\G\NA/:\2ERP.X9B]Y^WG
MZO9K&">DD\4X^]_#1\@CWBF)8^RKO.E_%_OWIJV*L9<HI<B^#==+V5]OPS_6
MC&%T@!@#Q#V _SQ C@'R1X#Z:8 : Q0(2(>I]+G996VV7M;5;5$/K_>:=:N(
M/ZN8_7W7V">[_R^FIXFM'VO#ENE'U\^(; 9$3!!^)]+8^7T$08VP$2A</ ZP
MQ82TC\@.(V9&A"2G*?MX.8T7=+PBXU4?KZ;Q$J1I0$R/E#VBO?/<@G1N"8XQ
M)ZP&4\:<DU)9Q6C=FM2ML6X%= ^(GHS#XSA*"0Z$$R S5C!G@'(,6J&59))6
M;DCE!BL'&=H8-,XOW$LIM8?2*5(;QZ0!Y(XDM?-,S:BWI'J+UYNAXQT9[_#L
MP9;8./PZE&<:)&E+8<PKL =W%,:YU[1H3XKV6+0#HCT>Q@BO.=A,6\P))H1G
M4#;FM.7,S[PKSN@SD&'A'AZ"#"O2FGEXEA&<<\R#/.P(C',I9LXD/G-V<Z0;
MGC8;@E$PV2/SL&&U8 IJQAC7<3'-B2;MX(4++)I#T9C!HO^?V8W,5+'A@LTL
M:DY;!Y=8L("")3XV9-QE2#3N"XLF^M*.SV69]BN.#<M"PQJ9AX&4M\Y#T11G
MM4/"*<XI-9=NVK$XMBP++8L35N2U\,)!Z1@4PGH-S7M'@,YQ;V;,EM.>Q;%I
M05O?<,IAK'3,0%%;$I6*,8O/$PI5EEGFYLY"VKBXQ5,P< J6,'BK#)2/,1TS
M"C_M"$QXP^=6#>V7'!NFA88Y,N8Q\TK'C*(E3Z%2&:88_$PC466E,9.7]#@%
MVCTYMD\+[7-DW'0P]B21?!I#BY[$U,Q)(VCS%-@\+31/@=U.*:-U_"R$I0!!
M,J<X0^()4FH>7Z: 'UKII!8J0GWJZ\QFL:_>R[:K*2:M]UKV172U%&C?Q!IW
MJ$A_=#,4R']D]>E2-HNWJHV56E]/':NJ#5$H>XH2S[$FOS_DX=AVMS;>UT-A
M.CRTU74LNM-[Y;_^#U!+ P04    "  =A8Q-+S]W8DX$  !&$P  &    'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;(U8VV[C-A#]%</O67&&-S%P#,06BA9H
M@<46;9\5FXF-E2Q74N+MWY>ZK%?FC))]L43ZS/#,B)Q#<G6IZJ_-P?MV\:TL
M3LW#\M"VY_LD:78'7^;-I^KL3^&?YZHN\S8TZY>D.=<^W_=&99&@$"8I\^-I
MN5[U?9_K]:IZ;8OCR7^N%\UK6>;U?QM?5)>')2R_=WPYOAS:KB-9K\[YB__3
MMW^=/]>AE5R][(^E/S7'ZK2H_?/#\A'N,S2=08_X^^@OS>1]T87R5%5?N\9O
M^X>EZ!CYPN_:SD4>'F]^ZXNB\Q1X_#LZ75['[ RG[]^]_](''X)YRAN_K8I_
MCOOV\+!,EXN]?\Y?B_9+=?G5CP'IY6*,_G?_YHL [YB$,795T?2_B]UKTU;E
MZ"50*?-OP_-XZI^7X1^3CF:\ 8X&>#4 \ZZ!' WD#P/UKH$:#51DD RA]+G)
M\C9?K^KJLJB'SWO.NUD$]RID?]=U]LGN_POI:4+OVSH5J^2M\S-"-@,$)Q"X
M(I+@_#H"<B-LD)CC[0!;BI#V%I)1B)DA(=DP96\OIV'.V"O67O7V:FH?1;$9
M(*:'G'K('5BEI1(NBI=#2F6$$CH*FT,J*XUQ*<]>L^PUC5[R]H:U-S1Z%45/
M(4I&87\,R0:(GL0+J)&G:EFJEE*-DKJA$$+U8TAF"56=2L%335FJ*:5J(JHI
M'42#%2+*_I;B%$BM;;24,\:?,(C&\KP=R]M1WM%RW5 (2?''D,P1MG<&<+)(
M;LB"X N<( /%:=DP&,)WQ-RPL1KC3Y%Q.-"@Q,PTAIFZ##3+:4R;8BCMCS'9
MB)E2EL+,I9FM\H^ M,:X&0]\B09)F9(/)6ERI5!(HJ8XK92,RROG#K6860W
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MIU$C2)T$(+XF7V<J 5,+F&::B=/&*M:H+V6K\*09X[M,6'@&-8!T@0,0JZZ
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M86_<( S]*X@?4.Y(VE6G)%*OU=1)FW3JM/4SES@)*L09D$OW[P<DS=(NVA?
MQN_YV9AL1/-B6P!'7K7J;$Y;Y_H#8[9L00M[A3UT_J9&HX7SIFF8[0V(*H*T
M8GRWNV%:R(X66?2=3)'AX)3LX&2(';06YO<1%(XYW=,WQY-L6A<<K,AZT<!W
M<#_ZD_$66U@JJ:&S$CMBH,[IW?YP3$-\#/@I8;2K,PF5G!%?@O&ERNDN" (%
MI0L,PF\7N >E I&7\6OFI$O* %R?W]@_Q]I]+6=AX1[5LZQ<F]-;2BJHQ:#<
M$XZ/,-=S3<E<_%>X@/+A08G/4:*R<27E8!WJF<5+T>)UVF47]W&Z29,9M@W@
M,X O@-N8ATV)HO('X421&1R)F7K?B_#$^P/WO2F#,[8BWGGQUGLOQ3[E&;L$
MHCGF.,7P=<P2P3S[DH)OI3CR?^!\&YYL*DPB/'FG,-DF2#<)TDB0_K?$K9CT
M0Q*VZJD&T\1ILJ3$H8N3O/(N WO'XYO\#9^F_9LPC>PL.:/S+QO[7R,Z\%)V
M5WZ$6O_!%D-![<+QDS^;:<PFPV$__R"V?./B#U!+ P04    "  =A8Q--9Y_
M^;0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q]4]MNG# 0
M_17+'Q O++EH!4C95%4K-=(J4=MG+PQ@Q1=JFR7Y^XP-H;1%?;$]XSEGSHS'
M^6CLB^L /'E54KN"=M[W!\9<U8'B[LKTH/&F,59QCZ9MF>LM\#J"E&3I;G?#
M%!>:EGGTG6R9F\%+H>%DB1N4XO;M"-*,!4WHA^-)M)T/#E;F/6_A&?SW_F31
M8@M++11H)XPF%IJ"WB>'8Q;B8\ / :-;G4FHY&S,2S"^U@7=!4$@H?*!@>-V
M@0>0,A"AC%\S)UU2!N#Z_,'^.=:.M9RY@P<C?XK:=P6]HZ2&A@_2/YGQ"\SU
M7%,R%_\-+B Q/"C!')61+JZD&IPW:F9!*8J_3KO0<1^GFRR98=N = :D"^ N
MYF%3HJC\$_>\S*T9B9UZW_/PQ,DAQ=Y4P1E;$>]0O$/OI4RRZYQ= M$<<YQB
MTG7,$L&0?4F1;J4XIO_ TVWX?E/A/L+W?RB\V2;(-@FR2)#]M\2MF-N_DK!5
M3Q78-DZ3(Y49=)SDE7<9V/LTOLGO\&G:'[EMA7;D;#R^;.Q_8XP'E+*[PA'J
M\(,MAH3&A^,MGNTT9I/A33__(+9\X_(=4$L#!!0    ( !V%C$T'SI]UM0$
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MTA6!;:#I,'3 !@0=MCXK-FT+U<63Y+C[^U&RZ[J=UQ=)I'@.#RDJ&XQ]<BV
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M^ G/=ARST?"FFWX0F[]Q\1=02P,$%     @ '86,30?V$-"T 0  T@,  !D
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MRC:4"^>*:E^")QUSK:\,\X31BS+#3(_%V#?'B>+]="= \\6D_ M02P,$%
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M=V]R:W-H965T<R]S:&5E=#$W+GAM;'54VV[;, S]%4$?4#E*O*6!;:!I,71
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MXZ_B2*GTWJJR%E/_*&4S"0*Q/=**B"?6T%H]V3->$:FF_!"(AE.R,Z2J#!
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M0KUF\KWK[SG]0+#6W.&"X2*Y^0]02P,$%     @ '86,34VS-8OO @  N@P
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MNCU-MQTMS]V70M!_KFS^ U!+ P04    "  =A8Q-E:>*QE\#  "7#0  &0
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MV$>*O7,NB(J8JD9.?:1 JV^9 QTAT-ZY?B3/^HXI<9P3Q7GLW$$TM24.=()
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M D%_8&>8(&0U=1+8GP'2%[,8(X-@^@(Q?7XOE,I7_.S,-",(K"\ U@?;H53
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M@2@AT^0>'$*+B$[T=G,<6L0$DNF9@]$'6G-Y=LU/!;FX--J^YZ/JT%\?L?W
M)_6-Z;M=FWR7Z9KV#R;/9:."@]"F?;B/_"2$YL8F?#!G4YC_Q#"I^$G;(35C
MV77+;J)%V_\(P/ WROX!4$L#!!0    ( !V%C$UA3XR1+@(  .$&   9
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MA"+?&[+_QLZL4G)-HF)L>27,7V][$I+7@Q>%4A>O_;-LS//2OZ%T,(,-\&"
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MLY=^;GR@Q;@\"7A]E\K?4$L#!!0    ( !V%C$W<E:^W_5,  ,Q! 0 4
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M;PID$<^J7;Q._O,'X %54GY)?OA=X(^Q*P"&_",3)(^K*O&??BQJ./"+SF<
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M,.30N1B7,HHVP]@+\J*Z.0,%5ZMY2&N:=JU3]5T6F1)7@V1ED$PQ09=5"C>
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M[2;Y'1PGSIIN$Y9_Z$A<XQ,:\^5<#4Z@L:%R=7:S:K)_\FI4<S4H[2.S2]?
MKG@NU!?0)T!&\3U,B%(+8.)G7IXQ0!# D>E&.V7YN&1B7#P1J"VP-GUH2,U;
M6C4NE@4!,J.TE1]_!ZWS;)KVK%60YY;SPIBU0?!RGRA>'0!*SX["KKONF7E3
M)!6).F1W8LL$L&?S&>AB+)0R1=ZSJ:@3GX1&W_7&!!O('*CD "E^8\)O)5;4
M93=PNL"A[M*61MQO]$!!>XUFPMJ*58:;@W0"CR6.'\#8=7-=?+S6*$Y&5FWX
M[9W)QIXQMZY!!\H1"<UT+"OBBIP0XZII.K""+^*44#VUAN4A\6 P]0UD6S3
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M !?N=49@/AV,E\;((\@W=SX9S]2$/QD!V1H3'N-IF4^BCF\6:@Y'%<&MC1>
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M)#FIUFL-!<VV[*7>*;HS%TI6NB.S[E@G;0*S%(:B##;&9%?>H":&LC#IB$>
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MQWG1D<82_)HTEN2T-!;5G\9B,ZS^Y])85$=2YQ=2SBEAMZXSL5+;V"R.>NX
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !V%C$V.L&%![@   "L"   1
M          "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !V%
MC$V97)PC$ 8  )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ '86,3=.NLQ;; @  H L  !@
M ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !V%
MC$V?7O\]_@(  (,+   8              "  0@,  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    "  =A8Q-Y^:N0/<!  ")!0  &
M        @ $\#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ '86,34Z#[+_@ P  !1   !@              ( !:1$  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !V%C$TO/W=B3@0  $83   8
M              "  7\5  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    "  =A8Q-N2$.W* '  #\,   &               @ $#&@  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ '86,384@;NC+ 0
M-00  !@              ( !V2$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( !V%C$WO,,N6L $  -(#   8              "  =HC
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  =A8Q-(1$-
M$[,!  #2 P  &               @ ' )0  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ '86,336>?_FT 0  T@,  !D
M ( !J2<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  =
MA8Q-!\Z?=;4!  #2 P  &0              @ &4*0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !V%C$U$*-0PM $  -(#   9
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M970Q-BYX;6Q02P$"% ,4    "  =A8Q-T(OPP<8!   W!   &0
M    @ $#-@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M !V%C$TC"M?"Y $  &H$   9              "  0 X  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ '86,3;W8>N:( @  IP@  !D
M             ( !&SH  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    "  =A8Q-IU:/_?<"  "8"P  &0              @ ':/   >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !V%C$W:1M0GL0$
M ,0#   9              "  0A   !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ '86,33[F<O/5 @  5 H  !D              ( !
M\$$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  =A8Q-
M3;,UB^\"  "Z#   &0              @ '\1   >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( !V%C$V5IXK&7P,  )<-   9
M      "  2)(  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ '86,39.-UK4K#   #%<  !D              ( !N$L  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  =A8Q-3T!K?$4"  "9!@
M&0              @ $:6   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( !V%C$UA3XR1+@(  .$&   9              "  99:  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ '86,3;F6)02R
M P  ]P\  !D              ( !^UP  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    "  =A8Q-QK^G)LD"  "<"@  &0
M@ 'D8   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !V%
MC$V$.'ZH @,  !4,   9              "  >1C  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ '86,31MSE"J7 @  3PD  !D
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M='EL97,N>&UL4$L! A0#%     @ '86,31T=OFDQ P  PQ4   \
M     ( !D\(  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !V%C$T/[$Q+
M> $  $44   :              "  ?'%  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( !V%C$WH]2X:D $  .84   3
M  "  :''  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     I "D $0L  &+)
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Equity Offering Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreements</Role>
      <ShortName>Equity Offering Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/Commitments</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxes</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Equity Offering Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/LincolnParkPurchaseAgreementDetailsNarrative</Role>
      <ShortName>Equity Offering Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferingAgreements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails1</Role>
      <ShortName>Commitments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails2</Role>
      <ShortName>Commitments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails3</Role>
      <ShortName>Commitments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails4</Role>
      <ShortName>Commitments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails5</Role>
      <ShortName>Commitments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Commitments (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails6</Role>
      <ShortName>Commitments (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="avxl-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Supplemental Cash Flow Information (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SupplementalCashFlowInformationDetailsNarrative</Role>
      <ShortName>Supplemental Cash Flow Information (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20180930.xml</File>
    <File>avxl-20180930.xsd</File>
    <File>avxl-20180930_cal.xml</File>
    <File>avxl-20180930_def.xml</File>
    <File>avxl-20180930_lab.xml</File>
    <File>avxl-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001615774-18-014328-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001615774-18-014328-xbrl.zip
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M.P1@_1, ;)>*_$I"8@63.?#U+7D@KK]$MEP?O/;@@U*/9=6C E<SP-5(U:C
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M<B56I1K+NEBEZP,#< B#P'(P/)3L 8, H=N_:"^Q",V:WIYBW"I5_A2:8,C
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MECWD@"<3IFXRSV^AI=> W+1%=&HBC@WZ$HCYI#V^58PZ@!?N#.B)NF5 ,+!
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M&;I3828HXPG2[*1,4JA0'&+!^T$3&+/56*A ,580$'#P41%S?9O]EKF:/$2
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MI(.>IU@S;7DF4&%X8__;:+OMEO9A\YI;/GJ=YB^G%:#H[5M NBOR.C-F,I_
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MEU3_/1L32,6.GHD'L%"Q:P6\-C,-[UI)^0;FB6'.*MO920LHXRY8X18;J]Q
MPP9CDMZQS70CC:EDJ*)+BM*06[U) #_[;C9@P,L_I-FV>E)^(:%1U.+8W+Y+
M"TQPU9ZDZ&*1"6>Q(+9#BXC!"##TSM(:J.PI9@U=FCG>)%V<1C9A_ VE-,E'
MMK>$M9\776FJ0J'XTI3HNAK1];?8(QQB6S;]AC=M$&Q9>72S6T3IZQD$( $]
MDD\@&&<3"%A@M& O$+O.)TI1]P>?@KD.L&-!WU!(Q(2&[!7!SR4*,-%%+QL2
M^04S'\T36D)2E#ZAOIN7CH-;0>E*3\*]?+.+&?Q.6)B+]$QJ4^'.UG-" +RN
M.,*C+OB"(XZ";=MM2KX7U0@2AS,1:3DW<;=K]KQ=M2XBLZ%$5"18Q9*6IX]2
MP<@3/I/BF9-X@147D !^+>YZ=9NTN *O!,H:SFBCO:0D;SV+0D9(1D9NE&@L
MWK)3LK !LO S9OEPI<B*U2*@QOX#63OZX9-LL("9 9G@0L#SE), 46K2+//!
MPS3(L'[V+ T8LQJI!0I7+TC8R67F;(/=+R_C\&9F6<M7]VFOJ>7X!;",5UY\
M QZ_<4'$__;O_X:9]+]8#T_N*\HDEB/[%F27Z^/66?(JC6O!+U_)]-<7[T%8
M4HO7:-^TC<AGBVATTVF_^*WZ R&'G@%YJN$,2!Z@+IE6<%[O$\ QZ;JSY\F+
M2H+A<;(XLC<,Q<5![M,<HKBPVA(U"NCTAJAMMT-=S%"O8C[O7+!I)OQ^@_LH
MME?L1J,+'O)5S.O;./$[(G[%@\82HS>.I*Z=1,4M>1J%P+M(:0G(:2R*TC';
M)*EM_T-O--"'0V[<LY=IS(%M$;'ZILS^\# A$"P+^%< OHC+JII:KLO+CS_0
M.$FFGN>CO^'%9/(L=XUGB(0F]["*VA(T0P5\&G'D)4F7F? 5 !,4)NE&%BU?
M:2U)##I;LX-XAE7+;"?GCT58QE\D'WXE$<S4RK/!2CE5"LJYE\\U+*1OV7IZ
MF6OTDG0-D=S*KG_CV;R\3BG@C!50X=]9XO35,]>FT=*1MH/[>>F=*^D-Q6_W
M7 CYA9UQ:W\PNB.]W>MI/^'Z?Z7]\,EQ7]--)/SIYV1+DPV:>0TB)[7PSCB^
M79MEDEH#%S/<+P =92=<Y"!+V F]P^T$<]C7N[U>UDY@F7]<:CHL;)Q5VMJZ
MPN;Y=]N%)CWMF2(5]WA07_,HRKTS6U@W!NUS&6'[,]]SP@7*Y"7XPEXD;OE*
MU3JV^,4*_@!3);.9AH%.VPEQR_M*9-SE#K)0NS]:8?XRU>T*/2E$+E1Z!K/<
MF-U3Y_,%D-'[CR1[96H%2A]4>Z+PC6Y;'W5-IO3I[X9NC'H_IXGU:^I?4ZK_
M>I;%SDNE,3\YN5CZ@IEP%3-=0O]O2A:FO/,"$;2]H??-D=XS.HFT,?6V:>JC
M=BIO>@-#;X\ZM&(HOPU3B!YKNXI/[S,':P DS@+ZF]+2M/Q4SVV,MV:XCN5E
M[N#>OG&QQQ9$;K?B'3VR_1G[!*[=S@+"=E[4AL6)-RRZ)]^P8%.OB;G7TLF_
MO.T+:01?!?%M>#GP79?'(==G\=["^QB2N6S^>"]S%C^+M")WI?6+E!%FS ?4
MD<1D>"V==>V9&==^PF:RYU37$)$]!DES1N[ SN4QY?=.]-<,SYO9O(7.\#7T
MW=)ITN*,-I]-S:1?:NE7V<9UO-DCC"WF[*8G'L4(L9@Z578\@\CE=\_077QV
M>)5'Z$ -Z<R#GLWP"M\(76X_! L>AH:*<T*(33^+E]C7#[VVWF[3?_@)5&?!
M<A7I?^=@=LS$L#/$;W!.L#A?9Z'QV+O,%?5]R?%B$Q>+':]8<N[2M5@R"2:D
MX,4NF9L#BE.^6!':29JSR>^/V2?9E:XU=B!.K#>] &@(?0IX^@T#_5A<%H^N
M.GR9I'QY64CR]"U>IMG?!&CR-UW$H#PR@Y%35SV7ST?O,Z#-\#KB2SS#R<I9
M\&[H>L&+>BQ6(-I*WA7./Q8EBNF)]^3;7*/L@"Q\BI=8X>$D:EKSVZV2G#Q:
MAMIZS-8BVD*UOCX;T V>IPZP'8^5+/*2N^3X]*:GJ#)9;9B?Y(\!A&(<"^L/
M5HPBI (3(VQL9M(;+M=$:3Y3#LC8,M-QB$$0P0G$#RU<1YL4TY7M#Z_'YFCE
MHV1LH[<.YCC ;RW/(+%50 0[9\7]$2OD V3BG&99H[0EP41<;&Z%OD<M>3(%
MJ1N%//.:WIL11LE%W1A#\?#^0Q>GR!;77+/6EWAXCT*%QIM8>J&H2$\C+ZP"
M'3_>3&<_B%W^/DAYFL*8W!>-\::83\LG*[2M/Y4@EG14W]:N#)M3TR$05X;#
M@MA$* TRAF&29TS#<R*G&.7XA%TJF:!6J/I.J_UC>JT=V@3"'&!GK$3]"2;!
MIEF!F[5.GEW<=!!NZ&='PL/W1>LM.;%J!2N^U6F3A9<YQ<'41Q0XXYA=GHIG
MR<)#@Z(BJ*K]8+0-W>AT, KA@JE$SY:Q=9\I/T)O> U#?\($;)(Y7, "O.Z2
M;7LX85H>"5I/XLGL<E!0#9M$)M$V)\P='&6W%29U,:D6H7?!\6L F0C$[%!6
M/&4J+,/MHKCYZ^:29, 7?J=?WA1J_K@N:8ZX"RJ.(9A&T9[HFAN:]:R2>QNM
MK:XGMJ<)+.QR03]BL-5E!.'^) A5)@C>PXK7M8\?[W)^)W^=;F66=3FIW<UD
M4LC*K&1;8V?W-\@!^96S%<78]0*/T_'2&S:H'EMS:C7JT!8XICQEK-._@;>
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M[+N-\/48%-X!DDE;<2V'G[1@J:P\M1=$AKC4-'!"(C(60 <X'EXX,?'C@"D
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MT!_4,U?OR3B(K8R8,[O/7!15D:@KE0=857QC,- -4V5A7WOB@=$R5?;?>:>
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M!0RB?7$NTG<3>PHE!(X91K*Y,C:7R2\OX_!F9EG+5VS' =3N6Q@"M  &\C=
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M>>BP\#^$MP&(INT@LW8H^?8GV^U1&%62FB,9N@XVW8FK.%CCW4A_30Z5G&[
M?JT-/_JBP-T[=5"Z,K4PM[XH.2P[WY6GL_79CFJY=V>;]TK.=LFQ/LO99G]T
M?0?!RZ_:HE8S;CRZG>>LEW:>;1D++3=AZ>ZVZ[TL?AC <M)R)0E/I>"-J,.*
M /9XY_AS"M!;.][/#SUX6!)50^^FX%H[)D>B[Y)K4:O?")B.6$=O[C85C',
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M/Y2<IT,P,)51,(5@"L$4O3"%IO&A-EV*87GM_'L3Q6!*$M,R#C=9&'.SEN)
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M@&7DP#+Y :MBQV]#M.@1LHI]; #9%CO*<UT]+SM6[/OQ:"C*_-A3!9/N\?5
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M^# T"M76$>>R:<[;<-$/C4*UU43S,LTPI;:>>)EN#K6VFGBA=KQ:6T_4+Y1
MM15%R](5\P*%M-JDN]M%LE C7?H2"53?VZK+,ZV-3A)#HU!M9?I2[[':NK1Z
MH3%5M;8N#>.0+Y)"M95I96BG['?2LB)I&TT&PC8<LG!"GH>JR^TZB4JPZ8E@
M%2,03LD]4^1V\QKX(5A%HN(I!+.T=@_D&0B694M&1XYI/.5(MJMHEN#2-KG>
M!^$2N3"4N))<W1Q(5=%UJT5ZE2#3$[TZ.H^FKL[.3*^JP?8Y5+(A"F<DAX&M
MEGQE16-8VQ<^-;H^MW=^-$TU5;6-VI)]\/="H/8X1%?DF:RV46I\+@*U-[6Q
M#MDJ9Q-UI(F?I>GFZ=0\0BFH'&1C=>/"' @UCY!YU7UB6Q1ZPZ/F$0*RDC=G
M@IH-"PNJ6Z9?M. \I@SA8.]_0<XF50N5Y-3:J,8=,3D;S4>0IW-!SH85$97<
MJ7<3A1H-.1M.,KALK?.8>HL*<AID,(0@9Y/JC$IRFH*<#:LYJLG9HJ-CC.3<
MC4-6D',VG0MR-JT5J61/HYMZQ_'0L^$TNKFPBYK6HE2+3Z$K-:U=J:"G.57:
M:.T[9GHVTN7-J2KXLVEE3 4]K6DKS9G&3,]&VKPV;3/.-DIZ-E+GM:DIO/)-
MBW0J]26MFVK!T="SI*BG4E_2NJDM' \]&^GSAKC?FY<,5=)3>.8;%QA5WD>Z
MH&?3>J3J^TC<[TW+ERKYLZ.>D..A9R/[2!5I#,UKHRKI:0GYV;22JI*>XKPW
MKKNJYL\!T#-J5&!2FZ;M%(54:_=-3G][:')&X1/K2*KC2TW\S:.E\(FE%M42
M8B04+JFKXD=4*'JS0'[+R+9.[)(B(WZDACYM-):G95QYI'5W\D-K%F'EG=;)
MVSFDM#)M-%ZQ54P[K!CKM^A$FRJMEO;60HLC:K8M#*P6PS$]4;-2A2$?PL2>
M][8;_MWV-F?6(_2IUF) MB&J'%*Z2].CS:SUX5.Z2Q.DE2F*?%#Z[RB"Y7P8
M\(46^,=O ?SIS-."6B^1KHL6C^1L4@*X3QBTW =KR.3D;Q+1.*G9V]RB<9*S
MMRE'XR1G7S.1QDG-OB8HC9.:O<U;&B<Y>YK.-$YB[H;#]^E([<YR&B<U^YK\
M-$YJ]C4G:J34[&FJU$BIV=,,JI%2LZ>)52.E9H-6LIK<9E^ND=*S?@-_2U=G
M+598C)2>O<W.&BD]ZROQ<_R/(">?<[G&2<WZ4[P4TQ2>N?9F?JF:UF;QSTC)
M65N-UV9SI<WD]9'2LW98PU#;C+*/E)JUS2)3..=:G%2F:$:KD\I&2L_]9M&/
MR'WEN]ZO+^)P@UY(OPP,L=KV"5RQ@D]:&UXFO.+M3CIK=V1G7^3,+?#!CT/7
MC]S%;EK@20G$>=+)H#J#7ZR;3D-%%+B@59.$M%UB&69G@T\YI%7#AO/;M+*T
M-C/2ATJJTAXK6Z12K'9UVJ'2JK1_RC:M%&4^;S,1?ZC$*FV.LD4L#1A+D*K.
M/:C/NIKY/2A2E;8TZ=[(:1F+TD8B@\.BM'W'X+ H;9HQ."S*>W,/#XT]FMO0
MT-BC50T-C3UW^-#0V'._#@V-<=Q]Y5V&AX?&.&Z_\IZZ@T.CO)7M\- 8Q_57
MWKAU>&CLL?>'AL8X;O'R[J##0V//+5XP]DUAZY?'_DKB \+A71[7*_&V:88N
MB+6O3^:VOZW'(WA_>*'[PPMM];?XBE:VZ^._WV":A?8BWMC>-Q2NU+H=/0Z'
MIGZ[U?\Y_Z2_W:+;>=$9$$4/![!^NS7^:7TR!45/IJ@J*-HR1;64HN8_37'J
M6Z"HGJ/H[--,4/1DBAH%BBKBV)].4C-'4D7YI,P%34^FJ972U/JGH.:IU)SE
MJ"FNI=/I.<_14Q$$;4&[EW,4U3X)@IY,4"5'4%,0]'2"J@6"JH8X]:?35,_1
M="Z8]'2"&@6"BINI!9*:!9(JP@9M@:9Y[1[?5*HFB'HZ43,E?R:4_#8(.L\1
M5!7.IS9<SG*>1S\ILJ#IZ315BC2U!$U/IZF:HZDE^+05FFHYFF)[7Q"U#:+J
M>:(*WW,[1,VLJ#F^^!55T/1TFIHYFAJ?%$'2TTEJ%4DJCGX+-)WE:(HO?F&8
MMD#3>8ZF^.+G+.1\[7G!PL8/EF>T03L)/ZH[Y*FZOMY0+%G.=62IMW1[ )?,
M_ZK.^%,TP\BW%3LWP"6CX:HI+)NJFF_3=VZ J[($?T<^YDSOVG>NG15FS2B&
MF;3?$7M=G<Q><S['&\(5 [6)'GZIDN\ R@&[M8B>ILHS5>WQ-%4QYU<4(3M<
M/&+\WJ+OR O6(&H;[-U,L72=4]8\&3E%F6GYR=\\,>:IR"DS0Y=/W[GR+]?(
M!T^'"UY'T69%K_6O;O3G^Q"A#Y@2(8KBKQB<YC?P[29$.VVGY*FL6FUT'JT+
M-Q>$JK[Y]Q)*:3+M?A2$JM8X]A%*:65ZY$F$.D:)+ELP;9^&=66E[IEK,87\
M($S]8E]VD$C>9UL.3<[Q+SL?L/N ?RN1A^/P;^NX)2O]/?#P:SPW?F[QZE&F
MLJFWT=RI/N2<$.N(ZT>9*HK1E53EFEA'7$&86'HKK?LX(]9;][OK(-]I5_]K
MISZV+MQ<$.HX_>\""76<_M</H>SO/[SC5WOWGPT^RA_\* XW\,?H2_R(PF^/
MML]\JUL.U7<_4+AP(W0;NHNJ,N.Z8^QGV.3L$0.^B9BXTS'#+1[QHO^P 98X
M*K/G]Y%8FP)7\D+B&\^.,(H,D2_A5_Q<!&X*-R3 O,6,G6!)/XVCAK&'/<3Z
MC7X3BSV#D>,86+:E$R;D*O!)F./&7KNQ[=%M '=,^!TY[X/P_2;&\N(#/LRV
M7VNWZ_2#WK/9IFS(AI'S:S2&K[!;:?3D?-$1<Z9:LJ&S+6H(P,[NE.QPOA=X
M/?FUC];63+-R;NI#B[4!G-E0+NP3N[JJS.;Z>6&W6H)=+MZSK8!.F\)_6=ZA
MQ29T8Q=%-[;G(>?-<Z4P:G=7E+DU5W7S &KU03T#YBWMJ:$:IMH9WD=?>V]1
MM A=(H@;WD'[1?AOWQZ1A-C]**V) O#D>IYTCS!58A2N7!\YTOVSA*]8Z3[
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M&@M\$4L@U@KZN3)QJ_6/:Q=-A].[532<^ICOP1:(>UE7%NU^!(]:YJ&XOH;
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M9'?98; 4(3]E_#WYAQ0^P=_\/U!+ P04    "  =A8Q->7!M[0E-  #TU 0
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M52ZWY:2DUB&BIY\D"F(9(8K8F(K:)D)D$3(Y*5B$J.-D/!YB&2"*()F*VB9
M9*$R.2E8@*@#9BPR8AD?BFB9BMHF/F0Q,SDI6'QT1,[HC-8R/A3K'Q6U37S(
M5D!R4K#X4*^!:+3$,CP4 305M4UXR,)H<E*P\.@(IN$G'-H&R(]& /D1 D!^
MU ?(C\ !\J,2(!_]U:/U->Y/1@#Y"0) ?M('R$_  ?*3$B"?_-#Z!.2]$3[>
M0\#'>WU\O >.C_=*?#S8'U_.WIC%R-Y  $A3:664[ UPB#04; TR 81IR)EA
M*!5&+-4DF H^FJH.ISX\X\#^:O?,+)YZ!B*@VE1:"1/H(=6S[IAJB@'T)V9Q
MLS,0@;.FTDJ@0 ^=G77%SI8@<&(6/[.00:"AM!(GT$-H'7D$]_X+")R8!=+.
M0$32FDHK<0(]EG:F$4P#@12SB-H9B)!:4VDE4J 'U<XTHFH0@&(663L#$5IK
M*JT$"O3@VEEW= T$4,Q";&<@8FQ-I95 @1YE.^L(LSV3H6=G&R8SLTC;#$2D
MK:FT,ML(>J1MIHZT93"YL1^SGYE%VV8@HFU-I950@1YMFW5&VRA4'IXCZU Q
MS& $$7%K*JV$"O2(VZPCXI9!A32L_7[%+)MQ!B*=L:FT$BS0$QIG'4> .5@@
M)#;.S"*T,Q 1VJ;22JQ C]#.U!':'"L DAQG9E':&8@H;5-I)5:@1VEGZBAM
MO@*RG_ X,PO4SD $:IM**Z$"/5 [4P=J<ZA R#J8F<5J9R!BM4VEE6"!'JN=
MJ6.U&5A )$+.S.*U,Q#QVJ;22K! C]?.U/':#"P0DB)G9B';&8B0;5-I)5:@
MAVQG'2%;FJ=RH)#M,,?2KT(W6N/BN<[\V6W%K19*CC&/IFNH7CV<KB"W#B]]
M'9L(XQRH8$$Y#ZC'4W_!(;UP=AYZ<V_MASY]8(%>U/#Q98/#! M[,4/>,9%G
M9$X5@UJ,8-!HHFT3EQDO>P'&J7$#ZP#%SXOH %.+<]PG$K5-J;^7V,D&!I+Z
MNDK?@*&(]"HOP,""(^_/'YR7^39]C&+QPQY=Q../PC*%VP-PDQ(,M)3J289=
M0HT*<E C[@51+TE]]SS:AFF\4W9D$MHQ4:14MPHB(2$8#*FT:T+H<^C35UW9
MS.W@-QY>1C'V5V&FEV)?7D(XVH)1J6BQ5!1264=!IVKM25*\=L(=@!=]S[=Q
MC$-7--BT?Q[K!5^14OG+O=7?K#>\1*'6^QL9R0$&BOS!,#<K@K;XC\5?M,5_
MK+1X_OT?'S_?-4RI_S1&2XN4H:U<_=YZ"PN4:27\;N,(<4=&W/M]G)P@^C6,
M*4&]9U+.",2D8TX(5,I6YP,B.NMHT5"N]?!*_NCD00:#GMW#_/.%S _83Z-V
M#Q5E:MT#^=YZ@PN4D3;P";J(@L")DT-=7HN)-GY*.A^#)T4UF,:[S%;7@/)2
MVRX.ZP Q4E-PQV3&=^@'2/<?9*ZC<)62:>T%7J0/.^4+7F+2,0<9E;+5049$
M9QU2&LJU'J(DI*>4%E'BDR'?^1H&/>=1^(3CU%\$F&JHG*-(:,?$CU+=*H"$
MA& 0I-*NW1>%?D0GN 4+Q1+IA[9$*W2QQ>A7%F4]^^D$S=Z\>W?HP,9%Y&[9
MP_2AQY_DO0J7$5E5LVVS!1URW534%^OQC3;FF9A1#'LZ3-9!9JII$W Y*R*\
M^:O+%6XKSVYS->[PBFUJA2E]D:!AMIQLK >X54KFKW"+:*PCID.QUKJ;8Z*D
M90]$6,3%.4$KF>E?A1Y^^4^\DUK7HAL7&1(UZ]!H$ '"AE@S"3@R8L2H$2&W
M H^\*Z/3+H%=]9_' H-(J1P#U=] -+U (>EX06FL-/-#['CT+>_=>A&)C&C\
M/E9#"]7*6[KV(XBF%FG42J_C-(@36?7I6QS[$9G<>!=.JG+N!MW87BY4L^GN
M-2(08%!I)NT .#&9,WJ(DEN!QYQHXE%M+@-G)3"L\?M8<!"JE<.@]B.(YA=I
MU(JOYC2($EEI;+Z_EU[ZB>L$_\!.+.\.Y*1C0:!+V1P-,CH0P.A03KP!2Q#"
MZ!%EL-L]\.GI;S@(_C.,GL-[["11B+VK)-FVXEX:].,N(#K4KB\D),0@4*2C
MH61AX2#*=OHGY4,Y(^*<%A'U]RC8AJD3[R[] ,?- +R";EP$2=2L(Z=!! @Q
M8LVD2"G($:.W"(_[1P+:\VB]<4)Y>*).-"XP1 K645&E  0)@5H2/#!*E)':
MC%;Q,?$.;Z(XI0NNU$FW\AY#1CYR[$JI=".$):0%A!FE@F+T_"5!!3GB]"@3
M8[-;63M!\&&;^"%.Y AJ4(W<L8A4;/0L51) ,!'I)>M;*"G*:2TBXN,:QRN"
MT5_BZ#E][!IQ)-3C(D2I<ATI0E) B%'I)T%.SH(X#X#QZ>/+0^R$B4\W^WA$
M1VZO@'1D\$B5;2"G10<)-C+E9)AY025#%G6S"!@VN3XG*_I5%,O[F@;5N# 1
MJEA'2(T$$#A$>DEPP4A13FL1$;?;1>"[ET'D-%-!)#3CHD&@7AT+%0) 2&AK
M)<$!)T2,TN9")UJOHY!=Q7#_Z)#ZN-FF2>J$= =)/C=7,HV\Z-$PH+'T47
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MI]RG+DH9X-#8-,\8E;F ::&SH?7^*+767]*TC0 GR3[]IDJ&9<1VF]>!6+D
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M)]0?JX7!<+[L#2DZ1R6UXOJX:^!2,8P:>>U4O!8SE5*# 6FGBI+GOV@,)N<
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M6-ITW)RD<U)\ &A]40^ C1O_V_LAR@-8+M\@)H)9'B$N>2?W1!B<=\'LGP@
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MI:,,4 Z4;841;&PEF](HW"G4<\FMBJ ;@]SF((B>%5=!:'%:]0^Y*4JXM]G
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M$^+%/&0'AEV_)_12</H94!6U9<=07B_NOQ*'1RKYDIXR#%\9X5V@%XFK[OQ
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M\PDKJZFF\;F^4U8Y\9-WH]T+=BXO;%165(XE [)D2LD7C)",/R4E>JP%/-R
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M-K]Y8#]%;)CSBHVJP*9V1W8@*+7&8OE^71'K>;U\4P9Y]31W?TI)PH3T. !
MA[V!JVB-6X7QH-JQ(QQR$P;3F-#Y!7F,N2W*)\/RUG:,)-!<6"Z R:"V.2A4
MY\NB]G; (3,L!2A6G2SGZK]S_E3+D* Y]L0FMZV=-SLE(MLQ;7&^-E7Z,X9Y
M,N+J3>#^G!\.2DJ8PWMH2X175R<M03(M*9N6FMT'ST(_V"/2'*RE"C)<.D@<
MGLK^PO_#WP=CO_E_4$L! A0#%     @ '86,3>)D\=LDO0  0^0, !$
M         ( !     &%V>&PM,C Q.# Y,S N>&UL4$L! A0#%     @ '86,
M3:#5*SI\#0  Q)\  !$              ( !4[T  &%V>&PM,C Q.# Y,S N
M>'-D4$L! A0#%     @ '86,31G6?(_K"@  H'T  !4              ( !
M_LH  &%V>&PM,C Q.# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( !V%C$U3J VE
M/!H  "'@ 0 5              "  1S6  !A=GAL+3(P,3@P.3,P7V1E9BYX
M;6Q02P$"% ,4    "  =A8Q->7!M[0E-  #TU 0 %0              @ &+
M\   879X;"TR,#$X,#DS,%]L86(N>&UL4$L! A0#%     @ '86,38R!)"#E
M*0  ]_@" !4              ( !QST! &%V>&PM,C Q.# Y,S!?<')E+GAM
7;%!+!08     !@ & (H!  #?9P$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
